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9General introduction
SOFT TISSUE DEFECTS AND CURRENT SURGICAL TREATMENT 
OPTIONS
A large portion of the plastic and reconstructive surgical procedures performed each 
year is aimed at repairing soft tissue defects, which result for example from traumatic 
injury or tumor resections [1,2]. Large soft tissue defects, lead to a change in function 
and ‘normal’ body contour, which in its turn can lead to disability and emotional stress 
[2]. Currently used methods to repair soft tissue defects include the use of autologous 
adipose tissue transplants and synthetic implants. Both procedures have their own 
advantages and drawbacks [3,4,5,6].
Figure 1. Example of a large soft tissue defect due to tumor resection. Drawing of an adult female 
before (left) and after (right) mastectomy. Adapted from fi gures at www.microsurgeon.org
Autologous adipose tissue transplants have the advantage for a low risk of an adverse 
immune response and have been reported to restore specifi c soft tissue defects [7,8,9]. 
However, donor-site morbidity remains the principal drawback of large autologous adi-
pose tissue transplants [10]. In addition, the success of non-vascularized autologous 
adipose tissue transplants is unpredictable, as they have the tendency to lose 40 to 60 
percent of the volume over time [10,11,12,13].
Synthetic materials such as silicone implants have the advantage of an endless 
supply and often yield good results. However, limitations of these synthetic fi ller mate-
rials include rupture, leakage, dislocation and suboptimal biocompatibility [14,15,16]. 
To address limitations of current reconstructive surgical procedures, adipose tissue 
engineering has emerged as a new alternative to repair soft tissue defects.
ADIPOSE TISSUE
Adipose tissue is a highly specialized connective tissue that is found in two forms: 
white and brown adipose tissue. Brown adipose tissue is so called because of its color, 
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which is due to its high vascularity and numerous mitochondria (containing colored cy-
tochromes) in the cells. Brown adipose tissue has a limited distribution throughout the 
body and functions primarily as a heat source [1,17,18]. During aging, brown adipose 
tissue is gradually replaced by white adipose tissue.
White adipose tissue is widely distributed throughout the entire body and is most 
widely known for its role as energy reservoir. However, the function of white adipose 
tissue is much more diverse. It also shapes the body contour, helps to keep organs 
into place, contributes to insulation/thermoregulation of the body and can serve as a 
mechanical cushion (think of adipose tissue in the hand palm/foot sole). Besides that, 
white adipose tissue also functions as a secretory organ. It synthesizes various factors 
(for example cytokines and leptin) that exert their effect locally or are transported by 
the blood to a distant organ [18,19,20].
Macroscopically, adipose tissue is subdivided into incomplete lobules. These lob-
ules are units of 102-103 adipose cells, which are separated by fi brous septa containing 
a rich vascular supply and nerves [21]. Apart from fi broblasts, vascular endothelial cells 
and neurocytes, adipose tissue is mainly composed of two cell types: adipocytes and 
adipose precursor cells. Adipocytes are differentiated cells with a diameter varying 
from 50 to 150μm and an eccentric, fl attened nucleus. They are specialized in storing 
energy as lipid. Adipose precursor cells are mesenchymally derived spindle-formed 
cells with small lipid inclusions that can readily proliferate and can differentiate into 
adipocytes [22,23,24,25].
Figure 2. Schematic drawing of the cellular composition of adipose tissue. Adipose tissue is mainly 
composed of (im)mature adipocytes, adipose precursor cells, adipose tissue matrix (every adipo-
cyte is surrounded by a lamina basalis and a network of thin collagen fi bers), fi broblasts and endo-
thelial cells. Immune cells such as macrophages are also present in adipose tissue.
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ADIPOSE TISSUE ENGINEERING
Tissue engineering is a relatively new multidisciplinary fi eld that combines engineer-
ing and life sciences to improve, repair or restore tissue function [26]. To date, tissue 
engineering techniques have been developed for several tissues of which some have 
already translated to the clinical bedside. Typically, in tissue engineering living cells are 
combined with nonliving biomaterials to ‘construct’ a tissue equivalent in vitro. The 
nonliving biomaterials allow three-dimensional tissue formation and provide structural 
support for the cells until they have synthesized their own extracellular matrix.
In vitro engineered tissue equivalents should be customizable, immune-compatible 
and able to adapt to the implantation environment similar to autologous tissue trans-
plants. However, in vitro engineered tissue equivalents will not be associated with 
donor site morbidity, as is the case with larger autologous tissue transplants.
In the fi eld of adipose tissue engineering two approaches have been used. In the 
fi rst approach, a scaffold is combined with bioactive factors that induce migration 
and differentiation of cells from the surrounding tissue, which is referred to as in situ 
adipogenesis. The second approach is cell-based and combines living adipogenic or 
adipogenic precursor cells with biodegradable matrices/scaffolds ex vivo to allow the 
development of a three-dimensional tissue structure. This approach is referred to as 
cell-based or de novo adipogenesis [27,28].
SUITABLE CELLS
Different cell types with different stages of differentiation can be distuinguished for use 
in adipose tissue engineering.
MATURE CELLS
Firstly, fully differentiated cells, adipocytes, can be used. Adipocytes have optimal 
tissue-specifi c characteristics and can readily be attained from clinical procedures; 
however they have low expandibility and poor ability for volume retention after in vivo 
implantation [2,28,29].
STEM CELLS
Secondly, stem cells can be used. Two broad types of stem cells can be distinguished: 
embryonic stem cells and adult stem cells. Embryonic stem cells are isolated from the 
inner cell mass of blastocysts. They have the unique attributes of endless self-renewal 
and pluripotency, that is, the ability to form all fully differentiated cell types in the 
adult body. Although embryonic stem cells have been successfully used for studying 
adipogenesis in vitro [30], they currently have several drawbacks that make them less 
suitable for clinical application. Firstly, they are allogenic and will face a substantial risk 
Femke BW.indd   11 26-11-10   13:19
Chapter 1
12
of immune-rejection in vivo. In theory this can be circumvented by somatic cell nuclear 
transfer (i.e. therapeutic cloning or SCNT). By transfer of a nucleus from a somatic cell 
into an enucleated oocyte, the oocyte can form a blastocyst upon stimulation, from 
which embryonic stem cells can be isolated that are genetically matched to the donor 
[31]. No such human embryonic stem cell lines however, have been obtained yet. Sec-
ondly, they retain tumorigenic potential as it is still diffi cult to regulate their proliferation 
and differentiation. Finally, debates relating to the ethical aspect of embryonic stem cell 
use are ongoing. Some of the disadvantages of embryonic stem cells (immune rejec-
tion and ethical issues) may be surpassed by the recent creation of induced pluripotent 
stem cells (iPS cells= mature cells that have been genetically reprogrammed to an em-
bryonic stem cell–like pluripotent state by being forced to express genes and factors 
important for maintaining the defi ning properties of embryonic stem cells) [32,33,34]. 
However, iPS cells will hold embryonic stem cells’ disadvantages of pluripotency (dif-
fi culty to regulate their differentiation) and tumorigenicity.
Adult stem cells can be isolated from multiple adult tissues (bone marrow, adipose 
tissue, blood, muscle, blood vessels, skin, hair follicles, intestine, brain, liver) and 
have the ability to differentiate into a restricted amount of cell types (multipotent). For 
adipose tissue engineering the use of mesenchymal stem cells derived from adipose 
tissue is preferred and has received the most attention [2,23,35,36]. Adipose tissue-
derived mesenchymal stem cells (ASC), also commonly referred to as adipose tissue-
derived stromal cells, are highly expandable and have the potential to differentiate into 
various cells of the mesodermal and endodermal lineage in vitro (such as adipocytes, 
chondrocytes, osteoblasts myoblasts, endothelial cells and hepatocytes) [37,38,39]. 
Adipose tissue-derived mesenchymal stem cells do not express specifi c cell surface 
markers, but rather a complex pattern of cell surface markers including stromal cell 
(CD105, CD90, CD146), endothelial cell (CD31, CD34) and hemopoietic markers (CD45) 
[40,41,42,43]. They can be isolated from adipose tissue by collagenase digestion 
followed by cell selection through centrifugation (to separate the fl oating adipocytes 
from the stromal-vascular fraction) and adherence to cell culture plastic. Differentiation 
towards adipocytes can be induced with for instance insulin, dexamethasone, indo-
methacin and isobutylmethylxanthin [40,44,45,46,47,48].
BIOMATERIALS
Biomaterials play an important role in adipose tissue engineering strategies. Apart from 
providing a temporary three-dimensional architecture, they also have to mediate cellu-
lar attachment and viability and must allow lipid accumulation inside the construct after 
implantation [49]. Moreover, engineered adipose tissue equivalents should be easy to 
manipulate, while being soft and fl exible, in order to avoid discomfort after implantation.
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A large variety of biomaterials have been tested for human adipose tissue engineer-
ing purposes, which can be divided into biologically derived materials and synthetic 
materials.
Biologically derived materials (e.g. purifi ed protein components derived from ani-
mal or human tissues such as collagen, fi brin, alginate, Matrigel™ or hyaluronic acid) 
are advantageous because of their inherent properties of being biocompatible and 
biodegradable. Synthetic materials however, provide a greater control over materials 
properties such as microarchitecture. In addition, the absence of animal or human 
substances reduces the risk of pathogen transmission [50,51].
Despite the successful generation of adipose tissue in both biologically derived 
(fi brin, hyaluronic acid, collagen, alginate and Matrigel™) and synthetic materials 
(poly lactic-co-glycolic acid and poly glycolic acid), tissue engineered adipose tissue 
equivalents have not made it into the clinical realm, yet. A critical point is construct size 
owing to limitations in blood supply [49].
BLOOD VESSELS AND BLOOD SUPPLY
Blood vessels carry blood to and from virtually every tissue in the body, assuring meta-
bolic homeostasis by delivering nutrients and oxygen and removing waste products. 
They are essential for tissue maintenance, growth and repair. There are 3 types of 
blood vessels: Vessels that carry blood away from the heart (arteries/arterioles), ves-
sels that facilitate the exchange of nutrients, oxygen and waste products between the 
blood and the tissues (the capillaries) and vessels that carry blood from the capillaries 
towards the heart (venules and veins).
All types of blood vessels consist of an inner endothelial cell lining surrounded 
by mural cells and a basal membrane. Endothelial cells form a barrier between the 
underlying tissue and the blood. They react with physical and chemical stimuli within 
the circulation and are involved in the immune response, coagulation, production of 
extracellular matrix components, and regulation of blood vessel tone. In addition, 
endothelial cells are pivotal in vessel growth.
Studies have shown that not all endothelial cells are alike. Endothelial cells can 
vary between tissues and between arteries and veins, expressing different markers and 
responding differently to similar stimuli [53,54,55,56,57].
Mural cells associate with and coat the endothelial tube. They play an important role 
in blood vessel formation by stabilizing vessel structures and suppressing endothelial 
cell growth. Mural cells are commonly subdivided into vascular smooth muscle cells 
and pericytes. Vascular smooth muscle cells are generally associated with arteries and 
veins. They are not in direct contact with the endothelial cells but are separated from 
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the endothelium through the basal membrane. Pericytes are generally associated with 
smaller diameter blood vessels (capillaries) and share their basal membrane with the 
endothelium [58,59]. The basal membrane surrounds the vascular cells and provides 
structural support. Its major constituents are type IV collagen, laminin, heparin-sulphate 
proteoglycans and nidogen/entactin. Due to different isoforms, quantity and assembly 
of these proteins the basal membrane composition varies from one tissue to another 
[60,61,62].
Figure 3. Composition of different types of blood vessels. Capillaries (top) consist of endothe-
lium surrounded by a basement membrane. They are covered loosely by pericytes. Arterioles and 
venules have an increased coverage of mural cells compared with capillaries. Arterioles are com-
pletely covered by vascular smooth muscle cells. Larger vessels (bottom) are composed of multiple 
layers: an intima, which consists of endothelium, basement membrane and an internal elastic layer; 
a media, which consists of a thick layer of smooth muscle with reticular fi bers (collagen III), elastin 
and proteoglycans; and an adventitia, which consists of fi broblasts with elastic fi bers and colla-
geneous matrix. Veins are characterized by valves preventing backfl ow of blood, whereas arteries 
have strong elastic vessel walls for withstanding the high blood pressures. Adapted from Ondine 
Cleaver & Douglas A. Melton [52].
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VESSEL GROWTH AND MATURATION
Vessels can grow in several ways. Vasculogenesis refers to de novo formation of blood 
vessels from endothelial progenitors, angiogenesis and arteriogenesis refer to sprouting 
and subsequent stabilization of the nascent vascular bed, and collateral growth refers 
to the growth and formation of collateral bridges between arterial networks [63,64,65]. 
During vasculogenesis, endothelial progenitors assemble into a primitive vascular 
labyrinth of small capillaries [65]. It was thought for many years that vasculogenesis 
only occurred during blood vessel development in the embryo. Recent data, however, 
indicate that endothelial progenitors also contribute to vessel growth in the adult. Even 
more, endothelial progenitors can be therapeutically used to stimulate vessel growth 
in ischemic tissues [66,67,68]. Vasculogenesis leads to an immature, poorly functional 
vasculature. It is followed by angiogenesis for growth and remodeling of the primitive 
vascular network into a complex network. During angiogenesis, endothelial cells from 
existing vessel walls degrade their surrounding basement membrane, proliferate and 
migrate into the interstitium resulting in the formation of sprouts [69,70,71].
Vessel maturation is an essential process in blood vessel formation. It involves both 
the maturation of the vessel wall and the maturation of the vessel network. Maturation 
of the vessel wall includes recruitment of mural cells, generation of surrounding matrix 
and elastic laminae and organ specifi c specialization of endothelial cells/mural cells/
matrix. Maturation of the vessel network includes patterning of the nascent vessel 
network by expansion, branching and pruning to meet local demands. Vessel matura-
tion is regulated by a myriad of cell-cell and cell-matrix signaling molecules as well as 
by mechanical forces generated by the circulation. When vessel growth is not followed 
by vessel maturation, a disorganized leaky vasculature will be formed that will generally 
regress over time due to the process of vascular remodeling [72,73].
BLOOD SUPPLY: A PREREQUISITE FOR SURVIVAL OF 
ENGINEERED TISSUES
Living tissues quickly starve without the delivery of oxygen and nutrients to the cells by 
the blood. Any tissue (except for the avascular cornea and cartilage) that is more than 
100-200 μm thick (the oxygen diffusion limit) needs a vascular network to ensure that 
every cell within the tissue is close enough to capillaries to exchange oxygen, nutrients 
and waste products. Hence, engineered adipose tissue constructs that are more than 
a few cells thick require an integrated vasculature for in vivo survival [69,73,74].
During in vitro culture, engineered tissues that have a size above the diffusion 
limit can be supplied with nutrients using perfusion bioreactor systems or microfl uidic 
technologies [75,76,77]. After implantation, however, the spontaneous ingrowth of 
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vessels is often too slow to provide adequate nutrient transport to the cells inside the 
constructs. Therefore, additional strategies to improve vascularization are crucial to 
ensure the survival of thick tissue-engineered constructs [73,78,79].
In the past few years a number of approaches to enhance vascularization within 
engineered tissue constructs have been devised, which will be briefl y explained below: 
(1) angiogenic factor delivery, (2) improving scaffold design, (3) in vivo prevasculariza-
tion and (4) in vitro prevascularization.
ANGIOGENIC FACTOR DELIVERY
Several studies have shown that controlled delivery of angiogenic factors to engineered-
tissue constructs can enhance vessel ingrowth after implantation [16,80,81]. Direct 
(such as VEGF, FGF, PDGF) and indirect (such as Sonic hedgehog) angiogenic agents 
have been used [80,81,82,83] and several strategies for the supply of these agents 
have been developed (such as the addition of recombinant protein, gene transfer and 
angiogenic factor-overexpression) [84,85,86,87]. Despite the development of new 
delivery strategies and the combined use of multiple agents however, vessels induced 
by angiogenic factor delivery are often immature and leaky [73]. A suboptimal mix of 
agiogenic agents and/or a suboptimal fashion of delivery likely cause this. Finding 
the optimal cocktail of molecules and delivering them in the optimal fashion remain 
therefore major challenges in this area of research.
IMPROVING SCAFFOLD DESIGN
The architecture of the scaffold used in tissue constructs signifi cantly affects blood 
vessel ingrowth. Highly porous scaffolds with pore sizes of ≥ 250 μm and high pore 
interconnectivity facilitate cell migration and vascularization [88,89,90]. Other than 
designing porous scaffolds, different strategies to enhance vascularization due to 
scaffold design have been employed. For instance, microfabrication techniques 
(such as Micro Electro Mechanical Systems or MEMS) have been used to fabricate 
microchannel networks within degradable biomaterials. Such microchannel networks 
can be seeded with endothelial cells in vitro, resulting in a capillary network that can 
be perfused in vivo [16,91,92]. In addition, scaffolds can be coated with angiogenic 
matrices such as fi brin and Matrigel™ [93,94,95,96]. The main purpose of a scaffold 
in tissue engineering is supporting attachment and growth of tissue cells. Since the 
requirements for supporting tissue vascularization and tissue development do not 
necessarily correspond, designing a scaffold that promotes both vascularization and 
development/growth of cells is a challenging task.
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IN VIVO PREVASCULARIZATION
This method involves wrapping a vascularized soft-tissue fl ap around the tissue con-
struct or inserting a vascular pedicle or loop within the tissue construct. Following an in 
vivo incubation period, the tissue construct is vascularized by a process of angiogenic 
outgrowth. Then, the vascularized tissue construct can be transferred to the desired 
location and its vascular network connected to the local vasculature using microsurgi-
cal techniques [83,97,98,99]. An advantage of this in vivo technique is that when the 
tissue construct is implanted at its fi nal location, it can be perfused immediately due to 
surgical anastomosis. The limitations of this technique however, are that two surgical 
procedures are necessary, a vascular loop is removed from its original location and 
extra cells may need to be seeded at the defect site, since oxygen/nutrient defi ciencies 
are likely during the vascularization period at the initial implantation site [79].
IN VITRO PREVASCULARIZATION
This method involves prefabrication of vascular structures within tissue constructs 
prior to implantation. When cultured under the right conditions and in the appropriate 
environment, endothelial cells are able to form vascular structures in vitro. For in vitro 
prevascularization, target cells and cellular components of vessel walls (endothelial 
cells and perivascular cells) are cocultured in a three-dimensional matrix, to obtain an 
engineered tissue equivalent with a primitive vascular network. This vascular network 
can then anastomose to ingrowing host blood vessels, reducing the time for vascular-
ization of the entire construct [73,79,100,101].
The fi rst three approaches mentioned above solely rely on spontaneous vessel 
ingrowth postimplantation. During this time, oxygen/nutrient transport to the cells 
is completely dependent on diffusion, which is inadequate to support cells deeper 
(that is deeper than the diffusion limit of 100 to 200 μm) within the implant. The in 
vitro prevascularization approach that includes a vascular network within the tissue 
construct in vitro, potentially overcomes this limitation. In this approach however, rapid 
anastomosis of the engineered vascular structures and those of the host is critical.
THESIS AIM AND OUTLINE
The aim of this thesis is twofold:
– To explore the angiogenic and vasculogenic potential of ASC in different tissue 
engineering settings and
– To investigate the potential positive effect of in vitro prevascularization on the 
vascularization of ASC-based adipose tissue constructs.
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Chapter 2: Although multiple studies have shown that ASC can release factors that 
stimulate blood vessel growth [102,103,104], detailed information about the effects of 
adipogenic differentiation on the angiogenic potential of ASC remains largely unknown. 
In this chapter we started out investigating the expression and secretion of a large 
panel of angiogenic factors during ASC differentiation and evaluated the effects of 
ASC-conditioned medium on endothelial cells.
Chapter 3: Another parameter infl uencing ASC behavior and vascularization of ASC-
based adipose tissue constructs is the extracellular environment. Various biomaterials 
have been combined with ASC for adipose tissue engineering purposes [49]. Consider-
ing limitations associated with synthetic and exogenous matrix-based tissues, we were 
interested in the use of scaffold/biomaterial-free ASC constructs for adipogenesis. In 
this chapter, we compared scaffold-free ASC-based adipose tissue constructs with 
another promising method that makes use of fi brin as a scaffold material. We evaluated 
in vivo construct adipogenic differentiation and vascularization. Additionally, we deter-
mined the impact of scaffold-free and fi brin-based environments on ASC adipogenic 
differentiation and their secretion of angiogenic factors in vitro.
Chapter 4: In this chapter we explored the supportive role of ASC in de novo vessel 
formation in vitro. We hypothesized that ASC can support the formation of vascular 
structures in engineered tissue constructs. Using a three-dimensional coculture system 
of ASC and endothelial cells we assessed the ability of ASC to support the formation 
of vascular-like structures from endothelial cells in vitro. In addition, we studied the 
mechanisms leading to the support of the formation of vascular structures in vitro.
Chapter 5: In the past few years a number of new approaches to promote the 
vascularization of implanted tissue constructs have been devised, such as optimi-
zation of scaffold architecture, the controlled release of angiogenic factors and the 
prefabrication of vascular structures within tissue constructs in vitro, also referred to 
as prevascularization. Although prevascularization has yielded promising results in 
skin, skeletal muscle and bone tissue constructs [100,105,106], the contribution of 
prevascularization in adipose tissue constructs has not been tested yet. The aim of 
this chapter was to generate prevascularized adipose tissue constructs by coculturing 
ASC and endothelial cells in spheroids, and to establish a proof of principal for the 
expected positive effect of prevascularization on in vivo vascularization of adipose 
tissue constructs.
Chapter 6: The in vivo results as described in chapter 5 pointed out that prevascu-
larization holds promising possibilities for adipose tissue engineering. Although the 
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small spheroid tissue constructs used in chapter 5 have been shown to form bigger 
tissue patches of mm3 scale [107,108], we reasoned that it is likely that the use of 
a scaffold material is needed to produce prevascularized adipose tissue equivalents 
of more clinically relevant dimensions (cm3 scale). Fibrin-based constructs can easily 
be scaled-up, and as described in chapter 4, positively affect ingrowth of host blood 
vessels. The aim of this chapter was to generate prevascularized fi brin-based adipose 
tissue constructs and to compare the in vivo vascularization of these constructs with 
the in vivo vascularization of non-prevascularized ASC-only fi brin-based constructs.
Chapter 7: In this fi nal chapter the main results described in this thesis are discussed 
and suggestions for further research are offered.
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ABSTRACT
Background: Improving vascularization of engineered adipose tissue constructs is 
a major challenge in the fi eld of plastic surgery. Although human adipose–derived 
stromal cells (hASCs) are known to release factors that stimulate new blood vessel 
formation, detailed information about the effects of adipogenic differentiation on 
the angiogenic potential of hASCs remains largely unknown. In the present study, 
we studied the expression and secretion of a large panel of angiogenic factors dur-
ing hASC differentiation and evaluated the effects of hASC-conditioned medium 
(hASC-CM) on endothelial cells (EC).
Methods: hASC were cultured on adipogenic medium or basal medium. Conditioned 
medium was collected and cells were harvested following 0, 3, 7, 14 and 22 days 
of culture. The stage of adipogenic differentiation of hASC was assessed using Oil 
Red O staining, fatty acid binding protein-4 gene expression (FABP4) and glycerol-
3-phosphate dehydrogenase (GPDH) activity.
Results: Gene expression of vascular endothelial growth factor (VEGF), placental 
growth factor (PGF), angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2) and protein 
secretion of VEGF signifi cantly increased during short-term adipogenic differentia-
tion of hASCs. Moreover, conditioned medium from differentiated hASCs strongly 
enhanced EC numbers compared to conditioned medium from undifferentiated 
hASCs
Conclusion: In vitro adipogenic differentiation of hASCs improves their ability to 
support endothelial viable cell numbers and suggests that hASCs differentiated for 
a short period potentially improve angiogenic responses for in vivo implantation.
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INTRODUCTION
The restoration of soft tissue contour defects remains a major challenge in plastic 
surgery. Soft tissue defects result, for example, after oncological resection or complex 
trauma or from congenital or acquired adipose atrophy [1,2]. Current reconstruc-
tive methods all have intrinsic disadvantages: large tissue transfers give donor site 
morbidity; foreign material injections or implants give unpredictable host responses; 
autografting of fat pads or injections of adipocyte cell suspensions give unsatisfactory 
results due to limited fat graft survival and necrosis [3,4]. Adipose tissue engineer-
ing using mesenchymal stem cells has been suggested as a promising technique for 
reconstruction of soft tissue defects. Mesenchymal stem cells derived from adipose 
tissue, also referred to as preadipocytes or adipose-derived stromal cells (ASC) are 
considered a feasible cell source for adipose tissue regeneration as they are easily 
obtained, expanded and differentiated to adipocytes [5,6]. Indeed, various studies 
have shown that in vivo implantation of hASCs is useful for fat pad formation [7,8,9,10]. 
However, long-term maintenance of tissue-engineered adipose tissue still remains 
elusive. Similar to autologous fat transplantation procedures, there is an apparent 
resorption of engineered adipose tissue over time. The absence of an adequate blood 
supply is thought to be the main cause for this progressive resorption of adipose tissue 
constructs [7,11,12,13].
Recently, several groups demonstrated that the ASC fraction of human adipose 
tissue is able to secrete numerous factors involved in new blood vessel formation 
[14,15,16,17]. In vitro adipogenic differentiation of these cells before implantation may 
infl uence their angiogenic activity as shown for the murine 3T3-F442A cell line [18,19], 
and subsequently affect their ability to stimulate blood vessel ingrowth in tissue engi-
neered constructs. Details about the angiogenic activity of human primary ASCs during 
adipogenic differentiation are unknown. The aim of this study was to investigate the 
changes in expression and secretion of important angiogenic factors during adipogenic 
differentiation of hASCs and to evaluate whether differences between undifferentiated 
and differentiated cells affect endothelial viable cell numbers in vitro.
MATERIALS AND METHODS
CHEMICALS AND MEDIA
Dulbecco’s modifi ed Eagle Medium 1g/l glucose (LG-DMEM) and 4.5 g/l glucose (HG-
DMEM), human endothelial-SFM medium, penicillin/streptomycin, collagenase type I 
and trypsin/ ethylenediaminetetraacetic acid (EDTA) were purchased from Invitrogen 
(Carlsbad, California). Fetal bovine serum (FBS) was purchased from PAA Laboratories 
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Gmbh (Cölbe, Germany). Human serum was purchased from Lonza (Verviers, Belgium). 
Bovine serum albumin (BSA) and other chemicals were from Sigma-Aldrich (Zwijndre-
cht, The Netherlands). Insulin was from Eli Lilly (Indianapolis, Indiana) and Fibroblast 
growth factor (FGF-2) and epidermal growth factor (EGF) were from Peprotech EC Ltd. 
(London, United Kingdom).
ISOLATION AND CULTURE OF HASCS
For this study, hASCs were isolated from breast or abdominal adipose tissue that was 
obtained from 4 donors, aged 23 (donor 1), 45 (donor 2), 58 (donor 3) and 37 (donor 
4) and with BMI values ranging from 24.8-30.4. Adipose tissue was received with ap-
proval of the Medical Ethical Committee (# MEC-2005-157). Excised human adipose 
tissue was washed with 70% (v/v) ethanol and LG-DMEM, minced and digested in 
sterile-fi ltered 0.1% collagenase type I solution in the presence of 1% bovine serum 
albumin. The mixture was suspended in LG-DMEM at 37˚C for 60 minutes in an orbital 
shaker. Human ASCs were isolated by differential centrifugation, washed with medium 
(LG-DMEM, 10% FCS, 1% penicillin/streptomycin, 0.5% gentamycin), fi ltered through 
a 100 μm mesh and grown in basal medium; i.e. medium supplemented with 10-12 M 
dexamethasone and 10-5 M ascorbic acid.
After 24 hours, cultures were washed with PBS with 2% FBS to remove erythro-
cytes and replenished with basal medium. The isolated hASCs were cultured at 37ºC in 
a humid atmosphere with 5% CO2 until they reached 90% confl uence. At 90% confl u-
ence, adherent cells were released with 0.5% trypsin-EDTA and then either replated at 
a density of 5.7 x 103 cells/cm2 or used in the experimental set-up.
IN VITRO ADIPOGENIC DIFFERENTIATION EXPERIMENTAL SET UP
First and second passage hASCs used in the experimental set-up were phenotypically 
characterized and plated at confl uence with a density of 2.0 x 104 cells/cm2 in basal 
medium and allowed to adhere overnight. Subsequently, cells were either replenished 
using basal medium or adipogenic medium (HG-DMEM, 10% FBS, 1μM dexametha-
sone, 0.01 mg/ml insulin, 0.2 mM indomethacin, 0.5 mM 3-isobutyl-I-methyl-xanthine, 
1% penicillin/streptomycin and 0.5% gentamycin). Cells were grown at 37ºC in a 
humid atmosphere with 5% CO2. Medium was refreshed every 2-3 days and 24 hours 
before each measurement. Cell and medium samples were collected at day 0, 3, 7, 14 
and 22 and adipogenic differentiation was assessed using Oil Red O staining, glycerol-
3-phosphate dehydrogenase (GPDH) activity and the gene expression levels of fatty 
acid binding protein 4 (FABP4).
In addition, differences in angiogenic capacity were evaluated by the gene expres-
sion of vascular endothelial growth factor (VEGF), fi broblast growth factor 2 (basic) 
(FGF-2), placental growth factor (PGF), platelet derived growth factor B (PDGFB), 
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transforming growth factor beta 1 (TGFß1), angiopoietin 1 (ANGPT1) and angiopoietin 
2 (ANGPT2) using quantitative RT-PCR, by the protein secretion of VEGF, PGF, ANGPT1 
and ANGPT2 using sandwich ELISAs and by the ability of the conditioned medium to 
stimulate endothelial cell survival using the MTT assay.
FLOW CYTOMETRIC CHARACTERIZATION OF HASCS
Early passage hASCs were washed and labeled for 30 minutes on ice with mouse anti-
human monoclonal fl uorescently labeled antibodies directed against CD34, CD105, 
CD90, CD144 (dilutions according to manufacturer’s instructions, R&D systems, 
Abingdon, United Kingdom) and CD31 (Chemicon, Huissen, The Netherlands). Cells 
were directly analyzed on a FACS-Calibur instrument (Becton-Dickinson, Franklin 
Lakes, New Jersey, www.bd.com).
OIL RED O STAINING
A 0.5% (w/v) stock solution of Oil Red O in isopropanol was diluted 3:2 with distilled 
water to prepare an Oil Red O working solution. Following 3, 7, 14 and 22 days of 
culturing, hASCs were rinsed with PBS, fi xed in 10% formalin in PBS for 10 minutes 
and stained for 15 minutes with 1 ml Oil Red O working solution. Then, cells were 
washed with 1ml distilled water to remove excess of Oil Red O solution. The adipogenic 
cells were identifi ed by accumulation of cytoplasmatic lipid vesicles. Representative 
pictures of Oil Red O stained cells within three different fi elds of one well of a 6-well 
tissue culture plate were taken using an inverted microscope (Nikon, Badhoevedorp, 
The Netherlands, www.nikon.com) at a 200x magnifi cation. These pictures were used 
to determine the number of hASCs with Oil Red O staining as percentage of the total 
number of cells within each picture using NIH ImageJ software. Statistical compari-
sons were performed with the two-way ANOVA (SAS software, SAS Institute Inc., Cary, 
North Carolina).
GLYCEROL-3-PHOSPHATE DEHYDROGENASE ACTIVITY
Glycerol-3-phosphate dehydrogenase (GPDH) activity was determined using the GPDH 
activity assay kit (Takara Mirus Bio, Otsu, Shiga, Japan) according to manufacturer’s 
instructions with slight modifi cations: Briefl y, cells were lysed with enzyme extraction 
buffer and centrifuged at 4ºC to separate the aqueous fraction from the fat fraction. 
Immediately after separation the aqueous fraction was stored at 4ºC and a 2-8 times 
serial dilution of the aqueous fraction with dilution buffer (supplemented with 0.1M ß-
mercaptoethanol) was prepared. The calibration curves were made using a 1% GPDH 
(Roche, Mannheim, Germany) solution in dilution buffer. GPDH activity was measured 
under zero-order kinetics at 25ºC in a Victor 2 Wallac spectrophotometer (PerkinElmer, 
Gouda, The Netherlands, www.perkinelmer.com). The reaction was initiated by addi-
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tion of 25 μl of the samples to 100 μl of substrate solution. The rate of NADH oxidation 
was measured by a decrease in absorbance at 340nm. One unit of GPDH activity 
corresponded to oxidation of 1 μmol NADH per minute. After assessing the GPDH 
activity, the aqueous fraction of the cell lysate was used to determine total protein 
with the Quant-it protein assay (Invitrogen, Carlsbad, California). GPDH activity values 
were corrected for total cellular protein and are expressed as mean ± SEM. Statistical 
analysis was performed using the mixed model ANOVA (SAS software)
RNA ISOLATION AND COMPLEMENTARY DNA (CDNA) SYNTHESIS
 RNA was extracted from non-differentiating and differentiating hASCs cultured for 0, 
3, 7, 14 and 22 days using Qiazol Lysis Reagent (Qiagen Benelux, Venlo, The Nether-
lands). Total RNA extraction was performed by adding 1/5 volume of chloroform per 1 
ml of Qiazol followed by 2-propanol precipitation.
Total RNA was quantifi ed by spectrophotometric analysis at wavelengths of 260nm 
and 280nm and RNA purity was determined by calculating the 260:280 ratio. One 
microgram RNA was reverse transcribed into cDNA using the Fermentas RevertAid™ 
First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according to 
manufacturer’s protocol. A 20 nanogram RNA equivalent was used for amplifi cation.
QUANTITATIVE PCR
The mRNA levels of FABP4 and angiogenic factors were analyzed with the ABI PRISM® 
7000 Sequence Detection System and 7000 System SDS software (ABI, Foster City, 
California, www.appliedbiosystems.com), using Taqman®Gene Expression Assays for 
FABP4 (Hs00609791_m1), VEGF (Hs00173626_m1), FGF-2 (Hs00266645_m1), PGF 
(Hs00182176_m1), PDGFB (Hs00234042_m1), TGFß1 (Hs00171257_m1), ANGPT1 
(Hs00181613_m1) and ANGPT2 (Hs 00169867) (ABI) according to the manufacturer’s 
instructions. Two-step thermal cycling parameters were 10 minutes at 95 ˚C, followed 
by 40 cycles of 15 seconds at 95 ˚C and 1 minute at 60 ˚C. Beta-2-microglobulin (B2M) 
mRNA levels were analyzed with the qPCR Master Mix Plus for SYBR® Green I dTTP 
(Eurogentec, San Diego, California) and the following, gene-specifi c primers set: Fw 
5’-TGCTCGCGCTACTCTCTCTTT -3’, Rv 5’-TCTGCTGGATGACGTGAGTAAAC-3’). As 
the expression of this gene was stable between experimental conditions, we used 
B2M for data normalization. These delta-Ct (dCt) values were then normalized to their 
Ct values in the samples taken at day 0 to obtain the delta delta-Ct (ddCt) values. 
Statistical analysis was performed by using the mixed model ANOVA (SAS software).
Femke BW.indd   32 26-11-10   13:19
33
Angiogenic capacity of human adipose-derived stromal cells
HASCS CONDITIONED MEDIA COLLECTION, PREPARATION AND 
ANALYSIS
On days 2, 6, 13 and 21 of culture hASCs were switched to fresh, low serum (0.5% 
FCS) basal medium or adipogenic medium and incubated at 37˚C and 5% CO2 for 24 
hours. Then, conditioned media were collected and centrifuged at 400xg for 5 minutes 
at 4˚C. The concentration of hASCs-secreted angiogenic factors in the conditioned 
medium was measured using commercially available sandwich ELISA kits according 
to manufacturer’s instructions (VEGF, PGF, ANGPT1 and ANGPT2; R&D systems). 
After media collection, cells were lysed with PBS with 0.1% Triton and total protein 
determined with the MicroBCA protein assay (Pierce, Pittsburgh, Pennsylvania). ELISA 
values are expressed as mean ± SEM picograms of the secreted factor per microgram 
total cellular protein. Statistical analysis was performed by using the mixed model 
ANOVA (SAS software).
EVALUATION OF BIOACTIVITY OF HASC CONDITIONED MEDIA
Isolated human umbilical vein endothelial cells (HUVEC) at passage 4 or less were 
seeded at a density of 5000 cells per well in fi bronectin coated 96-well plates and 
cultured for 24 hours in human endothelial-SFM medium supplemented with 20% FBS, 
10% human serum, 20 ng/mL FGF-2, and 100 ng/mL EGF. The next day, these cells 
were starved with HG-DMEM supplemented with 0.5% FBS. Twenty-four hours later, 
the HUVEC were refreshed with either fresh low serum (0.5%) basal or adipogenic 
medium, or conditioned low serum basal or adipogenic medium that had been har-
vested previously from hASCs. After 24 hours endothelial viable cell numbers were 
determined with the MTT viability assay based on the Mossman’s protocol [20]. Briefl y, 
3 hours before the end of the incubation 50 μl MTT reagent (3mg/ml) was added to the 
medium.
After incubation the medium was removed and the formazan crystals were dis-
solved in 100 μl DMSO and the optical density was read at 510nm in the Victor 2 
Wallac spectrophotometer (PerkinElmer). The optical densities obtained from low 
serum unconditioned media HUVEC cultures used as a control was set to 100% for 
comparative purposes. The optical densities of HUVEC cultured on conditioned media 
were expressed as a percentage of the optical densities measured in the corresponding 
unconditioned media. Statistical comparisons were performed with the Mixed model 
ANOVA (SAS software).
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RESULTS
CHARACTERIZATION OF HASCS
Since isolation and culture can affect the immunophenotype of primary hASCs [21,22], 
fl ow cytometry analysis of the hASCs used in this study was performed. FACS analysis 
demonstrated that the percentage of cells positive for the stromal mesenchymal cell 
markers CD105 (97.6% ± 1.8%) and CD90 (74% ± 15.3%) and the hematopoietic 
progenitor marker CD34 (85.1% ± 16%) was high. The percentage of cells positive for 
the endothelial markers CD144 (14.7% ± 7.8%) and CD31 (7.4 ± 2.8%) on the other 
hand, was low (data not shown).
A1 A2
B
Figure 1. HASCs differentiated toward the adipogenic lineage accumulate intracellular lipid droplets 
and display adipocyte-specifi c GPDH activity and FABP4 expression. (A) Images of differentiated and 
undifferentiated hASCs after fi xation and staining with Oil Red O at day 14 of culture (magnifi cation: 
200x). Differentiating hASCs (A.1) showed a round morphology and accumulation of intracellular red 
stained lipid droplets, while non-differentiating hASCs (A.2) maintained their spindle like shape and 
had minimal to no intracellular lipid droplet formation. (B) The percentage of hASCs with lipid droplet 
accumulation was determined by counting the cells positively stained with Oil Red O in pictures taken 
of representative fi elds within a well of a 6-well tissue culture plate (see Materials and Methods sec-
tion). Until day 14, a signifi cant increase in the amount of cells with lipid droplet accumulation was 
observed. The hASC % was calculated as percentage of the total number of cells within each fi eld. 
Values are expressed as mean ± SEM; n= 4 donors. Statistical comparisons were performed with 
the two-way ANOVA.*P<0.05, ***P<0.0005, ****P<0.0001. (see color section for a full-color version)
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HASCS CULTURED IN ADIPOGENIC MEDIUM SHOW ADIPOCYTE-
SPECIFIC CHARACTERISTICS
OIL RED O STAINING
Accumulation of lipid-containing vesicles in the cytoplasm is widely believed to be a 
prominent characteristic of adipogenic differentiation. After 3 days of differentiation, 
intracellular lipid droplet accumulation was fi rst observed in 38.5% ± 5.6% of the 
hASCs in all donors (Fig.1A.1), while the hASCs that were cultured on basal medium 
kept their spindle like shape and accumulated no small lipid droplets in the cytoplasm 
(Fig.1A.2). Until day 14, there was a signifi cant increase in the amount of cells with lipid 
droplet accumulation (Fig.1B).
GLYCEROL-3-PHOSPHATE DEHYDROGENASE ACTIVITY.
Another important feature of differentiated adipocytes is the secretion of the cytosolic 
enzyme GPDH, the activity of which in differentiating hASCs of one donor (= donor 2) 
was observed as early as 3 days after the start of differentiation. For the other donors, 
GPDH activity was fi rst observed in hASCs at the measurement on day 7. Highest 
GPDH activity in hASCs of all donors was seen at day 14. This peak was then followed 
by a decrease in enzyme activity at day 22 (Fig.1C). No detectable GPDH activity was 
measured at any time point in hASCs cultured on basal medium.
C D
(C) The GPDH activity in hASCs differentiated in tissue culture was directly measured by the rate 
of NADH oxidation (see Materials and Methods section). The hASCs cultured on adipogenic me-
dium displayed prominent NADH oxidation from day 7 until day 22, while NADH oxidation in un-
differentiated hASCs was not detectable. Values were corrected for total cellular protein and are 
presented as mean ± SEM; n= 4 donors. Statistical comparisons were performed with the Mixed 
model ANOVA.****P<0.0001 (compared to undifferentiated hASCs). (D) Quantitative PCR was used 
to measure the expression levels of the adipocyte specifi c gene FABP4. Differentiating hASCs dis-
played high expression levels of FABP4 that increased in time, while non-differentiating hASCs 
displayed very low FABP4 expression levels. Expression levels are relative to beta-2-microglobulin 
positive-control housekeeping gene and to the expression level at day 0 (ddCt). Values are pre-
sented as mean ± SEM; n= 4 donors. Statistical comparisons were performed with the Mixed model 
ANOVA. **P<0.01, ***P<0.0005, ****P<0.0001 (compared to undifferentiated hASCs).
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FABP4 EXPRESSION
PPARγ activation is considered to be an absolute requirement for the differentiation 
of adipose tissue [23,24]. The adipocyte-specifi c FABP4 gene is a downstream target 
of PPARγ activation and is the most widely used adipocyte differentiation marker [25]. 
We used the expression of the FABP4 gene to further confi rm the differentiation of the 
hASCs cultured on adipogenic medium. The expression of FABP4 in differentiating 
hASCs was fi rst observed at day 7 and increased in time. In contrast, FABP4 expres-
sion was not observed in non-differentiating hASCs, except for one donor (= donor 2) 
and here only at days 7 and day 22 (Fig.1D)
ASSESSMENT OF ANGIOGENIC FACTORS IN DIFFERENTIATING AND 
PROLIFERATING HASCS
GENE EXPRESSION
To study the effect of differentiation on the angiogenic capacity of hASCs, expres-
sion of a series of important angiogenic factors was measured in both differentiating 
and non-differentiating hASCs. Expression in differentiating hASCs was increased for 
ANGPT1 and ANGPT2, with elevated peaks at days 7 and 14, and for VEGF and PGF, 
starting from day 7. No changes in the expression profi le between differentiating and 
non-differentiating hASCs was found for FGF-2, PDGFB and TGFβ1 (Fig.2).
PROTEIN SECRETION
To determine whether the increase on mRNA levels of VEGF, PGF, ANGPT1 and ANGPT2 
in differentiating hASCs resulted in a similar increase in corresponding polypeptides, 
the concentrations of these proteins were measured in 24 hour conditioned media. The 
amount of VEGF secreted by non-differentiating hASCs was decreased at days 7 and 
14, while the secretion of VEGF in differentiating hASCs was elevated at day 7.
These changes resulted in a 5-fold higher VEGF secretion in differentiating hASCs 
compared to non-differentiating hASCs at day 7 [0.344 ± 0. 086 pg/μg protein versus 
0.061 ± 0.033 pg/μg protein, (P<0.0002, n=3)] and day 14 [0.244 ± 0.086 pg/μg protein 
versus 0.053 ± 0.054 pg/μg protein, (P<0.0122, n=3)). Unlike to VEGF, the different 
transcript abundances of PGF, ANGPT1 and ANGPT2 in differentiating and non-differ-
entiating hASCs were not refl ected in the protein secretion profi les. Enhanced secretion 
of ANGPT2 became apparent at day 22 [0.068± 0.045 pg/μg protein versus 0.011 ± 
0.021 pg/μg protein in non-differentiating hASCs (P<0.0051, n=3) of culture while the 
gene expression of ANGPT2 in differentiating hASCs was enhanced at day 7 and 14 of 
culture. Also, the secreted amounts of PGF and ANGPT1 between differentiating and 
non-differentiating hASCs did not differ signifi cantly (Fig.3). None of the angiogenic 
factors were detected in unconditioned basal culture media (data not shown).
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B
A
Figure 2. Differentiating hASCs express higher levels for VEGF, PGF, ANGPT1 and ANGPT2 com-
pared to non-differentiating hASCs. Real-time quantitative PCR was used to compare the expres-
sion patterns of a series of angiogenic genes between differentiating and non-differentiating hASCs. 
(A) Differentiated hASCs had signifi cantly higher expression levels of ANGPT1 and ANGPT2 at days 
7 and 14 after induction and of VEGF and PGF at days 7, 14 and 22 after induction. (B) The expres-
sion levels of FGF-2, TGFβ1 and PDGFB did not signifi cantly differ between differentiating and 
non-differentiating hASCs. Expression levels are relative to beta-2-microglobulin positive-control 
housekeeping gene and to the expression level at day 0 (ddCt). Values are means ± SEM; n= 4 
donors. Statistical comparisons were performed with the mixed model ANOVA. *P<0.05, **P<0.01, 
***P<0.0005 (compared to undifferentiated hASCs).
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EFFECTS OF HASC-CONDITIONED MEDIUM ON ENDOTHELIAL VIABLE 
CELL NUMBERS
To verify the activity of angiogenic factors secreted in the conditioned medium, the 
effects of hASC-conditioned medium (hASC-CM) on human endothelial cell growth 
were measured. Conditioned medium of non-differentiating hASCs collected at day 
3 gave equal viable cell numbers compared to unconditioned medium. Also, non-
Figure 3. Increased secretion of VEGF by differentiating hASCs at day 7 and 14 of culture.
The secretion of VEGF, PGF, ANGPT1 and ANGPT2 by differentiating and non-differentiating hASCs over 
24 hours was measured by ELISA at day 0, 3, 7, 14 and 22 of culture. (A) Differentiated hASCs secrete a 
signifi cantly higher amount of VEGF at day 7 and 14 of culture than undifferentiated hASCs. (B) Except 
for the increased ANGPT2 secretion of differentiating hASCs at day 22 of culture, the differences in the 
secretion of PGF, ANGPT1 and ANGPT2 between differentiating and non-differentiating hASCs were not 
signifi cant. Values were corrected for total cellular protein and are presented as mean ± SEM; n= 3 donors. 
Statistical comparisons were performed with the Mixed model ANOVA. *P<0.05, ***P<0.0005 (compared 
to undifferentiated hASCs).
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differentiating hASC-CM from days 7 and 14 slightly diminished endothelial cell num-
bers. In contrast, differentiating hASC-CM harvested at days 3, 7 and 14 resulted in 
higher endothelial cell numbers compared to unconditioned medium (Table 1). These 
fi ndings indicate that hASC adipogenic differentiation for 3 to 14 days positively affects 
endothelial viable cell numbers.
Table 1. Percentage viable HUVEC after 24 hours of incubation with conditioned medium from dif-
ferentiating and non-differentiating hASCs.
Conditioned mediuma
3 days 7 days 14 days 22 days
Differentiating
hASCs
136% ±13%b 119% ± 5.6%b 122% ± 8.4%b 110% ± 10%
Non-differentiating
hASCs
99% ± 5.2% 91% ± 4.9% 79% ± 5% 100% ± 5%
a) Low serum conditioned medium (CM) of differentiating and non-differentiating hASCs collected after 
3, 7, 14 and 22 days of culture. Viable cell numbers were measured using the MTT assay. Effects of con-
ditioned medium of differentiating and non-differentiating hASCs on endothelial viable cell numbers are 
shown as a percentage of the viable cell numbers measured in the corresponding unconditioned media 
(percentages are expressed as mean ± SEM; n=4 donors).
b) P<0.01 (versus percentage HUVEC cultured in CM of non-differentiating hASCs of the same culture day).
DISCUSSION
In the present study, we demonstrated that multiple angiogenic factors are expressed 
and secreted by both non-differentiating and differentiating human adipose-derived 
stromal cells in vitro. Unlike previous studies we were specifi cally interested in de-
termining how much better, if at all, differentiating hASCs could express and secrete 
these angiogenic factors when compared with non-differentiating hASCs. In addition, 
we aimed to evaluate the effects of non-differentiating and differentiating hASC- con-
ditioned medium on endothelial viable cell numbers in vitro.
In order to be able to relate hASC adipogenic differentiation and hASC angiogenic 
capacity, we evaluated adipogenic differentiation of hASCs for the fi rst time in a timeline 
manner using three different parameters of adipogenic differentiation [i.e. intracellular 
lipid droplet accumulation (as detected by Oil Red O), activity of GPDH and expression 
of FABP4 mRNA]. Using our isolation procedure, and culture conditions, we found 
that our CD34+/ CD90+/ CD105+ hASCs consistently differentiated into adipocytes 
following 3 days of adipogenic induction. In one donor FABP4 was also expressed in 
non-differentiating hASCs on day 7 and 22. It is known that basal transcription levels of 
FABP4 in undifferentiated hASCs differ between donors and even clones [26]. This may 
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be an explanation for the relatively high basal FABP4 expression in the undifferentiated 
hASCs cultures of this one donor.
The in vivo induction and control of neovascularization is complicated, as a myriad 
of angiogenic factors is needed for sprouting and subsequent vessel stabilization [27]. 
We therefore analyzed the expression of several angiogenic factors that are involved in 
both the sprouting [VEGF, PGF, FGF-2, ANGPT2] and the maturation of vessels [PDGFB, 
TGFβ1, ANGPT1] by hASCs, before and during differentiation. In addition, we analyzed 
the secretion of VEGF, PGF, ANGPT1 and ANGPT2 during hASC differentiation. Gene 
expression analysis showed that adipogenic induction of hASCs for 7 and 14 days sig-
nifi cantly increased the expression levels of both the sprouting factors VEGF, PGF and 
ANGPT2 and the maturation factor ANGPT1. Gene expression and protein secretion are 
not necessarily correlated. Discrepancies may be due to regulatory mechanisms at the 
(post-) transcriptional or the secretory level of the protein under investigation. Nonethe-
less, the protein analyses of hASC-conditioned medium demonstrated that the secretion 
of the VEGF protein was signifi cantly higher after 7 and 14 days of adipogenic induction.
The above-described results suggested that short-time in vitro differentiated hASCs 
may have a higher angiogenic capacity than undifferentiated hASCs. To investigate 
this further, we obtained conditioned medium from cultured hASCs before and during 
adipogenic differentiation and found that conditioned medium of hASCs differentiated 
for 3, 7 and 14 days signifi cantly improved endothelial viable cell numbers in vitro, 
compared to undifferentiated hASCs. Since only VEGF secretion was signifi cantly 
increased in differentiated hASCs when compared to undifferentiated hASCs, it is 
likely that this growth factor is mainly responsible for the higher viable endothelial cell 
numbers after incubation in conditioned medium obtained from differentiated hASCs. 
However, we can not exclude the infl uence of other growth factors and metabolites 
that were not monitored in this study (such as hepatocyte growth factor, granulocyte 
macrophage colony-stimulating factor and 1-butyryl glycerol [14,28].
Taken together, our results indicate for the fi rst time that short, adipogenic dif-
ferentiation of primary human ASCs is benefi cial for endothelial viable cell numbers 
in vitro. This is in agreement with studies directed at in vivo adipogenesis. In these 
studies, ASC differentiation (in mice) was linked to the sprouting of new blood vessels 
from the preexisting vasculature in intact living adipose tissue [29]. Also, impaired dif-
ferentiation of hASCs, by suppression of PPARγ activation, has been shown to prevent 
angiogenesis [30].
Adipose tissue formation, survival and especially vascularization are the most 
important requirements for achieving clinical success in cell-based adipose tissue 
engineering. Our study indicates an increase in endothelial viable cell numbers when 
cultured on conditioned medium of shortly differentiated hASCs, suggesting that short-
term adipogenic differentiation of hASCs may be benefi cial with respect to stimulation 
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of the vascularization of the transplant. However, the possibility of improving in vivo 
vascularization of hASC implants by short in vitro adipogenic differentiation of hASCs 
needs to be confi rmed by further in vivo studies, which was beyond the scope of the 
present project.
The development and clinical application of in vitro engineered adipose tissue 
constructs is still a futuristic goal. For engineered adipose tissue constructs to become 
a viable option for future clinical use, they must be able to survive and maintain their 
shape in vivo. For this, the presence of an adequate blood supply is a prerequisite. 
Several approaches to improve vascularization in tissue-engineered constructs have 
been used and suggested, including: surgical insertion of a pre-existing vessel network 
into the construct [31], surrounding the tissue construct with a highly vascularized 
tissue fragment (i.e. omentum) [32], and in vitro assembly of a vessel network in the tis-
sue construct by co-culturing with endothelial cells [33,34]. We believe that combining 
such techniques with a short in vitro adipogenic differentiation of hASCs may improve 
the long-term survival of adipose tissue constructs.
CONCLUSION
In summary, our data demonstrate that adipogenic differentiation of hASCs for a period 
of 7 to 14 days improves their angiogenic capacity, as demonstrated by increased 
gene expression of VEGF, PGF, ANGPT1, ANGPT2 and increased protein secretion of 
VEGF. Additionally, conditioned medium of shortly differentiated hASCs enhanced the 
endothelial viable cell numbers in vitro, suggesting that short adipogenic-differentiated 
hASCs are potentially the better choice for adipose tissue engineering applications.
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ABSTRACT
Success of adipose tissue engineering for soft tissue repair has been limited by 
insuffi cient adipogenic differentiation, an unfavorable host response and insuffi cient 
vascularization. In this study, we examined how scaffold-free spheroid and fi brin-
based environments impact these parameters in human adipose-derived stromal 
cell (ASC)-based adipose constructs. ASC were differentiated in spheroids or fi brin-
based constructs. After 7 days, conditioned medium was collected and spheroids/
fi brin-based constructs were either harvested or implanted subcutaneously in 
athymic mice. Following 7 days of implantation, the number of blood vessels in 
fi brin-based constructs was signifi cantly higher than in spheroids [93±45 versus 
23±11 vessels/mm2], and the infl ammatory response to fi brin-based constructs was 
less severe. The reasons for these results were investigated further in vitro. We 
found that ASC in fi brin-based constructs secreted signifi cantly higher levels of the 
angiogenic factors VEGF and HGF, and lower levels of the infl ammatory cytokine 
IL8. Furthermore, ASC in fi brin-based-constructs secreted signifi cantly higher levels 
of leptin and showed a 2.5-fold upregulation of the adipogenic transcription factor 
PPARG and a 4-to 5-fold upregulation of the adipocyte-specifi c markers FABP4, 
perilipin and leptin. Based on these results, we conclude that fi brin-based ASC-
constructs are more suitable for ASC-based adipose tissue reconstruction than 
scaffold-free spheroids.
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INTRODUCTION
Soft tissue defects due to tumor resection, trauma, deep burns or congenital defor-
mities require surgical replacement of lost soft tissue to regain shape and/or physi-
ological function. Current surgical procedures to repair soft tissue defects include the 
use of synthetic implants and adipose tissue transplants. Improved patient outcomes 
notwithstanding [1,2,3,4], both procedures have their limitations including implant 
dislocation and toxicity [5], donor-site morbidity or deformity [6] and an unsatisfactory 
long-term outcome due to resorption [5,7,8,9].
Adipose-derived stromal cell (ASC)-based reconstruction after soft tissue loss, 
promises to restore the shape and volume of the affected site. New human adipose 
tissue has been formed in immune-compromised rodents by injection of ASC [10] 
or delivery of ASC in tissue-like structures [6,11,12,13,14,15], but poor survival after 
transplantation due to ischemia, insuffi cient adipogenic differentiation and adverse 
effects of scaffold materials currently hinder the use of these techniques.
Scaffold–based tissue engineering, though promising, faces several challenges: (1) 
synthetic scaffolds and extracellular matrix–based xenograft materials elicit a foreign 
body response, (2) scaffold degradation products may release potentially toxic sub-
stances and (3) scaffold compliance is often different from adipose tissue [16,17] .
 The generation of three-dimensional tissues that are composed only of cells and 
their own secreted matrix, also called scaffold-free tissue engineering, addresses the 
limitations associated with synthetic and exogenous matrix-based tissues [18,19]. 
Scaffold-free human ASC cell sheets can be created and stacked to form adipose-
like substitutes [20,21]. We recently created three-dimensional spherical scaffold-free 
constructs composed of human ASC (ASC spheroids) of up to 600μm in diameter 
[22]. To date, it is unclear whether the use of scaffold-free ASC constructs is advanta-
geous for adipogenesis and/or in vivo-engraftment when compared to scaffold-based 
constructs.
To investigate this, we wanted to compare our scaffold-free methods with another 
promising method that makes use of scaffolds. Various scaffold materials have been 
combined with ASC for adipose tissue engineering purposes [16]. Along with collagen 
[23,24], hyaluronic acid [25], poly(lactic-co-glycolic-acid) (PLGA) [14,26], polyglycolic 
acid (PGA) [27], Matrigel™ [28] and alginate[11], fi brin has shown a promising scaffold 
material for generation of adipose tissue [29,30,31,32]. Besides that, fi brin is especially 
an attractive material for clinical use since it could be produced from a patient’s own 
blood, thereby avoiding the risk of a foreign body response [33].
Since the in vivo engraftment of ASC constructs is most of all dependent on ASC 
survival, a potential successful ASC construct not only supports adipogenesis but also 
encourages angiogenesis to minimize ASC ischemia and death. As the extracellular 
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environment infl uences cell behavior [34,35], it is likely that the scaffold (-free) envi-
ronment will impact important ASC biological features for in vivo-engraftment, such 
as adipogenic differentiation potential and the secretion of adipokines, which include 
angiogenic and infl ammatory factors.
In the current study we compared the in vivo engraftment of scaffold-free ASC 
spheroids with fi brin–based ASC constructs. We investigated in vivo construct survival, 
vascularization, and adipogenic differentiation. Complimentary to the in vivo experi-
ments, we evaluated the impact of spheroid and fi brin-based environments on ASC 
adipogenic differentiation and their secretion of adipokines in vitro.
MATERIALS AND METHODS
ISOLATION AND CULTURE OF ASC
Subcutaneous abdominal adipose tissue was obtained as leftover material from donors 
undergoing breast reconstruction surgery with approval of the Erasmus MC Medical 
Ethical Committee (# MEC-2005-157) and according to the Code of Conduct: “Proper 
Secondary Use of Human Tissue” (http://www.federa.org). Leftover adipose tissue was 
only used from donors who did not opt-out to such use.
ASC from 3 different donors of 56, 58 and 62 years of age were isolated from the 
adipose tissue using collagenase type I (Invitrogen, Carlsbad, California) as previously 
described [22,36] and grown on basal medium (Dulbecco’s Modifi ed Eagle Medium 
1g/l glucose (Invitrogen), 10% FCS (PAA Laboratories, Pasching, Austria), 10-12 M 
dexamethasone, 10-5 M ascorbic acid (both from Sigma-Aldrich, St. Louis, Missouri), 
1% penicillin/streptomycin, 0.5% gentamycin (both from Invitrogen)). The isolated 
primary ASC were grown until they reached 90% confl uence. At 90% confl uence, ad-
herent cells were released with 0.05% trypsin/ ethylenediaminetetraacetic acid (EDTA) 
and then stored in liquid nitrogen until further use. ASC at second passage were used 
in this study.
 FORMATION OF SPHEROIDS
ASC were pooled to a total of 0.5*106 cells in 10 ml polypropylene tubes (Techno 
Plastic Products, Trasadingen, Switzerland) in 350μl culture medium: human endothe-
lial-SFM (Invitrogen) supplemented with 5% FCS, 20ng/ml fi broblast growth factor 2 
(FGF2), 100ng/ml epidermal growth factor (EGF), 1% penicillin/streptomycin and 0.5% 
gentamycin. After centrifugation at 150 x g for 5 minutes, cell pellets were incubated 
overnight in 37ºC at 5% CO2 in a humidifi ed atmosphere to allow spheroid formation. 
After overnight incubation, the culture medium of the spheroids was replaced by 350μl 
of a 1:1 mixture of culture medium and differentiation medium (Dulbecco’s modifi ed 
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Eagle Medium 4.5g/l glucose (Invitrogen), 10% FCS, 1μM dexamethasone (Sigma-
Aldrich), 0.01 mg/ml insulin (Eli Lilly, Houten, The Netherlands) 0.2 mM indomethacin 
(Sigma-Aldrich), 0.5mM 3-isobutyl-I-methyl-xanthine (Sigma-Aldrich), 1% penicillin/
streptomycin and 0.5% gentamycin) from now on called adipogenic medium. Medium 
was refreshed every other day. At day 7, spheroids were collected for RNA isolation or 
implantation, or cultured for another 48 hours on fresh adipogenic medium to analyze 
secreted angiogenic and infl ammatory factors.
FORMATION OF FIBRIN-BASED CONSTRUCTS
Fibrin-based constructs were prepared with materials from the fi brin in vitro angio-
genesis assay® (Millipore Corporation, Massachusetts) according to manufacturer’s 
instructions with some slight modifi cations. In short, ASC were suspended in 30 μl of 
fi brinogen solution at a density, of 1.67*104 cells/μl (= total of 0.5*106 cells per con-
struct). After addition of 20μl of thrombin solution, the cultures were immediately placed 
in individual wells of a 96-wells plate (Costar®, Corning Inc.). After gel formation, the 
plates were incubated at 37ºC in 5% CO2 in a humidifi ed atmosphere for 15 minutes to 
ensure polymerization of the gels. Following polymerization, 350μl of culture medium 
was added to each well. After overnight equilibration, the culture medium was replaced 
by 350μl adipogenic medium. Medium was refreshed every other day. At day 7, fi brin 
constructs were collected for RNA isolation or implantation, or cultured for another 48 
hours on fresh adipogenic medium to analyze secreted angiogenic and infl ammatory 
factors.
RNA ISOLATION AND COMPLEMENTARY DNA (CDNA) SYNTHESIS
For each of the three ASC donors 0.5*106 second passage undifferentiated ASC were 
harvested for RNA isolation. In addition, 9 spheroid and 9 fi brin constructs were pre-
pared for each of the three ASC donors. The spheroids were fragmented with a pestle 
on ice and subsequently sheared using an insulin syringe. The fi brin cultures were snap 
frozen and processed using the Mikro-Dismembrator S® (B. Braun Biotech Interna-
tional GmbH, Melsungen, Germany). Total RNA was extracted from undifferentiated 
ASC, spheroids and fi brin cultures using Qiazol Lysis Reagent (Qiagen Benelux, Venlo, 
The Netherlands) and further purifi ed using the RNeasy Micro Kit (Qiagen, Venlo, The 
Netherlands) with on-column DNA-digestion. Total RNA was quantifi ed using a Nano-
Drop™ 1000 spectrophotometer (Nanodrop technologies, Wilmington, DE) according 
to manufacturer’s instructions and 250 nanogram RNA was reverse transcribed into 
cDNA using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, St. Leon-
Rot, Germany).
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QUANTITATIVE POLYMERASE CHAIN REACTION (Q-PCR)
The mRNA levels of the adipogenic markers peroxisome proliferator-activated receptor 
gamma (PPARG), fatty acid binding protein 4 (FABP4), perilipin 1 (PLIN 1) and leptin 
(LEP) together with beta-2-microglobulin (B2M) were analyzed with the ABI PRISM® 
7000 Sequence Detection System and 7000 System SDS software (ABI, Foster City, 
USA, www.appliedbiosystems.com), using the Taqman®Gene Expression Assays for 
PPARG (Hs01115510_m1), FABP4 (Hs01086177_m1), PLIN1 (Hs01106927_m1), LEP 
(Hs00174877_m1) and B2M (Hs00984230_m1) (ABI) according to the manufacturer’s 
instructions. The B2M mRNA levels were analyzed for data normalization.
 CONDITIONED MEDIA COLLECTION AND ANALYSIS
On culture day 7, spheroid- and fi brin-based ASC cultures were switched to fresh ad-
ipogenic medium and incubated at 37˚C and 5% CO2 for 48 hours. Then, conditioned 
media were collected and assayed for the concentration of ASC-secreted infl ammatory 
cytokines, angiogenic factors and leptin.
ANALYSIS OF INFLAMMATORY CYTOKINES AND ANGIOGENIC FACTORS
A human cytokine-infl ammation multiplex chemiluminescent ELISA kit (cat. 
no.110451HU, Quansys Biosciences, West Logan, Utah) and a human angiogenesis 
multiplex chemiluminescent ELISA kit (cat. no.150251HU; Quansys Biosciences) were 
used to assay the conditioned medium for the release of the following infl ammatory 
cytokines and angiogenic factors: interleukin 1 alpha (IL1 alpha), interleukin 1 Beta 
(IL1 beta), interleukin 2 (IL2), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 8 (IL8), 
interleukin 10 (IL10), tumor necrosis factor alpha (TNF alpha) interferon gamma (IFN 
gamma), platelet derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF), angiopoietin 2 (ANG2), fi broblast growth factor 2 (FGF2), hepatocyte growth 
factor (HGF), and the tissue inhibitors of metalloproteinases (TIMP): TIMP1, and TIMP2. 
These multiplex chemiluminescent ELISA kits were performed according to manufac-
turer’s instructions. The plate was imaged using the Kodak Digital Science ™ Image 
Station 440CF system (NEN Life Science Products Inc, Boston, Massachusetts) with 
custom software. Q-view software® (Quansys Biosciences) was used for calculation of 
angiogenic factor concentration using linear regression of the standard curve.
LEPTIN QUANTIFICATION
The concentration of leptin in the conditioned medium was measured using a sand-
wich ELISA kit (Leptin Human ELISA Kit®, cat no. KAC2281, Invitrogen) according to 
manufacturer’s instructions. The plate was read at 450 nm using a microplate reader 
(Versamax®, Molecular Devices, Sunnyvale, California). The amount of leptin was 
determined from standard curves provided with the kit.
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IN VIVO IMPLANTATION
For in vivo implantation, three spheroid- and fi brin -based constructs, each initially seeded 
with 0.5*106 ASC, were created from each of the three donors, resulting in a total of 9 ASC 
spheroids and 9 fi brin-based constructs. After 7 days of in vitro culture, the spheroids and 
fi brin-based constructs were implanted subcutaneously in the left and right scapular area 
of 9 nine-weeks-old athymic male nude mice (NMRI-nu/nu, Taconic, Hudson, New York). 
The mice were placed under general anesthesia with 2.5% isofl urane after which two 
separate 0.5 cm incisions were made through the dorsal skin. Next, two separate subcuta-
neous pockets were prepared by blunt dissection of the subcutaneous tissue. One pocket 
was fi lled with an ASC spheroid and the other pocket was fi lled with an ASC seeded 
fi brin-based construct. Pockets were closed with discontinuous sutures using Mersilk 5-0 
(Ethicon, Somerville, New Jersey). Seven days after implantation, the mice were sacrifi ced 
and the constructs retrieved. All animal procedures were approved by the institutional 
Animal Experiments Committee of the ErasmusMC (EUR. 1292). (i.e. adherence to the 
rules prescribed in the national Animals Act, which implements the ‘Guidelines on the 
protection of experimental animals’ by the Council of Europe, 1986: Directive 86/609/EC).
HISTOLOGY
Spheroids and fi brin-based constructs harvested before or after 7 days of implantation 
were embedded in Tissue-Tek (Sakura, Finetek Europe, Zoeterwoude, The Netherlands) 
and snap frozen or fi xed in 10% formalin in PBS followed by embedding in paraffi n. 
Paraffi n sections (5 μm) were deparaffi nized and rehydrated. Cryo-sections (5 μm) were 
fi xed with 3.7% formalin in deionised water for 1 hour.
VIMENTIN STAINING
To distinguish human tissue from mouse tissue in paraffi n and cryo-sections of implant-
ed spheroids and fi brin-based constructs, a monoclonal mouse anti-human vimentin 
antibody (Clone V9, cat no. V6630, 1:40 dilution in PBS/ 1% BSA, Sigma-Aldrich) was 
used. To reduce unspecifi c binding of the secondary goat anti-mouse antibody (Dako, 
Glostrup, Denmark) to mouse IgGs, the mouse-on mouse HRP-Polymer Kit (Biocare 
Medical, Concord, California) was used, according to manufacturer’s instructions with 
some slight modifi cations. In short, antigen retrieval was performed through incubation 
in Rodent Decloaker® (Biocare Medical) for 60 minutes at 95˚C. Non-specifi c binding 
sites were blocked with Rodent Block M® (Biocare Medical) and sections were stained 
overnight with vimentin at 4˚C. The MM-polymer-HRP® secondary antibody (Biocare 
Medical) was used, followed by incubation in diaminobenzidine (Sigma-Aldrich) to vi-
sualize vimentin expression. The slides were weakly counterstained with hematoxylin, 
dehydrated through graded alcohols and mounted with Permount (VWR International, 
Amsterdam, The Netherlands).
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KI-67 STAINING
A monoclonal mouse anti-human Ki-67 antibody (Clone MIB-1, cat no. M7240, Dako) 
was used to identify actively proliferating cells in cryo-sections of spheroids and fi brin-
based constructs after 7 days of culture. Sections were fi xed in acetone for 10 minutes, 
washed in PBS and incubated for 60 minutes with Ki-67 antibody (1:200 dilution in 
PBS /1% BSA) at room temperature. Subsequently, a secondary biotin-conjugated 
goat anti-mouse antibody (1:200 dilution in PBS/1% BSA, cat no. E0433, Dako) was 
used for 30 minutes followed by incubation with streptavidin-horseradish peroxidase 
(1:300 dilution in PBS/1% BSA, cat no. P0397, Dako) for 30 minutes. Diaminobenzi-
dine (Sigma-Aldrich) was used to visualize Ki-67 expression. The slides were weakly 
counterstained with hematoxylin, dehydrated through graded alcohols and mounted 
with Permount (VWR International). Cell proliferation was quantifi ed on 2-3, high 
resolution (0.23 μm/pixel), low magnifi cation (40×) digital micrographs (Nanozoomer 
HT, Hamamatsu Photonics, Hamamatsu City, Japan) covering complete Ki-67 stained 
cross-sections of each construct using NIH ImageJ software (http://rsb.info.nih.gov/
ij/). The mitotic index was determined on 4 fi elds of view per construct cross-section 
and calculated as the percentage of Ki-67 positively stained cells to total cells.
OIL RED O STAINING
Accumulated lipid in spheroids and fi brin constructs were determined after 7 days of 
in vitro culture and after 7 days of implantation. In short, a 0.5% (w/v) stock solution of 
Oil Red O in triethyl-phosphate (Sigma-Aldrich) was diluted 3:2 with deionised water 
to prepare an Oil Red O working solution. After fi xation, cryo-sections were rinsed in 
deionised water. Subsequently, the sections were immersed in the Oil Red O work-
ing solution for 30 minutes. Hereafter, sections were washed with three exchanges of 
deionised water for 3 times. Then, sections were counterstained with hematoxylin for 1 
minute. Finally, sections were rinsed with running tap water for 10 minutes and covered 
with Imsolmount (Klinipath, Zevenaar, The Netherlands).
QUANTIFICATION OF CONSTRUCT VASCULARIZATION AND 
INFLAMMATION
H&E staining was performed to evaluate vascularization and infl ammation after im-
plantation. High resolution (0.23 μm/pixel), low magnifi cation (40×) digital micrographs 
covering 3 complete H&E stained cross-sections taken from top, middle, and bottom 
sections of each retrieved construct were made with a Nanozoomer HT (Hamamatsu 
Photonics) for analysis.
The rate of vascularization was estimated by counting the total number of vessel 
lumens per cross-section area using NIH ImageJ software. Likewise, the average ves-
sel diameter was determined by measuring the diameter of the vessel lumens in each 
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cross-section. The infi ltration of infl ammatory cells was scored on a scale from 0 to 
3; a score 0 indicated no or only few infl ammatory cells present (minimal infl amma-
tion), a score 1 indicated groups of infl ammatory cells around the construct and no or 
only few cells inside the construct (mild infl ammation), a score 2 indicated groups of 
infl ammatory cells around and inside the construct (severe infl ammation) and a score 
3 indicated infl ammatory cells throughout the construct and the surrounding tissue 
(intense infl ammation).
STATISTICAL ANALYSIS
The mitotic indices and all gene expression and protein secretion data were analyzed 
with the Kruskal-Wallis test followed by post hoc Dunn’s multiple comparison tests 
and are expressed as median (interquartile range, IQR). All vascularization data were 
analyzed with the unpaired t-test with Welch correction and are expressed as mean± 
standard deviation. For statistical comparisons of the infl ammation scores, the number 
of spheroids and fi brin-based constructs with score 0-1 (indicating minimal to mild 
infl ammation) were compared to the number of spheroids and fi brin constructs with 
score 2-3 (indicating severe to intense infl ammation) using the Fisher’s exact test. Sta-
tistical signifi cance was defi ned as P<0.05. Statistical analysis was performed using 
SPSS 15.0 (SPSS Inc., Chicago, Illinois).
RESULTS
IN VIVO PERFORMANCE OF ASC TISSUE CONSTRUCTS
Following 7 days of culture, spheroids and fi brin-based constructs were implanted 
subcutaneously in athymic mice, to determine construct in vivo engraftment. Seven 
days after implantation, we could identify 8 out of 9 engrafted spheroids and 8 out of 
9 engrafted fi brin-based constructs. Gross examination revealed that both spheroids 
and fi brin-based constructs had a spherical to oval shape, appeared light yellow in 
color and were invaded by vessels (Fig.1A).
H&E stained cross-sections of the retrieved constructs showed that host blood 
vessels were present at the periphery of all constructs while 4 out of 8 spheroids and 
5 out of 8 fi brin-based constructs contained host blood vessels within the constructs 
(Fig.1B). To provide more insight in the vascularization of these spheroids and fi brin-
based constructs, we determined the number of vessel lumens per cross-section and 
their average diameter. In fi brin-based constructs the number of vessel lumens per 
cross-section [93± 45 lumens/mm2] was signifi cantly higher when compared to spher-
oids [23±11 lumens/mm2], while the average vessel lumen diameter was comparable 
[spheroids: 10±2μm versus fi brin constructs: 10±1μm].
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A profound infl ammatory response was generally noted in cross-sections of spheroids 
(minimal to mild infl ammation: 1 construct; severe to massive infl ammation; 7 constructs), 
whereas the infl ammatory response in fi brin construct cross-sections was grossly mild 
(minimal to mild infl ammation: 6 constructs; severe to intense infl ammation: 2 constructs) 
(Fig.2). In addition, immunostaining of construct cross-sections for human-vimentin 
demonstrated no to minor positive staining in the severe to intense infl amed constructs 
B. 1 B. 2
A. 1 A. 2
Figure 1. Host blood vessels invade spheroids and fi brin-based constructs. Spheroids and fi brin-
based constructs were cultured for 7 days in vitro, and then implanted subcutaneously in the right 
and left scapular region of athymic mice for 7 days. Representative images of (A.1) a spheroid and 
(A.2) a fi brin-based construct taken at day 7 postimplantation. Scale bars= 1mm. (B) Construct 
cross-sections were stained with hematoxylin (blue) & eosin (pink). (B.1) spheroid cross-section 
and (B.2) fi brin-based construct cross-section, showing invasion of host blood vessels (see white 
arrows). Scale bars = 100μm. (see color section for a full-color version)
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Figure 2. Upon 7 days of implantation fi brin-based 
constructs elicit a less severe infl ammatory re-
sponse than spheroids. Representative hematoxylin 
(blue) & eosin (pink) stained sections of spheroids 
and fi brin-based constructs after 7 days of implan-
tation in athymic mice. (A.1) Overview of a spheroid 
cross-section and (A.2) high magnifi cation image of 
selection in (A.1) (see white square). (B.1) Overview 
of a fi brin-based construct cross-section and (B.2) 
high magnifi cation image of selection in (B.1) (see 
white square). Areas with infl ammatory cell infi ltra-
tion (see white #) and infl ammatory cells (see ar-
rows) are indicated. Scale bars= 100μm. (C) Scoring 
of the infl ammatory response to the constructs. 
High infl ammatory response to spheroids (score 
0-1= minimum to mild infl ammation; 1 construct, 
score 2-3= severe to intense infl ammation; 7 con-
structs) was noted while the infl ammatory response 
to fi brin-based constructs was grossly mild (score 
0-1= minimum to mild infl ammation; 6 constructs, 
score 2-3= severe to intense infl ammation; 2 con-
structs). (see color section for a full-color version)
A. 1 A. 2
B. 1 B. 2
C
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A. 1
A. 2
Figure 3. Assessment of ASC presence and lipid accumulation in transplanted spheroids and fi brin-
based constructs. To detect ASC in spheroids and fi brin-based constructs after 7 days of implanta-
tion, cross-sections were stained with human specifi c vimentin antibody (brown) and counterstained 
with hematoxylin (blue). (A) Representative images of anti-human vimentin-stained cross-sections 
of a spheroid (A.1) and a fi brin-based construct (A.2) after 7 days of implantation. Note the limited 
vimentin staining in the infl amed spheroid when compared to the fi brin-based construct. (B) To de-
tect lipid accumulation in constructs after 7 days of implantation, cross-sections were stained with 
Oil Red O (red) and counterstained with hematoxylin (blue). (B.1) Spheroid and (B.2) fi brin-based 
construct. (C) Anti-human vimentin (brown) stained consecutive cross-section of the same spheroid 
(C.1) and fi brin-based construct (C.2) as shown in (B.1) and (B.2). Note that Oil Red O-positive cells 
and vimentin-positive cells are located within the same area. Scale bars= 100μm. (see color section 
for a full-color version)
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(mainly spheroids) whereas the minimal to mild infl amed constructs (mainly fi brin-based 
constructs) were strongly positive, indicating that cells of human origin were only sparsely 
present in the severely infl amed constructs (Fig.3A). Furthermore, Oil Red O –positive 
cells were present in both spheroids and fi brin-based constructs. Notably, the Oil-Red O 
positive cells are located within the same area as vimentin-positive cells in consecutive 
cross-sections of the same spheroid and fi brin-based constructs, suggesting that the Oil 
Red O-positive cells were from human origin (Fig.3B-C).
ANGIOGENIC FACTOR SECRETION BY ASC IN SPHEROIDS AND FIBRIN-
BASED CONSTRUCTS
The ability of ASC to secrete angiogenic factors may have benefi cial effects on the 
vascularization and survival of ASC constructs in vivo. To assess the ability of ASC to 
B. 1
C. 1 C. 2
B. 2
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Figure 4. ASC in fi brin-based constructs secrete higher levels of the angiogenic factors VEGF and 
HGF than ASC in spheroids. The secretion of the angiogenic factors FGF2, ANG2, PDGF, TIMP2, 
TIMP1, HGF and VEGF by ASC in spheroids and fi brin-based constructs over 48 hours was mea-
sured by multiplex chemiluminescent ELISA at day 7. Unconditioned adipogenic medium was used 
as control condition. Values are presented as median (interquartile range); n= 5, 3 ASC donors. *= 
P≤ 0.05, **= P≤ 0.01, ***= P≤ 0.001 (fi brin-based construct conditioned medium versus spheroid 
conditioned medium and control).
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secrete angiogenic factors, we analyzed the release of several angiogenic factors into 
the culture medium over a 48-hour period. Figure 4 illustrates the data from several 
important angiogenic factors assayed by multiplex chemiluminescent ELISA at day 7. 
Of these, FGF2 was added to the culture medium, which masks any differences in the 
levels of FGF2 between the conditioned media and unconditioned medium.
No signifi cant differences in the levels of ANG2 and PDGF between conditioned and 
unconditioned medium were observed. In contrast, the levels of TIMP2 in conditioned 
medium from fi brin constructs and the levels of TIMP1 in conditioned medium from 
both spheroids and fi brin-based constructs were signifi cantly higher when compared 
to unconditioned medium. Moreover, the levels of HGF and VEGF in conditioned 
medium from fi brin-based constructs were signifi cantly higher when compared to 
spheroid conditioned and unconditioned medium.
INFLAMMATORY CYTOKINE SECRETION BY ASC IN SPHEROIDS AND 
FIBRIN-BASED CONSTRUCTS
The secretion of a vast amount of pro-infl ammatory cytokines may have a negative ef-
fect on the in vivo-engraftment of ASC constructs. To assess if culture of ASC in spher-
oids or fi brin-based constructs modulated the secretion of infl ammatory cytokines we 
analyzed the release of several infl ammatory cytokines into the culture medium over 
a 48-hour period. Figure 5 illustrates the data from 9 different proteins assayed by 
multiplex chemiluminescent ELISA at day 7. No statistically signifi cant differences in 
the secretion of the cytokines IL1α, IL2, IL4 and IL10 were observed between con-
ditioned media of spheroids and fi brin-based constructs when compared to uncon-
ditioned medium (= control). In contrast, IL1β, IL6, IFNγ and TNFα were secreted in 
signifi cant amounts in both spheroids and fi brin-based constructs when compared to 
unconditioned medium. In addition, the levels of IL8 in spheroid-conditioned medium 
were signifi cantly higher when compared to conditioned medium from fi brin-based 
constructs and unconditioned medium.
ASC ADIPOGENIC DIFFERENTIATION IN SPHEROIDS AND FIBRIN-
BASED CONSTRUCTS
Previous studies have shown that adipogenic differentiation of ASC in vitro can im-
prove adipogenesis in vivo [37,38]. Important characteristics of adipogenic differentia-
tion are the accumulation of lipid, the expression of adipogenesis-related markers and 
the secretion of leptin [39,40]. To qualitatively determine lipid accumulation in ASC in 
spheroids and fi brin-based constructs after 7 days of culture, we stained cryo-sections 
with Oil Red O. Oil Red O positive cells were evident in both spheroids and fi brin-based 
constructs (Fig.6A).
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Figure 5. ASC in fi brin-based constructs secrete lower levels of the cytokine interleukin 8 than ASC 
in spheroids. The secretion of the infl ammatory cytokines IL1 alpha, IL2, IL4, IL10, IL1 beta, IL6, 
TNF alpha, IFN gamma and IL8 by ASC in spheroids and fi brin-based constructs over 48 hours was 
measured by multiplex chemiluminescent ELISA at day 7. Unconditioned adipogenic medium was 
used as control condition. Values are presented as median (interquartile range); n= 5, 3 ASC donors. 
*= P≤ 0.05, **= P≤ 0.01, ***= P≤ 0.001 (spheroid and fi brin-based construct conditioned medium 
versus each other and control).
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To quantitatively assess adipogenic differentiation of the ASC in spheroids and 
fi brin-based constructs, we measured the gene expression of the adipogenic markers 
PPARG, PLIN1, FABP4 and LEP after 7 days of culture. In addition, we measured 
the release of leptin into the culture medium over a 48-hour period. Q-PCR analysis 
showed that all four adipogenic markers were expressed in ASC cultured in spheroids 
or fi brin-based constructs. Notably, only ASC in fi brin-based constructs showed a 
signifi cantly higher expression of these adipogenic markers when compared to undif-
ferentiated ASC harvested at day 0 (= control) (Fig.6B). Moreover, the levels of leptin 
in conditioned medium from fi brin-based constructs were signifi cantly higher when 
compared to conditioned medium from spheroids and unconditioned medium (=con-
trol) (Fig.6C).
To determine the proliferative activity of differentiating ASC in spheroid and fi brin-
based constructs Ki-67 staining was used. Mitotic indices were calculated. Compari-
son of the mitotic index revealed no signifi cant difference in ASC proliferative activity 
between spheroids and fi brin-based constructs (spheroid mitotic index median: 3%, 
[IQR: 9.7-1.1%] versus fi brin median: 3.5%, [IQR: 8.9-0.7%]).
DISCUSSION
The results of our study suggest that fi brin-based ASC constructs better support in vivo 
engraftment than scaffold-free ASC spheroids, as indicated by a less severe infl am-
matory response and a higher degree of vascularization after in vivo transplantation. In 
addition, fi brin-based ASC constructs better support ASC adipogenesis as indicated 
by the higher expression levels of adipocyte-specifi c markers and the increased secre-
tion of leptin.
An important parameter determining the success of ASC constructs for soft tissue 
repair is an unfavorable host response. In our study the infl ammatory response after 
subcutaneous transplantation in nude mice was more profound in spheroids than in 
Figure 5. (continued)
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Figure 6. ASC in fi brin-based constructs display increased adipogenic differentiation when com-
pared to ASC in spheroids. (A) ASC in spheroids and fi brin-based constructs were cultured for 
7 days in vitro in adipogenic medium. Cross-sections were stained with Oil Red O (red, showing 
intracellular lipid) and counterstained with hematoxylin (blue). (A.1) Spheroid. (A.2) Fibrin-based 
construct. Scale bars= 100 μm. (B) Q-PCR was used to measure the expression levels of the ad-
ipocyte-specifi c markers PPARGγ, PLIN, FABP4 and LEP. Expression levels are relative to beta-
2-microglobulin positive-control housekeeping gene (delta Ct). Values are presented as medians 
(interquartile range). For each of the three ASC donors 9 spheroids, 9 fi brin-based constructs and 
0.5*106 undifferentiated ASC (=control) were prepared and assayed. *= P≤ 0.05, **= P≤ 0.01 and 
***= P≤ 0.001 (relative expression in fi brin-based constructs compared to spheroids and control). 
(C) The secretion of leptin by ASC in conditioned medium of spheroids and fi brin-based constructs 
over 48 hours was measured by sandwich ELISA at day 7. Unconditioned adipogenic medium was 
used as control condition. Values are presented as median (interquartile range); n= 9, 3 ASC donors. 
**= P≤ 0.01, ***= P≤ 0.001 (fi brin-based construct conditioned medium versus spheroid conditioned 
medium and control). (see color section for a full-color version)
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fi brin-based constructs. In line with this fi nding, ASC cultured in spheroids secreted 
higher amounts of the pro-infl ammatory mediator IL8 than ASC cultured in fi brin-based 
constructs. Taken together, these fi ndings indicate that the ASC in spheroids induce a 
higher infl ammatory response than ASC in fi brin-based constructs, which likely results 
from a higher secretion of IL8. However, the possibility that other than the investigated 
factors contributed to the higher infl ammatory response in spheroids, such as more cell 
death due to less suffi cient diffusion of oxygen and nutrients, cannot yet be ruled out.
Another important parameter determining the success of ASC constructs is vascu-
larization [41,42,43]. We quantifi ed the vascularization of construct cross-sections upon 
transplantation and found that the number of vascular lumens-per construct-area was 
B
C
Figure 6. (continued)
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signifi cantly higher in fi brin-based constructs when compared to spheroids, indicating 
augmented ingrowth of mouse vessels. In line with this fi nding, we found that ASC in 
fi brin-based constructs secreted higher amounts of the prominent pro-angiogenic fac-
tors VEGF and HGF when compared to ASC in spheroids. In all, these fi ndings indicate 
that fi brin favors the vascularization of ASC constructs upon transplantation. Such a 
positive effect of fi brin on in vivo vascularization has also recently been shown for bone 
marrow-derived stromal cell/ fi brin-based constructs by Huang et al. [44].
Although previous studies demonstrate that scaffold-free spheroid culture provides 
favorable conditions for reconstruction of liver [45], pancreas [46], blood vessel [47], 
myocardial muscle [48], ganglion [48], cartilage [49] and bone tissue [50,51], its use for 
reconstruction of adipose tissue has not been investigated until now. In our study the 
adipogenic differentiation of ASC was clearly increased in fi brin-based cultures when 
compared to scaffold-free spheroid cultures. Therefore, we conclude that the spheroid 
culture environment is less favorable for ASC adipogenic differentiation than the fi brin 
culture environment. Possibly, differences in cell density accounted for the observed 
differences in ASC adipogenic differentiation between spheroid and fi brin-based cul-
tures. In fi brin-based cultures the ASC are more loosely packed than in the spheroid 
cultures, as can be seen in Figures 6A-B. Mueller-Klieser et al. [52], and others [53,54] 
showed that the relatively high cell density of especially larger (>150-200μm) spheroids 
limits the diffusion of many molecules to individual cells inside the spheroids, leading 
to nutrient deprivation. It could therefore be hypothesized that the observed difference 
in adipogenic differentiation between spheroids and fi brin-based cultures are due to a 
difference in nutrient delivery to individual cells.
Collectively, our in vitro and in vivo experiments with fi brin are promising and dem-
onstrate that fi brin provides favorable conditions for adipose tissue reconstruction. 
Further studies should determine the in vivo survival of fi brin-based adipose constructs 
in the long term, as well as attempt to develop fi brin-based adipose constructs of 
appropriate size and predictable forms to repair soft tissue defects.
A potential strategy that could benefi t the in vivo survival of especially larger fi brin-
based adipose constructs is the prefabrication of a vascular network within the tissue 
construct, as previously demonstrated by Levenberg et al. [55] for engineered skeletal 
muscle tissue. Furthermore, advanced techniques such as inkjet printing and magneti-
cally infl uenced self-assembly can be used to alter the geometry of the fi brin-based 
constructs into appropriate and predictable forms [56,57,58,59].
CONCLUSION
The use of fi brin-based ASC constructs leads to increased expression of adipocyte-
specifi c markers, a higher secretion of angiogenic factors and a lower secretion of the 
cytokine IL8 when compared to scaffold-free ASC spheroids. In addition, fi brin-based 
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ASC constructs display a higher degree of vascularization and elicit a less severe 
infl ammatory response than ASC spheroids upon transplantation. Therefore, we con-
clude that fi brin-based constructs are more suitable for ASC-based adipose tissue 
reconstruction than scaffold-free ASC spheroids.
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ABSTRACT
Inadequate vascularization of in vitro-engineered tissue constructs after implanta-
tion is a major problem in most tissue engineering applications. In this study we 
evaluated whether adipose tissue-derived stromal cells (ASC), similar to bone 
marrow-derived stromal cells (BMSC), can support the organization of endothelial 
cells into prevascular-like structures using an in vitro model. In addition, we inves-
tigated the mechanisms leading to the support of endothelial organization by these 
cells. We cultured human umbilical vein endothelial cells (HUVEC), ASC and BMSC 
either alone or in combination in fi brin embedded spheroids for 14 days. We found 
that BMSC and ASC formed cellular networks that expressed alpha smooth muscle 
actin, and in the case of ASC also CD34. Furthermore, BMSC and ASC secreted 
hepatocyte growth factor (HGF) and tissue inhibitor of metalloproteinase (TIMP) 1 
and -2. In addition, ASC conditioned medium induced HUVEC outgrowth whereas 
BMSC-conditioned medium and HGF-supplemented medium did not. Finally, both 
BMSC and ASC supported HUVEC organization into prevascular-like structures 
when co-cultured. Our results suggest that both BMSC and ASC can support the 
formation of prevascular-like structures in vitro. Furthermore, our fi ndings indicate 
that cell-cell contacts and reciprocal signaling play an important role in the forma-
tion of these prevascular structures.
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INTRODUCTION
The realization of a viable and adequate vascular supply in engineered replacement 
tissues or organs is a prerequisite for their survival after implantation and has become 
one of the major challenges in tissue engineering. The lack of an adequate blood supply 
in the core of tissue engineered constructs thicker than approximately 150μm results 
in hypoxia and an inadequate supply of nutrients, eventually leading to cell death [1,2].
For new blood vessels to be formed in tissue-engineered constructs, a balanced 
array of angiogenic factors involved in both angiogenesis and vessel maturation needs 
to be delivered in the right way at the right time, and at the site of implantation [3]. 
Finding this cocktail of angiogenic factors for the development of functional vessels 
is an elaborate and demanding task and forms a major hurdle in tissue engineering.
In vitro studies demonstrated that bone marrow-derived stromal cells (BMSC) as 
well as adipose tissue-derived stromal cells (ASC) are able to express many angiogenic 
factors that can stimulate endothelial and smooth muscle cells to proliferate and migrate 
[4,5,6,7,8], and can even differentiate into cells that express markers of the endothelial 
lineage [6,9,10,11,12,13,14]. Several in vivo studies also indicated that both cell types 
could be used in therapeutic revascularization of ischemic tissues [6,9,11,15,16].
The requirements for therapeutic revascularization and the vascularization of en-
gineered tissues share many similarities. BMSC and ASC may therefore not only be 
benefi cial for therapeutic revascularization of ischemic tissues, but may also represent 
suitable cell sources to support new vessel formation in engineered tissue constructs.
Another approach to promote the in vivo vascularization of tissue constructs 
would be to already incorporate endothelial cells into the engineered tissues in vitro 
[17,18,19,20]. Recently, Rouwkema et al.[19] showed that BMSC were able to sup-
port the formation of endothelial cell networks in a bone tissue-engineered construct. 
Similar to BMSC, ASC have multilineage potential and can be used in various tissue-
engineering applications [21,22,23,24,25]. ASC might even be preferred over BMSC 
since they require a less invasive harvesting procedure and, are generally present in 
higher numbers in adipose tissue than BMSC are present in bone marrow [26]. The 
idea that not only BMSC but also ASC could support the formation of prevascular-like 
structures in an in vitro tissue-engineering context is therefore very attractive.
We hypothesized that stromal derived cells of adipose tissue origin, similar to 
those of bone marrow origin, can be used to support the formation of prevascular-like 
structures within engineered tissues in vitro. To test this hypothesis, we assessed the 
ability of both ASC and BMSC to support the formation of prevascular-like structures 
from HUVEC using an in vitro model. In addition, we studied the mechanisms leading 
to the support of the formation of prevascular structures in vitro.
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Since vessel growth in situ frequently takes place in a microenvironment promot-
ing vascularization, we cultured HUVEC-, ASC-, and BMSC-spheroids in fi brin, using 
endothelial growth medium supplemented with VEGF. We then assessed their organi-
zation capabilities and the release of several factors known to be involved in vessel 
formation. In addition, we determined the expression of the vascular markers CD34 
and alpha smooth muscle actin (αSMA) by ASC and BMSC. Furthermore; we tested 
the effect of factors secreted by ASC or BMSC on HUVEC outgrowth and organization. 
Finally, we labeled HUVEC with superparamagnetic iron oxide particles (SPIO) and 
co-cultured them with different ratios of ASC and BMSC, to assess their organization 
and collective three-dimensional (3D) assembly.
MATERIALS AND METHODS
MATERIALS
Dulbecco’s modifi ed Eagle’s medium containing either 1 g/L glucose (LG-DMEM) or 
4.5 g/L glucose (HG-DMEM), human endothelial serum free medium (SFM), penicillin/
streptomycin, fungizone, collagenase type I, and trypsin-ethylenediaminetetraacetic 
acid (EDTA) were purchased from Invitrogen (Carlsbad, California).
Fetal bovine serum (FBS) for ASC was purchased from PAA Laboratories (Cölbe, 
Germany) and FBS for BMSC was purchased from Invitrogen. Both fetal bovine sera 
were pre-selected from a batch to maintain multipotential capacities of the cells. Hu-
man serum was purchased from Lonza (Verviers, Belgium). Insulin was from Eli Lilly 
(Indianapolis, Indiana), and vascular endothelial growth factor (VEGF), fi broblast growth 
factor (FGF-2), epidermal growth factor (EGF) and hepatocyte growth factor (HGF) 
were obtained from Peprotech EC (London, United Kingdom). Monoclonal Anti-HGF 
antibody was obtained from R&D systems (R&D systems Europe, Abingdon, United 
Kingdom). Bovine serum albumin (BSA) and other chemicals were from Sigma-Aldrich 
(St. Louis, Missouri) unless stated otherwise.
METHODS
ISOLATION AND EXPANSION OF HUMAN BONE MARROW-DERIVED 
STROMAL CELLS (BMSC)
BMSC of four donors (two men/ two women, 31-61/ 42-53 years old) were obtained 
during total hip arthroplasty after informed consent and with approval of the local 
medical ethical committee (METC 2004-142). Bone marrow aspirates were taken from 
the greater trochanter. Heparinized aspirates were seeded at a density of 30-90 *106 
nucleated cells per T175 culture fl ask. After 24 hours, non-adherent cells and cell de-
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bris were washed out. BMSC were further expanded using a standard culture medium; 
LG-DMEM, with 10% FBS, 0.5% gentamycin and 0.015% fungizone, 10-4M L-ascorbic 
acid 2-phosphate (Instruchemie B.V.Delfzijl, The Netherlands) and 1 ng/ml FGF-2. Cells 
were cultured at 37ºC under humidifi ed conditions in air containing 5% carbon dioxide. 
Medium was changed twice a week. When cultures reached near confl uence, they 
were trypsinized using 0.05% trypsin-EDTA and stored in liquid nitrogen until further 
use. BMSC from passage 2 or 3 were thawed and used in the experiments after reach-
ing near confl uence.
ISOLATION AND CULTURE OF HUMAN ADIPOSE TISSUE-DERIVED 
STROMAL CELLS (ASC)
For this study, ASC from four female donors 43, 46, 49 and 56 years of age were 
isolated from subcutaneous abdominal adipose tissue. Adipose tissue was received 
with approval of the Medical Ethics Committee (# MEC-2005-157). Excised human 
adipose tissue was washed with LG-DMEM, minced, and digested in sterile-fi ltered 
0.1% collagenase type I solution in the presence of 1% BSA. The mixture was sus-
pended in LG-DMEM at 37˚C for 60 min in an orbital shaker. ASC were isolated by 
differential centrifugation, washed with medium (LG-DMEM, 10% FBS, 1% penicillin/
streptomycin, and 0.5% gentamycin), fi ltered through a 100 μm mesh, and grown in 
basal medium supplemented with 10-12M dexamethasone and 10-5 M ascorbic acid. 
After 24 hours, cultures were washed with phosphate-buffered saline (PBS) with 2% 
FBS to remove erythrocytes and replenished with the supplemented basal medium. 
Cells were cultured at 37ºC under humidifi ed conditions in air containing 5% carbon 
dioxide. Medium was changed twice a week. When cultures reached near confl uence, 
they were trypsinized using 0.05% trypsin-EDTA and stored in liquid nitrogen. ASC 
from passage 1 or 2 were thawed and used in the experiments after reaching near 
confl uence.
HUMAN UMBILICAL VEIN ENDOTHELIAL (HUVEC) CELL CULTURE
We obtained HUVEC isolates from four donors. Each isolate was derived from an in-
dividual umbilical vein. HUVEC at passage 4 or less were seeded at a density of 1*104 
cells/cm2 in culture fl asks and cultured in endothelial growth medium (EGM) consisting 
of human endothelial-serum free medium supplemented with 10% FBS, 20ng/ml FGF2 
and 100ng/ml EGF. Medium was changed twice a week. Cells were subcultured at near 
confl uence with 0.05% trypsin/EDTA.
LABELING OF HUVEC WITH IRON OXIDE NANOPARTICELS
HUVEC at passage 5 or less were labeled with the so-called superparamagnetic iron 
oxide (SPIO) particles. These SPIO particles have a mean particle diameter of 150nm, 
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consist of an iron oxide core of 4nm and are coated with a low-molecular-weight dex-
tran [27,28]. Labeling of HUVEC with SPIO was performed at near confl uence using 
Endorem (Guerbet S.A., Paris, France) and Lipofectamine 2000 (Invitrogen). Briefl y, 
40μl of both Endorem and Lipofectamine 2000 were mixed separately with 1 ml of 
Opti-MEM (Invitrogen). The two solutions were then combined and incubated for 20 
minutes at room temperature. HUVEC at passage 4 or less were cultured to near con-
fl uence in a T175 culture fl ask. After reaching near confl uence, the cells were washed 
three times with phosphate buffered saline (PBS) and the culture medium was replaced 
by 20 ml Opti-MEM. The total volume of SPIO-Lipofectamine suspension (equivalent 
to 460.5μg iron content) was added drop-wise to 20 ml Opti-MEM. Subsequently, the 
cells were incubated at 37°C/5%CO2 for 24 hours. Following 24 hours of incubation 
the cells were rinsed three times in PBS and incubated with 10%FBS for 1 hour to 
remove loose SPIO-Lipofectamine complexes. The SPIO-labeled HUVEC were then 
trypsinized and used in the experiments.
FORMATION AND CULTURE OF SPHEROIDS IN FIBRIN MATRIX
We used an in vitro fi brin based culture model, slightly modifi ed from models developed 
by Vernon and Sage [29] and Xue [30] et al.
To form spheroids of cells for culture in a fi brin matrix, we used the hanging droplet 
method. A cell suspension of 500,000 cells per ml EGM was prepared. Forty microliters 
of this suspension (containing 20,000 cells) was pipetted onto the inside of the lid of 
a six-well culture plate coated with sterile parafi lm. The lid was then overturned and 
placed on top of the six-well culture plate containing sterile PBS. These hanging drop-
lets were left for two days to form coherent spheroids. For spheroid formation, HUVEC, 
BMSC and ASC were used separately or the SPIO-labeled HUVEC were mixed with 
different percentages of BMSC or ASC (60%, 80% and 95%). For the single culture 
experiments, 3 different donors were used to generate 18 BMSC, ASC or HUVEC 
spheroids. Since little variation between donors was seen in these experiments, cells 
from a single donor were used to generate 6 spheroids per co-culture condition in the 
co-culture experiments.
To form the fi brin gels, human fi brinogen (6mg/ml, Sigma-Aldrich) was dissolved in 
serum free HG-DMEM and was sterile fi ltered through a 0.2μm fi lter. Human plasma 
thrombin (0.32U/ml, Sigma-Aldrich) was added to 200μl of the fi brinogen, and this 
mixture was immediately placed in individual wells of a 48-well culture plate. After 
gel formation, the spheroids were placed carefully onto these gels and another 200μl 
fi brinogen solution was added on top of the spheroids and lower gel. In this way the 
spheroid was fully immersed in the fi brin matrix. After gel formation, EGM supple-
mented with 50ng/ml vascular endothelial growth factor (VEGF) was added to each 
well. The spheroids were cultured for 14 days and medium was changed every other 
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day. Medium was collected and stored at -80ºC. After 14 days, immersed spheroids 
were fi xed in 10% formalin in PBS and embedded in paraffi n.
HISTOMORPHOMETRY OF BMSC, ASC, HUVEC/ BMSC AND HUVEC/ASC 
SPHEROIDS
Histomorphometric analysis was used to quantify length, width and density of the 
cellular strands growing out of the BMSC and ASC (co-) culture spheroids. Low mag-
nifi cation (40X) digital micrographs of randomly selected spheroids were made with 
the Olympus U-CMAD3 camera (Olympus Soft Imaging Solutions, Münster, Germany) 
coupled to a light microscope (Olympus) at day 3, 7, 10 and 14 of culture for the 
analysis. Four spheroids per experiment group were analyzed. Subsequently, NIH 
ImageJ software (http://rsb.info.nih.gov/ij/) was used to measure the length, width 
and density of the cellular strands. The mean density was assessed by counting the 
number of cellular strands in three separate areas of 40 μm2 in each image. The mean 
width was determined by measuring the widths at the middle of 10 separate strands 
in each image. The mean maximum length of the cellular strands was determined by 
measuring the lengths of the three longest strands originating from the center of an 
individual spheroid.
HISTOLOGY
IMMUNOCYTOCHEMISTRY OF CULTURED BMSC AND ASC BEFORE SPHEROID 
FORMATION:
To determine the expression of CD34 and alpha smooth muscle actin (αSMA) in BMSC 
and ASC after passage 1 or 2 expansion and before spheroid formation, BMSC and 
ASC were suspended in fi brin (0.5*106 cells/50μl fi brin) in a 96-wells plate. Gels were 
then directly fi xed in 10% formalin/PBS and embedded in paraffi n.
IMMUNOHISTOCHEMISTRY OF CD34 AND αSMA:
Paraffi n sections of cultured BMSC and ASC or of fi brin immersed BMSC and ASC 
spheroids were deparaffi nized and rehydrated.
Antigen retrieval for the mouse anti-human CD34 antibody (Biocare Medical, Con-
cord, California) was performed through boiling in BORG Decloacker (Biocare Medical) 
at 95ºC for 45 minutes, while antigen retrieval for the mouse anti-human αSMA antibody 
(clone 1A4, Sigma-Aldrich) required incubation in 0.1% pronase at 37ºC for 30 minutes. 
Endogenous peroxidase was blocked with 3% H2O2 in PBS. Non-specifi c binding sites 
were blocked with 10% goat serum in PBS/1%BSA and sections were stained overnight 
at 4ºC with primary antibodies recognizing CD34 (1:50), or αSMA (1:20,000). Sections 
were incubated with goat anti-mouse secondary antibody diluted in PBS/1%BSA 1:200 
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(DAKO, Glöstrup, Denmark) for 30 minutes followed by incubation with streptavidin-
horseradish peroxidase (DAKO) diluted in PBS/1%BSA 1:300 for 30 minutes. To visualize 
bound antibodies di-aminobenzidine was used as a substrate. The slides were weakly 
counterstained with hematoxylin, dehydrated through graded alcohols and mounted 
with Permount (VWR International B.V., Amsterdam, The Netherlands).
PERL’S IRON STAIN:
To localize SPIO-labeled HUVEC in mixed stromal cell/labeled HUVEC spheroids, 
Perl’s stain (Klinipath, Duiven, The Netherlands) was used for iron detection. Slides 
were incubated with Perl’s reagent (2% potassium ferrocyanide/ 2% hydrochloric acid, 
50:50, vol/vol) for 15 minutes at room temperature and then washed three times in 
deionised water. Nuclear fast red was used as a counter stain. After staining, the slides 
were dehydrated through graded alcohols and mounted with Permount.
MULTIPLEX ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
A multiplex chemiluminescent ELISA (Quansys Biosciences, West Logan, Utah) was used 
to assay 48-hours conditioned medium of the 100% BMSC, 100% ASC and 100% HU-
VEC spheroid cultures for the release of the angiogenic factors: platelet derived growth 
factor B (PDGFB), VEGF, angiopoietin 2 (ANG2), FGF2, thrombopoietin (TPO), tumor 
necrosis factor alpha (TNFα), hepatocyte growth factor (HGF), and the tissue inhibitors 
of metalloproteinases (TIMP): TIMP1, and TIMP2 at day 14 of culture. This multiplex 
chemiluminescent ELISA was performed according to the manufacturer’s instructions 
and provided values in pg/ml based on standard curves of samples provided with the kit.
EFFECT OF BMSC AND ASC CONDITIONED MEDIUM ON HUVEC 
OUTGROWTH AND ORGANIZATION
HUVEC spheroids were cultured in 48-hour BMSC or ASC conditioned medium 
collected at day 14 of culture, or in EGM +50ng/ml VEGF (control medium). Control 
HUVEC spheroids were cultured in control medium. Cultures were continued for 14 
days and images were taken at 3, 7, 10 and 14 days of culture.
EFFECT OF HGF ON BMSC, ASC AND HUVEC OUTGROWTH
To examine the role of HGF on HUVEC outgrowth, HUVEC spheroids were exposed 
for 14 days to control medium, control medium supplemented with 14ng/ml HGF (an 
amount equal to the maximum amount of HGF measured in BMSC and ASC condi-
tioned medium) or control medium supplemented with 100ng/ml HGF. The autocrine/
paracrine role of endogenous HGF on BMSC and ASC outgrowth was tested by cultur-
ing BMSC and ASC spheroids in control medium, and in control medium supplemented 
with 0.04 and 0.3μg/mL anti-HGF. The neutralization dose50 (ND50) for this antibody was 
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0.1–0.3μg/ml of the antibody in the presence of 100ng/ml of recombinant human HGF. 
Images of spheroids were taken at 3, 7, 10 and 14 days of culture.
STATISTICAL ANALYSIS
Statistical analysis was performed using Graphpad Prism 5.01 (Graphpad Software, 
San Diego, California). All values are expressed as mean ± standard deviation. The 
levels of secreted factors in BMSC conditioned medium, ASC conditioned medium, 
HUVEC conditioned medium or unconditioned medium were compared with a one-
way analysis of variance (ANOVA) followed by a post hoc Tukey-Kramer test. The 
cellular strand length, width and density of BMSC, ASC, HUVEC/BMSC and HUVEC/
ASC spheroids were compared with a Kruskall-Wallis test followed by post hoc Dunn’s 
multiple comparison tests. Values with P<0.05 or less were considered signifi cant.
RESULTS
HUVEC, IN CONTRAST TO BMSC AND ASC, DO NOT GROW OUT IN 
CELLULAR STRANDS TO FORM AN ORGANIZED NETWORK IN FIBRIN.
Upon 14 days of culture we observed in 100% HUVEC spheroids only very minor 
cellular outgrowth and organization. Occasionally, HUVEC did form small colonies in a 
monolayer around the spheroids (Fig.1A). In contrast, both the BMSC and ASC spher-
oids were capable of forming cellular strands already after 3 days of culture. These 
cellular strands organized into a complex branched interconnecting network over time 
(Fig.1B-C). Cellular strands emanating from the BMSC spheroids organized into a less 
dense network than the cellular strands emanating from the ASC spheroids [1.1 ± 
0.12 cellular strands/mm2 in BMSC spheroids versus 1.6 ± 0.1 cellular strands/mm2 
in ASC spheroids (P<0.05)] (Fig.1D-F). Contrary to this difference in strand density, 
strand length [863 μm ± 386 μm in BMSC spheroids versus 806 μm ± 326 μm in ASC 
spheroids] and width [8.8 μm ± 2.7 μm in BMSC spheroids versus 5.2 μm ± 1.8 μm in 
ASC spheroids] did not differ signifi cantly between BMSC and ASC spheroids.
Before use in the spheroid culture, BMSC did not express CD34 whereas 6.0 ± 4.8% 
of ASC expressed CD34. Cellular networks subsequently growing out of the BMSC spher-
oids did not express the vascular marker CD34 (Fig.2A) whereas CD34 expression was 
found in the center of the ASC spheroids, as well as in the emanating cellular networks, 
especially at the periphery (Fig. 2B). Expanded BMSC and ASC expressed low levels of 
αSMA [BMSC 10% ± 17.2%; ASC 5.3% ± 4.7%] before spheroid culture. Surprisingly, 
expression of αSMA was abundantly found in the organized cellular networks as well as 
in the center of both BMSC- and ASC containing spheroids (Fig.3). The HUVEC, BMSC 
and ASC of different donors gave similar results regarding cellular organization.
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Figure 1. Bone marrow-derived stromal cell (BMSC) and adipose tissue-derived stromal cell (ASC) 
spheroids but not human umbilical vein endothelial cell (HUVEC) spheroids form an interconnected 
cellular network in fi brin. Images of 100% HUVEC, 100% BMSC and 100% ASC spheroids in fi brin 
cultured for 3, 7 or 14 days (magnifi cation 40x). (A) One hundred percent HUVEC spheroid at day 
14 of culture. HUVEC showed very minor organization. (B) BMSC and (C) ASC spheroids grow out 
in cellular strands resembling tubular structures (day 14 of culture, arrows indicate tube-like struc-
tures). (D, day 3; F, day 7) Cellular strands emanating from 100% BMSC spheroids organize into a 
less dense network than cellular strands emanating from 100% ASC spheroids (E, day 3; G, day 7).
Figure 2. Cellular networks of ASC but not BMSC express CD34. One hundred percent BMSC and 
100% ASC spheroids were cultured in fi brin in vitro for 14 days, and cross-sections were immu-
nostained with anti-human CD34 antibody (brown). Scale bar = 200μm. (A) BMSC networks do not 
express CD34. (B) Cell clusters in the center of ASC spheroids, as well as ASC networks express 
CD34 (arrows indicate CD34 positive cell clusters in spheroid core and outer rim). (see color section 
for a full-color version)
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BMSC AND ASC CONDITIONED MEDIUM; ANGIOGENIC FACTORS AND 
ITS EFFECT ON HUVEC OUTGROWTH AND ORGANIZATION.
To further assess the ability of BMSC and ASC to support the formation of vessel-
like structures, we analyzed the release of several angiogenic factors and TIMPs into 
the culture medium. Figure 4 illustrates the data from 9 different proteins assayed by 
multiplex chemiluminescent ELISA at day 14.
Of these, VEGF and FGF2 were added to the culture medium, as can be observed 
from the analysis of unconditioned medium. No signifi cant differences in the secre-
tion of the angiogenic factors ANG2, PDGFB, TNFα and TPO were observed between 
conditioned media of BMSC- and ASC spheroids when compared to unconditioned 
and HUVEC conditioned medium.
In contrast, TIMP1, TIMP2 and HGF were secreted in signifi cant amounts when 
compared to unconditioned medium and HUVEC conditioned medium. There was no 
signifi cant difference in the release of these factors between BMSC spheroids and ASC 
spheroids.
To examine whether BMSC/ASC conditioned medium or secreted HGF levels infl u-
enced HUVEC outgrowth, HUVEC spheroids were cultured on BMSC/ASC conditioned 
medium or medium supplemented with HGF. When cultured on BMSC conditioned 
medium or medium supplemented with HGF, no additional effect on HUVEC outgrowth 
Figure 3. Cellular networks of ASC and BMSC both express α smooth muscle actin (αSMA). One 
hundred percent BMSC and 100% ASC spheroids were cultured in fi brin in vitro for 14 days, and 
cross-sections were immunostained with anti-human αSMA antibody (brown). Scale bar = 200μm. 
αSMA expression was found in the center of BMSC (A) and ASC spheroids (B) as well as in the cel-
lular networks formed by BMSC (C) and ASC (D). (see color section for a full-color version)
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over the control spheroids was observed (Fig.5A-C). In contrast, when cultured on 
ASC conditioned medium, enhanced organization of HUVEC into cellular strands was 
observed over the controls (Fig. 5D). In addition, we examined whether blocking HGF 
in BMSC and ASC spheroid cultures inhibited ASC or BMSC outgrowth. Anti-HGF 
antibody did not inhibit the outgrowth of BMSC and ASC spheroids (Fig.5E-F).
A
B
C
D
Figure 4. Release of pro- and anti-angiogenic factors by BMSC and ASC. The secretion of vascular 
endothelial growth factor (VEGF) (A), fi broblast growth factor (FGF2) (B), angiopoietin 2 (ANG2) (C), 
platelet-derived growth factor B (PDGFB) (D), tumor necrosis factor α (TNFα) (E), thrombopoietin 
(TPO) (F), hepatocyte growth factor (HGF) (G), tissue inhibitor metalloproteinase 1 (TIMP)1 (H) and 
TIMP2 (I) by 100% BMSC, 100%ASC and 100%HUVEC spheroids over 48 hours was measured
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by multiplex ELISA at day 14 of culture. The secretion of 100% BMSC- and 100% ASC spheroids were 
compared with HUVEC conditioned and unconditioned medium. Conditioned medium of three different 
HUVEC, BMSC and ASC donors were assayed in duplicate. Error bars represent standard error of the 
mean. Statistical comparisons were performed with the one way analysis of variance (ANOVA) followed by 
the Tukey-Kramer posttest. *P<0.05, **P<0.01, ***P<0.001.
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Figure 5. Culture of HUVEC spheroids on ASC conditioned medium but not BMSC conditioned me-
dium or hepatocyte growth factor (HGF) supplemented medium affects HUVEC outgrowth. Images 
of HUVEC, BMSC or ASC spheroids in fi brin at 3 days of culture. Scale bar = 200μm. (A) HUVEC 
spheroid cultured in endothelial cell growth medium supplemented with 50ng/ml vascular endothe-
lial growth factor (VEGF) (control medium). (B) HUVEC spheroid cultured in control medium supple-
Femke BW.indd   86 26-11-10   13:20
87
Bone marrow- and adipose-derived stromal cells support prevascularization
HUVEC +ASC CM 
BMSC+ anti-HGF 
ASC+ anti-HGF 
D
E
F
mented with 100ng/ml HGF. (C) HUVEC spheroid cultured on 48-hour BMSC conditioned medium col-
lected at day 14. (D) HUVEC spheroid cultured on 48-hour ASC conditioned medium collected at day 14. 
(E) BMSC spheroid cultured on control medium supplemented with anti-HGF antibody (0.3 μg/mL). (F) 
ASC spheroid cultured on control medium supplemented with anti-HGF antibody (0.3 μg/mL).
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BMSC AND ASC SUPPORT HUVEC OUTGROWTH IN FIBRIN
Increasing percentages of BMSC or ASC (60%, 80% and 95%) were co-cultured with 
SPIO-labeled HUVEC in fi brin embedded spheroids, to assess their organization and col-
lective 3D-assembly. By labeling HUVEC intracellularly with SPIO particles, we were able 
to track these specifi c cells within the pellets by performing iron stains on the sections. 
HUVEC organization was similar in both the HUVEC/BMSC and HUVEC/ASC spheroid 
co-cultures. After 14 days of co-culture, a large portion of the HUVEC was located in 
clusters of variable size in the periphery of the spheroid cores. Originating from these 
peripheral HUVEC clusters, spindle-shaped cells grew out in cellular strands and formed 
cord-like structures, integrated and surrounded by the interconnecting cellular network 
of ASC or BMSC. HUVEC outgrowth independent of ASC or BMSC was not observed 
in our cultures. In addition, we were unable to observe the formation of a lumen in 
the combined HUVEC/ASC or HUVEC/BMSC cell strands (Fig.6A-B). The outgrowing 
cellular strands in these cultures therefore resemble mostly prevascular structures.
B 
ASC BMSC 
A 
D 
5% HUVEC + 95% ASC 5% HUVEC + 95% BMSC  
C 
Figure 6. HUVEC organize into prevascular-like structures when co-cultured with BMSC and ASC. 
HUVEC/BMSC and HUVEC/ASC co-culture spheroids were cultured in fi brin in vitro for 14 days, 
and cross-sections were stained with Perl’s iron stain to detect superparamagnetic iron oxide 
(SPIO) labeled HUVEC (blue). Nuclear fast red was used as a counter stain. Images at the left show 
HUVEC/BMSC co-culture spheroids. Images at the right show HUVEC/ASC spheroids. Scale bar = 
200μm. (A-B) (see color section for a full-color version)
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Organization of HUVEC in clusters was independent of the amount of BMSC and 
ASC added to the co-culture spheroids, however, lower proportions of BMSC or ASC 
in the co-culture spheroids resulted in the formation of more HUVEC clusters in the 
core of the spheroids. Furthermore, outgrowing HUVEC structures were only observed 
in co-culture spheroids containing 80% or 60% of BMSC or ASC (Fig.6C-H). HUVEC 
structures in the co-culture spheroids expressed the vascular marker CD34 (Fig.7). In 
addition, αSMA was expressed by cells in the center and in the periphery as well as 
in the outgrowing cellular networks of the co-culture spheroids (Fig.8). Moreover, co-
staining of αSMA and Perl’s iron stain showed that outgrowing SPIO-labeled HUVEC 
structures were surrounded by αSMA-expressing cells (Fig.9).
The co-culture of 60% BMSC or 60% ASC with HUVEC affected the organiza-
tion of the outgrowing cellular strands. Compared to the 100% BMSC and 100% 
ASC spheroids, cellular strands emanating from 40% HUVEC/60%BMSC and 
40%HUVEC/60%ASC co-culture spheroids organized into a denser network [3.2 ± 
0.9 cellular strands/mm2 in 40%HUVEC/60%BMSC versus 2.1 ± 1.0 cellular strands/
mm2 in 100% BMSC (P<0.05); 4.1 ± 0.8 cellular strands/ mm2 in 40%HUVEC/60%ASC 
versus 3.4 ± 0.4 cellular strands/mm2 in 100% ASC (P<0.05)]. Little change in the orga-
nization of the cellular strands was observed in co-culture spheroids containing 95% 
40% HUVEC + 60% BMSC 
G 
40% HUVEC + 60% ASC 
H 
E 
20% HUVEC + 80% BMSC 20% HUVEC + 80% ASC 
F 
Blue stained prevascular-like structures from SPIO-labeled HUVEC alongside of BMSC or ASC networks. 
(C-D) Five percent HUVEC seeded. (E-F) 20% HUVEC seeded. (G-H) 40% HUVEC seeded.
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or 80% BMSC or ASC [2.3 ± 0.9 and 2.6 ± 0.6 cellular strands/mm2 in 5% HUVEC/95% 
BMSC and 20% HUVEC/80% BMSC versus 2.1 ± 1.0 cellular strands/mm2 in 100% 
BMSC; 3.5 ± 0.34 and 3.2 ± 0.6 cellular strands/mm2 in 5% HUVEC/95% ASC and 20% 
HUVEC/80% ASC versus 3.4 ± 0.4 cellular strands/mm2 in 100% ASC]. (Fig.10).
DISCUSSION
The results of our study suggest that ASC similar to BMSC support the formation of 
prevascular-like structures by HUVEC in vitro. This is based on our fi nding that in vitro 
cultured spheroids with 100% HUVEC did not form any organized structures, while 
co-culture spheroids of HUVEC with ASC or BMSC did form elongated cord-like struc-
tures in fi brin. In addition, our study showed that BMSC and ASC displayed several 
proneovascular features: both the BMSC spheroids and the ASC spheroids generated 
a branched interconnected cellular network that abundantly expressed αSMA and in 
the case of ASC spheroids also CD34.
Figure 7. Prevascular-like structures in HUVEC/BMSC and HUVEC/ASC co-culture spheroids ex-
press CD34. HUVEC/BMSC and HUVEC/ASC co-culture spheroids were cultured in fi brin in vi-
tro for 14 days, and cross-sections were immunostained with anti-human CD34 antibody (brown). 
Scale bar = 200μm. CD34 positive vascular-like structures in HUVEC/BMSC (A, C) and HUVEC/
ASC spheroids (B, D). (see color section for a full-color version)
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Our fi nding that only low levels of αSMA were expressed by ASC and BMSC prior 
to use in the spheroid cultures suggests an affi liation of BMSC and ASC to the smooth 
muscle lineage under our culture conditions. Moreover, these αSMA-expressing cells 
surrounded the endothelial cord-like structures in the co-culture spheroids, suggesting 
a stabilizing role for the BMSC and ASC in this setting. To investigate the mechanism 
by which the BMSC and ASC support the formation of endothelial outgrowth in our cul-
tures in more detail, we investigated the secretion of several factors known to infl uence 
angiogenesis. We found signifi cantly higher amounts of HGF, TIMP1 and TIMP2 in the 
conditioned medium of BMSC and ASC spheroid cultures when compared to HUVEC 
conditioned medium or unconditioned medium. In contrast, the levels of ANG2, TPO, 
PDGFB and TNFα in BMSC and ASC conditioned medium did not signifi cantly differ 
from HUVEC conditioned or unconditioned medium.
Figure 8. αSMA is expressed in both HUVEC/BMSC and HUVEC/ASC co-culture spheroids. Forty 
percent HUVEC/ 60%BMSC and 40% HUVEC/ 60% ASC co-culture spheroids were cultured in 
fi brin in vitro for 14 days, and cross-sections were immunostained with anti-human αSMA antibody 
(brown). Scale bar = 200μm. Similar to 100% BMSC and 100% ASC spheroids (Figure 3), αSMA 
was expressed by cells in the center and in the periphery as well as in the outgrowing cellular 
networks of the HUVEC/BMSC (A) and HUVEC/ASC (B) co-culture spheroids (arrows indicate out-
growing aSMA-positive cells). (see color section for a full-color version)
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Secretion of these factors, however, could be signifi cant but too little to be discrimi-
nated from the levels already present in the unconditioned medium. HGF, TIMP1 and 
TIMP2 are known to be involved in new vessel formation: HGF stimulates endothelial 
cell proliferation and induces angiogenesis [31], whereas TIMPs are known to inhibit 
the activities of matrix metalloproteinases (MMPs) [32,33]. Although HGF is known to 
be an important angiogenic factor, experiments using varying concentrations of HGF to 
stimulate outgrowth in HUVEC spheroids showed that HGF on its own was not able to 
initiate outgrowth and organization of HUVEC in this system. Given the elevated levels 
of TIMPs in the medium, it would have been interesting to also analyze the activity 
of MMPs in our cultures by zymography. However, MMPs are abundantly present in 
Figure 9. αSMA expressing BMSC and ASC surround outgrowing HUVEC strands in the co-culture 
spheroids. Forty percent HUVEC/ 60%BMSC and 40% HUVEC/ 60% ASC co-culture spheroids 
were cultured in fi brin in vitro for 14 days, and cross-sections were co-stained with anti-human 
αSMA antibody (brown) and Perl’s iron stain (blue) to identify simultaneously αSMA-positive cells 
and SPIO-labeled HUVEC. Scale bar = 20μm. (A) Blue stained SPIO-labeled HUVEC (see black ar-
row) are surrounded by brown stained αSMA expressing BMSC (see white arrow). (B) Blue stained 
SPIO-labeled HUVEC (see black arrow) that co-localize with brown stained αSMA-expressing ASC 
(see white arrow). (see color section for a full-color version)
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Figure 10. Co-culture of 60% BMSC or ASC with HUVEC affect cellular outgrowth. Images of 
(co-) culture spheroids in fi brin at 3 days of culture. Scale bar = 200μm. Images at the left show 
spheroids containing BMSC. Images at the right show spheroids containing ASC. (A) 100% BMSC 
(B) 100% ASC (C) 5% HUVEC + 95% BMSC (D) 5% HUVEC + 95% ASC (E) 20% HUVEC + 80% 
BMSC (F) 20% HUVEC +80% ASC (G) 40% HUVEC + 60% BMSC (H) 40% HUVEC + 60% ASC. 
Cellular strands emanating from HUVEC/BMSC or HUVEC/ASC co-culture spheroids, containing 
60% BMSC or 60% ASC, organized into a denser network when compared to 100% BMSC or 
100% ASC spheroids. No signifi cant change in network density was measured in HUVEC/BMSC 
and HUVEC/ASC spheroids containing 95% and 80% BMSC or ASC.
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serum and given the high levels of serum in our medium, this would have obscured 
measuring the secreted MMPs specifi cally by the stromal cells.
Despite the high TIMP levels however, we observed removal of much of the fi -
brin within the network (as observed histologically, data not shown), suggesting that 
enough endoproteases (MMPs or other factors such as tissue plasminogen activator) 
were secreted to facilitate fi brin degradation and subsequent cell migration.
The secretion of angiogenic factors by BMSC and ASC in vitro has been reported 
before [4,5]. To our knowledge however, this is the fi rst study in which both the an-
giogenic factor secretion by BMSC and ASC and their interaction with HUVEC can 
be compared in a 3-D setting in vitro. Although we did not fi nd signifi cant differences 
in the secretion of the measured angiogenic factors between BMSC and ASC, ASC 
conditioned medium did have a positive effect on HUVEC outgrowth and organization 
(Figure 5D) while no such effect was observed for HUVEC spheroids cultured on BMSC 
conditioned medium (Figure 5C). These results suggest that other, yet uncharacterized 
trophic factors or metabolites were secreted by ASC.
Despite this difference in the effect of ASC and BMSC conditioned medium on HU-
VEC outgrowth and organization, BMSC and ASC both supported HUVEC outgrowth 
in the direct co-culture, indicating that HUVEC outgrowth, particularly in the BMSC 
co-culture spheroids, is not merely achieved by the secretion of growth factors. The 
exact mechanism by which BMSC and ASC support HUVEC outgrowth in this system 
remains unknown. However, since both BMSC and ASC formed integrated cellular 
networks with the outgrowing HUVEC, we hypothesize that direct cell-cell contacts 
and reciprocal signaling play an important role.
The outgrowth and organization of HUVEC into prevascular-like structures in HU-
VEC/BMSC and HUVEC/ASC spheroid co-cultures was seen in samples that contained 
80% or 60% stromal cells. No organized endothelial structures were observed in 5% 
HUVEC/95% stromal cell co-cultures. In contrast, Rouwkema et al.[19] reported that 
spheroid co-cultures of BMSC and HUVEC containing 98% BMSC or more, promoted 
the formation organized endothelial structures. It is uncertain whether this difference 
is due to the use of a higher total cell number (500,000 cells instead of 20,000 cells), a 
different method of spheroid formation (centrifugation instead of the hanging droplet 
method) or the use of osteogenic culture medium. All these factors, however, might 
affect the interaction of the HUVEC with the stromal cells. For example, spheroids 
obtained by centrifugation of cells, are more densely packed when compared to those 
obtained by the hanging droplet method. This, in combination with a higher total cell 
number, may create a more hypoxic environment in the core of the spheroids, hereby 
affecting HUVEC-stromal cell interactions.
Mimicking the complete physiological process of vessel formation in vitro for tissue 
engineering purposes still poses a future challenge. For example, not all HUVEC in our 
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co-culture grew out and formed cellular strands. In addition, the outgrowing HUVEC 
structures in our cultures did not yet include a lumen. Possible reasons for this could 
be an insuffi cient culture time, and/or suboptimal interaction between the stromal cells 
and the endothelial cells. The signals required for an optimal interaction between stro-
mal cells and endothelial cells are mostly unknown, but likely include specifi c cell-cell 
contacts as well as paracrine- (direct angiogenic factors and indirect angiogenic factors 
such as HIF-1alpha), mechanical- (shear stress) and physical (oxygen tension) stimuli. 
In this light, several strategies might be considered to improve the supportive role of 
stromal cells in the formation of organized endothelial structures in vitro. For example, 
the selected culture medium in combination with the supplementary growth factors 
most certainly plays an essential role in vascular network formation of HUVEC-stromal 
cell co-cultures in vitro. In this study, we used endothelial growth medium supplemented 
with VEGF, a medium that stimulates endothelial cell growth and sprouting. Although 
endothelial proliferation is an important step in new vessel formation, endothelial cell 
differentiation, organization and stabilization are at least equally important. Moreover, 
the culture medium should also support the tissue that actually is being constructed. 
Finding a culture medium that supports tissue-specifi c needs and enables BMSC and 
ASC to provide the critical support for endothelial differentiation, organization and 
stabilization should therefore be a matter of further investigation. Likewise, in vivo, 
tissue-hypoxia is a potent stimulus triggering expansion of the nascent vessel network 
via upregulation of many angiogenic factors through hypoxia inducible factors [34]. In 
addition, culture of BMSC and ASC under hypoxic conditions in vitro has shown to 
augment the expression of a wide array of angiogenic factors [4,35,36,37]. Exposure of 
stromal cell-HUVEC co-cultures to hypoxic conditions may therefore possibly induce 
the appropriate angiogenic milieu, promoting the formation of more mature vascular-
like structures.
CONCLUSION
In summary, our results suggest that ASC, similar to BMSC, can support the forma-
tion of prevascular-like structures in vitro partly through the release of trophic factors 
but also by the formation of direct cell-cell contacts. Thus, ASC may be an attractive 
alternative source of cells for the use in complex tissue engineering applications.
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ABSTRACT
Vascularization is still one of the most important limitations for the survival of en-
gineered tissues after implantation. In this study, we aim to improve the in vivo 
vascularization of engineered adipose tissue by pre-forming vascular structures 
within in vitro-engineered adipose tissue constructs that can integrate with the host 
vascular system upon implantation. Different cell culture media were tested and dif-
ferent amounts of human adipose tissue-derived mesenchymal stromal cells (ASC) 
and human umbilical vein endothelial cells (HUVEC) were combined in spheroid co-
cultures to obtain optimal conditions for the generation of prevascularized adipose 
tissue constructs. Immunohistochemistry revealed that prevascular structures were 
formed in the constructs only when 20% ASC and 80% HUVEC were combined and 
cultured in a 1:1 mixture of endothelial cell medium and adipogenic medium. More-
over, the ASC in these constructs accumulated lipid and expressed the adipocyte-
specifi c gene fatty acid binding protein-4. Implantation of prevascularized ASC/
HUVEC constructs in nude mice resulted in a signifi cantly higher amount of ves-
sels (37±17 vessels/mm2) within the constructs compared to non-prevascularized 
constructs composed only of ASC (3± 4 vessels/mm2). Moreover, a subset of the 
pre-formed human vascular structures (3.6±4.2 structures/mm2) anastomosed with 
the mouse vasculature as indicated by the presence of intravascular red blood cells. 
Our results indicate that pre-formed vascular structures within in vitro-engineered 
adipose tissue constructs can integrate with the host vascular system and improve 
the vascularization upon implantation.
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INTRODUCTION
Despite various levels of clinical success, currently used surgical procedures to repair 
soft tissue defects are not optimal. Autologous adipose tissue grafts suffer from donor-
site morbidity [1] and have a tendency to lose volume over time [2,3,4]. Synthetic 
implants also have signifi cant drawbacks such as infection, rejection, leakage and/or 
dislocation [4].
The in vitro development of autologous adipose tissue substitutes using human 
adipose tissue-derived mesenchymal stromal cells (ASC) may offer a future alternative 
to these current treatments [5,6,7,8,9]. However, limited survival of in vitro-engineered 
adipose tissue after in vivo implantation is still a major hurdle for clinical use [1,10]. 
The reason for this limited survival is that ingrowth of blood vessels from the host into 
the engineered adipose tissue construct can take several days [11], which is too slow 
and fatal for many of the cells in the construct. A suffi ciently rapid in vivo vascular-
ization, preventing cell-death in the core of the implanted engineered adipose tissue 
constructs, has not been realized yet.
We and others have shown that endothelial cells (EC) co-cultured with stromal cells 
derived from bone marrow, skin, cardiac muscle, skeletal muscle or adipose tissue can 
form primitive vascular-like structures in vitro [12,13,14,15,16,17,18,19,20]. Few stud-
ies also indicate that such in vitro preformed vascular-like structures (or prevascular 
structures) are able to connect to the host vessels after implantation [17,18,19,21] . The 
ability of prevascular structures to promote the in vivo vascularization of engineered 
adipose tissue constructs, however, has not been tested yet.
In this study, we generate prevascularized adipose tissue constructs using three-
dimensional (3D) spheroids (about 0.6 mm in diameter) containing co-cultured ASC 
and endothelial cells (EC) and test this hypothesis. Specifi cally, we investigated the 
following questions: (1) can we induce in vitro prevascularization of the 3D spheroid 
HUVEC/ASC constructs while simultaneously enabling adipogenic differentiation of 
the ASC? (2) Can the in vitro generated prevascular structures integrate with the host 
vasculature?
MATERIALS AND METHODS
CELL CULTURE
Subcutaneous abdominal adipose tissue was obtained from donors with approval of 
the Medical Ethical Committee (# MEC-2005-157). ASC from 3 different donors of 47, 
54 and 59 years of age were isolated from the adipose tissue as previously described 
[22] and grown on basal medium (Dulbecco’s Modifi ed Eagle Medium 1g/l glucose 
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(Invitrogen, Carlsbad, California), 10% FCS (PAA Laboratories, Pasching, Austria), 10-12 
M dexamethasone, 10-5 M ascorbic acid (both from Sigma-Aldrich, St. Louis, Missouri), 
1% penicillin/streptomycin, 0.5% gentamycin (both from Invitrogen)).
Commercially derived pooled human umbilical vein endothelial cells (HUVEC) 
(Lonza, Verviers, Belgium) were cultured in endothelial growth medium consisting of 
human endothelial serum-free medium (Invitrogen), supplemented with 20% FCS, 
10% human serum (PAA Laboratories), 20ng/ml fi broblast growth factor 2 (FGF2) and 
100ng/ml epidermal growth factor (EGF) (both from Peprotech EC, London, United 
Kingdom). Cells were maintained at 37°C in a humidifi ed atmosphere with 5% CO2, 
and the medium was replenished every 3 days. Passage 2 ASC and passage 5 or less 
HUVEC were used in this study.
MEDIUM SELECTION: PROLIFERATION OF ASC AND HUVEC IN 
DIFFERENT MEDIA
The proliferation of ASC and HUVEC in different media was tested in 6-well (ASC) 
and 24-well (HUVEC) plates (Costar®, Corning Inc., Corning, New York) seeded with 
1042 cells/cm2 and 5000 cells/cm2, respectively. ASC and HUVEC were seeded onto 
the culture plates in basal medium and endothelial growth medium respectively and 
incubated overnight at 37ºC in a humid atmosphere with 5% CO2 to ensure attachment 
of the cells. The next day, these media were removed and the cells were washed 
with PBS and replenished with 3 different test media: (1) endothelial cell medium 
consisting of endothelial-serum free medium supplemented with 5% FCS, 20ng/ml 
FGF-2 and 100ng/ml EGF; (2) adipogenic medium consisting of Dulbecco’s modifi ed 
Eagle Medium 4.5g/l glucose (Invitrogen), 10% FCS, 1μM dexamethasone, 0.01 mg/
ml insulin (Eli Lilly, Houten, The Netherlands) 0.2 mM indomethacin (Sigma-Aldrich), 
0.5mM 3-isobutyl-I-methyl-xanthine (Sigma-Aldrich), 1% penicillin/streptomycin and 
0.5% gentamycin; (3) 1:1 mixture of endothelial cell medium and adipogenic medium 
(endothelial/adipogenic mix medium). The culture media were refreshed every 3 days 
and cell numbers of duplicate wells were counted twice with a Casy® cell counter 
(Innovatis, Bielefeld, Germany) at 0, 3, 7 and 10 days of culture.
FORMATION OF SPHEROIDS
Spheroids containing only ASC or ASC with different amounts of HUVEC (5% HU-
VEC/95% ASC, 20% HUVEC /80% ASC, 40% HUVEC /60% ASC and 80% HUVEC 
/20% ASC) were prepared in 10 ml polypropylene tubes (Techno Plastic Products, 
Trasadingen, Switzerland) in 0.5 ml endothelial cell medium. ASC or HUVEC/ASC sus-
pensions containing a total of 2.5*105 cells were added to the tubes and subsequently 
centrifuged at 150 x g for 5 minutes. The tubes with the resulting cell pellets were 
then incubated overnight at 37ºC with 5% CO2 in a humidifi ed atmosphere to allow 
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the formation of spheroids. After overnight incubation, the endothelial cell medium 
of the ASC/HUVEC co-culture spheroids was replaced by endothelial/adipogenic mix 
medium and in ASC spheroids by endothelial/adipogenic mix medium or adipogenic 
medium. Medium was replenished every 2 days.
FLOW CYTOMETRIC ANALYSIS OF CO-CULTURE SPHEROIDS
Following 2, 7 and 14 days of culture, HUVEC/ ASC co-culture spheroids were harvested 
for fl ow cytometric analysis. To obtain a single cell suspension, spheroids were washed 
twice with PBS and digested in a sterile-fi ltered collagenase type I solution (1000 units/
ml in PBS) for 20 minutes at 37˚C. After digestion, cell suspensions were washed with 
FACS buffer (Hanks’ Balanced Salt Solution (Invitrogen), 2% BSA, 0.05% sodium azide 
(both from Sigma-Aldrich) and 2% heat-inactivated human serum (PAA Laboratories)) 
and labeled for 30 minutes on ice in the dark with mouse anti-human CD31 fl uores-
cently labeled antibody (dilution 1:1 in FACS buffer, BD Biosciences Pharmingen (cat 
no.555446), Erembodegem, Belgium). Cells were washed again, resuspended in 300μl 
of FACS buffer and directly analyzed on a FACS-Calibur instrument (Becton-Dickinson 
Biosciences, Franklin Lakes, New Jersey).
 RNA ISOLATION, COMPLEMENTARY DNA (CDNA) SYNTHESIS AND 
QUANTITATIVE POLYMERASE CHAIN REACTION (Q-PCR)
ASC spheroids were cultured in endothelial/adipogenic mix medium or adipogenic 
medium for 7 days in vitro. Six spheroids were prepared from each ASC donor, and 3 
pools of 2 spheroids from each donor were used for RNA isolation. The spheroids were 
fragmented with a pestle on ice and sheared using an insulin syringe.
Total RNA was extracted from ASC spheroids using Qiazol Lysis Reagent (Qiagen, 
Venlo, The Netherlands). RNA was further purifi ed using the RNeasy Micro Kit (Qia-
gen) with on-column DNA-digestion. Total RNA was quantifi ed using a NanoDrop™ 
1000 spectrophotometer (Thermo Scientifi c, Wilmington, Delaware) according to 
manufacturer’s instructions and 250 ng RNA was reverse transcribed into cDNA using 
RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany).
The mRNA levels of the adipogenic marker fatty acid binding protein 4 (FABP4), were 
analyzed using the Taqman®Gene Expression Assay for FABP4 (Hs00609791_m1) (ABI) 
according to the manufacturer’s instructions. Beta-2-microglobulin (B2M) mRNA levels 
were analyzed for normalization with the Q-PCR MasterMix Plus for SYBR® Green I 
dTTP (Eurogentec, San Diego, California) and the following, gene-specifi c primers set: 
Fw 5’-TGCTCGCGCTACTCTCTCTTT -3’, Rv 5’-TCTGCTGGATGACGTGAGTAAAC-3’). 
Q-PCR was performed with an ABI PRISM® 7000 Sequence Detection System and 
analyzed using 7000 System SDS software (ABI, Foster City, California).
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IN VIVO IMPLANTATION
Four spheroids consisting of ASC and four spheroids consisting of 80% HUVEC /20% 
ASC were created from each of the three donors, resulting in a total of twelve ASC 
spheroids and twelve 80% HUVEC /20% ASC spheroids. After 7 days of in vitro cul-
ture, the spheroids were implanted subcutaneously in the left and right scapular area 
of six nine-weeks-old athymic male nude mice (NMRI-nu/nu, Taconic, Hudson, New 
York). The mice were placed under general anesthesia with 2.5% isofl urane after which 
two separate 0.5 cm incisions were made through the dorsal skin. Next, two separate 
subcutaneous pockets were prepared by blunt dissection of the subcutaneous tissue. 
One pocket was fi lled with two ASC spheroids and the other pocket was fi lled with two 
80% HUVEC/20% ASC spheroids. Pockets were closed with discontinuous sutures 
using Mersilk 5-0 (Ethicon, Somerville, New Jersey). The content of each pocket was 
regarded as one construct.
Seven days after implantation, the mice were sacrifi ced and the constructs re-
trieved. All procedures were approved by the animal ethical committee (EUR. 1292).
HISTOLOGY
Constructs harvested 7 days after culture or 7 days after implantation were fi xed in 
10% formalin in PBS and embedded in paraffi n, or directly embedded in Tissue-Tek 
(Sakura, Finetek Europe, Zoeterwoude, The Netherlands) and snap frozen.
Paraffi n-embedded sections (5 μm) were deparaffi nized and rehydrated. Cryo-
sections (5 μm) were fi xed with 3.7% formalin in deionised water for 1 hour.
CD31 STAINING OF IN VITRO CULTURED SPHEROIDS
To determine HUVEC organization in spheroid cultures, a monoclonal mouse anti-human 
CD31 antibody (Clone JC70A, Dako (cat no. M0823), Glostrup, Denmark) was used. 
Antigen retrieval was achieved by heating at 95˚C for 15 minutes in Dako Cytomation 
Target Retrieval Solution high pH. After overnight incubation with CD31 antibody (1:40 
dilution in PBS /1% BSA) at 4˚C, a secondary biotin-conjugated goat anti-mouse an-
tibody (1:200 dilution in PBS/1% BSA, Dako (cat no. E0433)) was used for 30 minutes 
at room temperature followed by incubation with streptavidin-horseradish peroxidase 
(1:300 dilution in PBS/1% BSA, Dako (cat no. P0397)) for 30 minutes. Diaminobenzi-
dine (Sigma-Aldrich) was used to visualize CD31 expression. The slides were weakly 
counterstained with hematoxylin, dehydrated through graded alcohols and mounted 
with Permount (VWR International B.V., Amsterdam, The Netherlands).
CD31 AND VIMENTIN STAINING IN SPHEROID CONSTRUCTS POST-IMPLANTATION
To distinguish human tissue from mouse tissue and to determine the number and relative 
area occupied by human vascular structures in construct sections post-implantation, 
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monoclonal mouse anti-human vimentin antibody (Clone V9, 1:40 dilution in PBS/ 1% 
BSA, Sigma-Aldrich (cat no. V6630)) and monoclonal mouse anti-human CD31 anti-
body (Dako) were used, respectively. To reduce unspecifi c binding of the secondary 
goat anti-mouse antibody (Dako) to mouse IgGs, the mouse-on mouse HRP-Polymer 
Kit (Biocare Medical, Concord, California) was used, according to manufacturer’s 
instructions with some slight modifi cations. In short, antigen retrieval was performed 
through incubation in Rodent Decloaker® (Biocare Medical) for 60 minutes at 95˚C. 
Non-specifi c binding sites were blocked with Rodent Block M® (Biocare Medical) and 
sections were stained overnight with CD31 or vimentin at 4˚C. The MM-polymer-HRP® 
secondary antibody (Biocare Medical) was used, followed by incubation in diami-
nobenzidine (Sigma-Aldrich) to visualize CD31 or vimentin expression, respectively. 
The slides were weakly counterstained with hematoxylin, dehydrated through graded 
alcohols and mounted with Permount (VWR International B.V., Amsterdam, The Neth-
erlands).
OIL RED O STAINING
Accumulated lipid in ASC in spheroids was detected after 7 days of in vitro culture 
and after 7 days of implantation. In short, a 0.5% (w/v) stock solution of Oil Red O in 
triethyl-phosphate (Sigma-Aldrich) was diluted 3:2 with deionised water to prepare an 
Oil Red O working solution. Subsequently, cryo-sections were fi xed, rinsed and im-
mersed in Oil Red O working solution for 30 minutes. Hereafter, sections were washed 
with deionised water and counterstained with hematoxylin for 1 minute. Finally, sec-
tions were rinsed with running tap water for 10 minutes, and covered with Imsolmount 
(Klinipath, Zevenaar, The Netherlands).
HISTOMORPHOMETRY
High resolution (0.23 μm/pixel), low magnifi cation (40×) digital micrographs covering 
2-to-3 complete vimentin/CD31 immunostained cross-sections of each construct were 
made with a Nanozoomer HT (Hamamatsu Photonics, Hamamatsu City, Japan) for 
analysis. Subsequently, NIH ImageJ software (http://rsb.info.nih.gov/ij/) was used to 
count the number of CD31 positive prevascular structures, the area occupied by these 
structures and the complete area of human tissue in the constructs.
STATISTICAL ANALYSIS
All data are expressed as mean ± standard deviation, except a part of the in vivo 
vascularization data, which are expressed as median (IQR). The FACS data were ana-
lyzed with the mixed model analysis of variance using SAS software (SAS Institute, 
Cary, North Carolina). The FABP4 expression data were analyzed with the unpaired t 
test with Welch correction using Graphpad Prism 5.01 software (Graphpad Software, 
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San Diego, California). Differences in the number of (mouse) vascular lumens per 
cross-sectional area between prevascularized and non-prevascularized constructs 
were analyzed with the nonparametric Mann-Whitney test using Graphpad Prism 5.01 
software. Values with P≤0.05 were considered signifi cant.
RESULTS
HUVEC AND ASC PROLIFERATION IN DIFFERENT MEDIA
To fi nd the appropriate culture conditions for our HUVEC/ASC spheroid co-cultures 
we determined the proliferation potential of both ASC and HUVEC in 3 different media: 
endothelial cell medium, adipogenic medium and endothelial/adipogenic mix medium.
ASC and HUVEC proliferated on both endothelial cell medium and endothelial/ad-
ipogenic mix medium, while neither cell type proliferated in adipogenic medium (Fig.1). 
ASC and HUVEC proliferation was higher on endothelial cell medium than on endothe-
lial/adipogenic mix medium. However, ASC had a more spindle-like morphology and 
accumulated no lipid on endothelial cell medium when compared to the ASC cultured 
in endothelial/adipogenic mix medium (data not shown), indicating that endothelial/
adipogenic mix medium had a more positive effect on the adipogenic differentiation 
of ASC. Since endothelial/adipogenic mix medium supported both ASC and HUVEC 
proliferation and was more likely to support ASC adipogenic differentiation than endo-
thelial cell medium, subsequent co-culture experiments were conducted in endothelial/
adipogenic mix medium.
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FORMATION OF SPHEROIDS
Following the described method, ASC and HUVEC/ASC co-cultures formed solid 3D 
spheroids with a diameter of 0.63 ± 0.12mm. These spheroids were stable during the 
total subsequent culture period of 14 days.
FLOW CYTOMETRIC ANALYSES OF CD31-POSITIVE CELLS IN HUVEC/
ASC SPHEROID CO-CULTURES
To determine whether the amount of HUVEC seeded in the spheroid co-cultures re-
mained stable during culture we determined the percentage of CD31-positive cells 
in the co-culture spheroids after 2, 7 and 14 days of culture using fl ow cytometric 
analysis. The percentage of CD31-positive cells decreased in all spheroids during 
culture (Fig.2A). Especially between days 2 and 7 there was a signifi cant decline in the 
percentage of CD31-positive cells in almost all spheroids. However, after 14 days of 
culture all spheroids still contained CD31-positive cells, with the spheroids seeded with 
80% of HUVEC still containing almost 25% of CD31-positive cells. This percentage 
decreased with decreasing HUVEC seeding densities (Fig.2A-E). Spheroids containing 
no HUVEC also contained a small percentage (0.77-3.21%) of CD31-positive cells.
Figure 1. Proliferation of ASC and HUVEC in tissue culture fl asks in different media. (A) ASC and 
(B) HUVEC were cultured in tissue culture fl asks for 10 days in three different media; endothelial cell 
medium, adipogenic medium and a 1:1 mixture of endothelial cell medium and adipogenic medium 
(endothelial/adipogenic mix medium). The number of cells was determined at days 3, 7 and 10 of 
culture. Results are shown as mean ± standard deviation. Proliferation of ASC was determined for 3 
different donors. HUVEC and ASC numbers were assayed in duplicate wells.
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Figure 2. Flow cytometric analysis of CD31-positive cells in HUVEC/ASC spheroid co-cultures. 
The percentage of CD31-positive cells in co-culture spheroids seeded with different percentages of 
HUVEC and ASC was determined using fl ow cytometric analysis after 2, 7 and 14 days of culture. 
(A) Graph depicting the percentage of CD31+-cells in co-culture spheroids seeded with 0%, 5%, 
20%, 40% and 80% HUVEC after 2, 7 and 14 days of culture. Values are shown as mean ± stan-
dard deviation. For each of the three ASC donors two spheroid co-cultures seeded with 0%, 5%, 
20%, 40% and 80% HUVEC were assayed. Statistical comparisons were performed with the mixed 
model analysis of variance. *P<0.05, **P<0.01, ***P<0.001 (compared to day 7 and 14 of culture). 
(B-E) Representative dot-plots, depicting the expression of CD31 in co-culture spheroids seeded 
with (B) 5% HUVEC (C) 20% HUVEC (D) 40%HUVEC and (E) 80% HUVEC after 7 days of culture. 
The percentages in the gated areas represent the percentage of CD31-positive cells
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HUVEC ORGANIZATION IN HUVEC/ASC SPHEROID CO-CULTURES
After 7 days of culture in endothelial/adipogenic mix medium, cross-sections of spher-
oids co-cultures were stained with CD31 to determine endothelial organization. CD31-
positive cells in ASC spheroids seeded with 5, 20, and 40% HUVEC were present as 
round cell clusters dispersed throughout the spheroids (Fig.3A-C).
In ASC spheroids seeded with 80% HUVEC however, the CD31-positive endo-
thelial cells aligned and formed prevascular structures amidst the ASC (Fig.3D). This 
endothelial organization was observed in spheroids of all 3 donors. Although HUVEC 
aligned and formed loops, no lumen formation was observed.
Figure 3. HUVEC elongate and form organized prevascular structures in 80%HUVEC/20%ASC 
spheroid co-cultures. Spheroid co-cultures seeded with different percentages of HUVEC were cul-
tured for 7 days in vitro, and immunostained with anti-human CD31 (brown), showing organization 
of HUVEC. Cross-sections were counterstained with hematoxylin (blue). (A) 5% HUVEC seeded 
(B) 20% HUVEC seeded (C) 40% HUVEC seeded (D) 80% HUVEC seeded (white arrows point at 
strand and loop formation). Scale bars= 20 μm. Insets show general overview of cross-sections. 
Inset scale bars= 200μm. (see color section for a full-color version)
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ADIPOGENIC DIFFERENTIATION OF ASC IN SPHEROID CULTURES IN 
VITRO
To assess adipogenic differentiation of the ASC in the spheroids, we measured the 
expression of the adipogenic marker FABP4 in ASC spheroids after 7 days of culture. 
Q-PCR analysis showed that FABP4 is expressed by ASC in spheroids cultured in 
endothelial/adipogenic mix medium, albeit signifi cantly lower than in the ASC cultured 
in adipogenic medium (Fig.4A).
To further characterize adipogenic differentiation, we evaluated the ability of ASC to 
accumulate lipid after 7 days of culture in endothelial/adipogenic mix medium. Oil Red 
O staining showed that Oil Red O-positive cells were evident in ASC in these spheroid 
cultures (Fig.4B).
ASSESSMENT OF HUMAN VASCULAR STRUCTURES IN HUVEC/ASC 
SPHEROIDS FOLLOWING IMPLANTATION IN NUDE MICE
Following 7 days of culture, the prevascularized 80% HUVEC/20% ASC spheroids and 
non-prevascularized ASC spheroids were implanted subcutaneously in nude mice, in 
order to determine if preformed human vascular structures were able to promote in vivo 
vascularization. After 7 days the spheroid constructs were retrieved. Gross examination 
revealed that the constructs still had a spherical shape and were invaded by vessels (Fig.5). 
To determine whether human vascular structures were present inside the retrieved 
constructs, we performed immunostaining with anti-human CD31. Cross-sections of 
Figure 4. ASC in spheroid cultures express the adipocyte specifi c gene fatty acid binding protein 4 
(FABP4) and stain positive for Oil Red O. ASC spheroid cultures were cultured for 7 days in vitro in 
endothelial/adipogenic mix medium or in adipogenic medium. (A) Q-PCR was used to measure the 
expression levels of FABP4. Expression levels are relative to beta-2-microglobulin positive-control 
housekeeping gene (dCt). Values are means ± standard deviations. Six ASC spheroid cultures were 
prepared from each of the three ASC donors, and three pools of two spheroids from each donor 
were assayed. Statistical comparisons were performed with the unpaired t test with Welch correc-
tion. *P<0.05 (compared to adipogenic medium).
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(B) Cross-section of an ASC spheroid stained with Oil Red O (red) and counterstained with hematoxylin 
(blue). Note the presence of red-stained lipid droplets. Scale bar= 50μm
Figure 5. Macroscopic view of spheroid constructs 7 days after implantation. Representative im-
ages of (A) ASC spheroid construct and (B) 80% HUVEC/20%ASC spheroid construct taken at day 
7 postimplantation. Scale bar= 1mm. (see color section for a full-color version)
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the retrieved spheroid constructs showed that none of the ASC spheroid constructs 
and 4 out of the 6 80% HUVEC /20% ASC spheroid constructs contained human 
CD31-positive structures. To provide insight in the vascularization of the constructs, 
we measured three parameters: (1) the number and (2) density of vascular lumens of 
human origin and (3) the percentage of human CD31-positive cells per cross section. 
The number of human vascular lumens per cross-section ranged from 13 lumens/mm2 
to 45 lumens/mm2 (average 23±15 lumens/mm2) with a lumen density that ranged from 
0.1 to 4.5% (average 1.8±2.0%) and a human CD31-positive-cell-density of 6.9±4.5%. 
The number of human vascular lumens and the lumen density were variable in cross-
sections of different spheroid constructs of the same ASC donor as well as between 
ASC donors.
Importantly, the human CD31-positive vascular structures showed an increased 
organization when compared to the constructs prior to implantation (compare Fig.3D 
with Fig.6A) and frequently contained lumen. A subset of human vascular lumens 
(3.6±4.2 lumens/mm2) with a lumen density of 1.0±1.1% was fi lled with red blood cells 
indicating that these lumens were perfused (Fig.6A-B).
The number of vascular lumens of mouse origin (lumens not stained with CD31) 
and the total number of vascular lumens (lumens not stained with CD31 plus the 
CD31-positive lumens) per tissue section were also evaluated for the ASC and 
80%HUVEC/20%ASC constructs. Both the median values of the number of mouse 
vascular lumens/mm2 and the total number of vascular lumens were signifi cantly higher 
in 80%HUVEC/20%ASC constructs when compared to ASC constructs (number of 
Figure 5. (continued)
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mouse vascular lumens/mm2 median: 17 [IQR: 14-17] versus median: 0 [IQR: 0-6], 
p<0.05; total number of vascular lumens median 38 [IQR: 35-47] versus median: 0 
[IQR: 0-6], p<0.05).
Figure 6. In vivo organization of prevascular structures in spheroid constructs. Spheroid co-cultures 
seeded with 80% HUVEC /20% ASC were cultured for 7 days in vitro, and then implanted subcuta-
neously in the right and left scapular region of nude mice for 7 days. Cross-sections were immunos-
tained with human specifi c CD31 antibody (brown) and counterstained with hematoxylin (blue). (A) 
Overview of a cross-section, showing human CD31-positive vascular structures (spheroid located 
in white oval). Scale bar = 50μm. (B) High-magnifi cation image of human CD31-positive lumina (see 
black arrows) and unstained mouse vessels (see white arrows). Scale bar = 20μm. Note the pres-
ence of red blood cells in human CD31-positive lumina. (see color section for a full-color version)
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ASSESSMENT OF LIPID ACCUMULATION IN SPHEROIDS FOLLOWING 
IMPLANTATION IN NUDE MICE
To evaluate whether ASC in spheroid constructs also contained lipids after implanta-
tion, cross-sections of retrieved constructs were stained with Oil Red O. Similar to the 
in vitro cultures, Oil Red O-positive cells were evident in spheroid constructs (Fig.7A). 
Vimentin staining of consecutive cross-sections of the same spheroid constructs 
showed that Oil Red O-positive cells and vimentin-positive cells coincide in the same 
area, indicating that the Oil Red O-positive cells were from human origin (Fig.7B).
p p
p p
Figure 7. Accumulated lipid in HUVEC/ASC spheroid constructs 7 days after implantation. Spheroid 
co-cultures seeded with 80% HUVEC and 20% ASC were cultured for 7 days in vitro, and then 
implanted subcutaneously in the right and left scapular region of nude mice for 7 days. (A) Cross-
sections were stained with Oil Red O (red) or (B) immunostained with vimentin (brown) and counter-
stained with hematoxylin (blue). Scale bar = 50μm. Note that Oil Red O-positive cells and vimentin-
positive cells coincide in the same area. (see color section for a full-color version)
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DISCUSSION
The present study demonstrates that our HUVEC/ASC spheroid co-culture system leads 
to the formation of prevascular structures while simultaneously enabling adipogenic dif-
ferentiation of ASC in vitro, as indicated by the accumulation of lipid and the expression of 
FABP4. Moreover, our study shows that the prevascular structures within the implanted 
constructs are able to continue their development in vivo and can be incorporated into 
the host vasculature, thereby contributing to the vascularization of the constructs.
After 7 days of implantation of the spheroids, we found that most of the 80% HUVEC 
/20% ASC spheroid constructs contained human CD31-positive vascular structures. 
These vascular structures regularly included lumen, indicating stability and advanced 
development of the vascular structures in vivo. In contrast, ASC spheroid constructs 
did not contain any human CD31-positive vascular structures, demonstrating that the 
addition of HUVEC to ASC spheroids is necessary for the formation of human vascular 
structures in vivo.
In vitro formed vascular structures have been shown to be able to connect to host ves-
sels upon implantation [17,18,19,21]. In our study, we observed red blood cells in a subset 
of human CD31-positively stained lumina, indicating a connection of the HUVEC-derived 
vascular structures with the mouse vasculature. In addition, we found a higher total number 
of vascular lumens in cross- sections of 80% HUVEC/20%ASC constructs when compared 
to the total number of lumens in ASC constructs. This higher total number of vascular 
lumens in 80% HUVEC/20%ASC constructs is partly due to the presence of HUVEC-
derived lumens, but also the result of a higher number of mouse-derived lumens, indicating 
augmented ingrowth of mouse vessels. This increased ingrowth of host (mouse) vessels 
likely results from paracrine signalling induced by the implanted HUVEC/ASC co-culture 
spheroids. Taken together, these fi ndings indicate that the in vitro formation of prevascular 
structures in spheroid cultures can contribute to the development of vascular structures in 
vivo. Such a contribution of in vitro prevascularization on in vivo vascularization has also 
recently been shown in HUVEC/fi broblast fi brin-based co-cultures by Chen et al. [23].
Spheroids composed of combinations of tissue-derived stromal cells and endothe-
lial cells for the purpose of prevascularization have been used before [18,24,25]. To our 
knowledge however, this is the fi rst study in which ASC are combined with HUVEC in a 
spheroid co-culture. We found that only spheroids seeded with a high (80%) percentage 
of HUVEC lead to the formation of prevascular structures. In contrast, Rouwkema et 
al. [18], showed that the formation of prevascular structures in HUVEC/bone marrow-
derived stromal cell (BMSC)/ spheroid co-cultures, was positively affected by low (2%) 
percentages of HUVEC seeding. It is uncertain whether this difference is due to the 
use of ASC instead of BMSC, or the use of a different culture medium (endothelial/
adipogenic mix medium instead of osteogenic medium).
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Although HUVEC are an easily accessible source of endothelial cells, they will not 
be able to be used in a clinical setting due to their incompatibility with the recipient’s 
immune system. A potential alternative is the use of microvascular endothelial cells 
derived from adipose tissue [26]. Microvascular endothelial cells have already been 
demonstrated to be able to form vascular structures in cultured skin substitutes after 
implantation [27]. In addition, endothelial progenitor cells derived from blood [28,29] 
are a promising alternative.
An optimal engineered tissue is assembled from multiple tissue-specifi c cells, has 
a typical tissue architecture and function and supports a vasculature compatible with 
the native vascular system [30,31,32]. Endothelial cell/ASC spheroid constructs may 
be appropriate tissue units for engineering vascularized adipose tissue equivalents. 
We have shown that the ASC in our spheroid constructs obtain adipocyte-specifi c 
characteristics whereas the HUVEC remain able to form prevascular structures that 
can integrate with the host (mouse) vasculature in vivo. Spheroid constructs have also 
been shown to be able to form coherent macrotissue patches (mm3 scale), indicating 
that spheroid constructs can be scaled-up and used for the generation of larger-sized 
tissue constructs [24]. Further studies should determine the in vivo survival of prevas-
cularized adipose tissue constructs in the long term, as well as attempt to engineer 
thicker prevascularized adipose tissue equivalents. Potential strategies to produce 
prevascularized adipose tissue equivalents with clinically relevant dimensions could 
be the integration of spheroid constructs with biomaterials such as photocrosslinkable 
gels and advanced techniques such as microfl uidics [33,34].
CONCLUSION
Based on our results, we conclude that a spheroid co-culture of ASC with endothelial 
cells is suitable for the engineering of prevascularized adipose tissue constructs and 
that prevascularization improves the vascularization of engineered adipose tissue con-
structs in vivo. Integration of these prevascular structures in the host vasculature might 
make the difference between cell survival and cell death in especially thicker (>0.6mm 
in diameter) adipose tissue constructs following the initial period after implantation.
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ABSTRACT
Adipose regeneration strategies have been hampered by the inability to supply an 
adequate vascular supply following implantation. Vascularization in vitro, also called 
prevascularization, is a promising method that could promote the vascularization of 
engineered adipose tissue constructs upon implantation. Herein, we compared the 
ability of prevascularized-to-non-prevascularized fi brin-based human adipose tissue 
to promote vascularization. Human adipose tissue-derived stromal cells (ASC) and 
different mixtures (1:1, 1:2 and 1:5) of ASC with human umbilical vein endothelial 
cells (HUVEC) were cultured in fi brin at two different densities (1.0*106 and 10*106 
cells/ml) for 7 days. Histological analysis revealed that prevascular structures formed 
in 1:5 ASC/HUVEC fi brin-based constructs seeded with a total of 10*106 cells/ml. 
These constructs and ASC-only constructs were implanted subcutaneously in athy-
mic mice for 7 days and generated lipid-containing grafts. The number and density 
of blood vessels within the ASC/HUVEC constructs was similar to that of ASC-only 
constructs. Furthermore, immunostaining studies demonstrated human-derived 
vasculature within few of the ASC/HUVEC and ASC-only constructs. A subset of 
this human-derived vasculature contained erythrocytes, indicating integration with 
the host vasculature. In conclusion, our study indicates no difference in the rate of 
vascularization of prevascularized ASC/HUVEC and non-prevascularized ASC-only 
fi brin-based constructs, suggesting that prevascularization of these fi brin-based 
constructs does not promote vascularization. Our results further indicate that not 
only endothelial cells, but also ASC may contribute to the formation of vascular 
lumens upon implantation. This fi nding is interesting since it demonstrates the pos-
sibility of vascularized adipose tissue engineering from a single cell source.
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INTRODUCTION
For patients with soft tissue defects, soft tissue repair with autologous in vitro engi-
neered adipose tissue could be a promising alternative to current surgical therapies. 
Unfortunately, the inability to maintain larger masses of living cells in vivo currently 
limits the size of in vitro engineered adipose tissue constructs. Insuffi cient vasculariza-
tion is thought to be the main reason for this obstacle [1,2,3].
Any tissue that is more than a few hundred microns thick needs a vascular network 
to ensure that every cell is close enough to the blood supply to absorb oxygen and 
nutrients by diffusion [2,4,5,6,7]. The lack of an adequate vascular network will result in 
hypoxia and an inadequate supply of nutrients, eventually leading to cell death. Hence, 
promoting rapid in vivo-vascularization is crucial for the survival of large engineered 
adipose tissue constructs.
One method that can accelerate the process of vascularization upon transplan-
tation is to preform vascular networks within engineered tissue constructs in vitro, 
also referred to as prevascularization [6,8,9,10]. We recently reported the formation of 
three-dimensional prevascularized adipose tissue constructs by co-culturing adipose 
tissue-derived stromal cells (ASC) and human umbilical vein endothelial cells (HUVEC) 
in spheroids and showed that the preformed vascular networks within these constructs 
(with a diameter of approximately 600 microns) could integrate with the host vascular 
system and improve the vascularization upon transplantation [11]
Although spheroids have been shown to be able to form bigger macrotissue patches 
(mm3 scale) [12], it is likely that the use of a scaffold material is needed to produce 
prevascularized adipose tissue equivalents with more clinically relevant dimensions 
(cm3 scale). For this, a scaffold material is needed that can easily be scaled-up and 
used in a clinical setting. Fibrin has shown a successful scaffold material for generation 
of adipose tissue [13,14,15,16] and is especially useful for clinical aims since it can be 
derived from a patient’s own blood thereby avoiding a foreign body response [17]. In 
addition, fi brin-based constructs can easily be scaled-up and molded into any desired 
shape [18]
In the current study we generate prevascularized fi brin-based adipose tissue 
constructs by coculturing ASC and endothelial cells (EC) in fi brin gel and compare 
the vascularization of these fi brin-based ASC/HUVEC constructs with the vascular-
ization of ASC-only fi brin-based constructs following subcutaneous implantation in 
nude mice. We demonstrate that the rate of vascularization in currently used (1.3 ± 0.5 
mm in diameter) prevascularized ASC/HUVEC fi brin-based constructs and ASC-only 
constructs is comparable. Moreover, our results suggest that ASC can be incorporated 
in vascular lumens perfusing the implanted constructs. This indicates the possibility of 
vascularized adipose tissue engineering from a single cell type.
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MATERIALS AND METHODS
ISOLATION AND CULTURE OF ASC
Subcutaneous abdominal adipose tissue was obtained as leftover material from donors 
undergoing breast reconstruction surgery with approval of the Erasmus MC Medical 
Ethical Committee (# MEC-2005-157) and according to the Code of Conduct: “Proper 
Secondary Use of Human Tissue” (http://www.federa.org). Leftover adipose tissue was 
only used from donors who did not opt-out to such use.
ASC from 3 different donors of 47, 54 and 59 years of age and with a BMI of 25.7, 
25.2 and 23.2 were isolated from adipose tissue using collagenase type I (Invitrogen, 
Carlsbad, California) as previously described [19,20] and grown on basal medium (Dul-
becco’s Modifi ed Eagle Medium 1g/l glucose (Invitrogen), 10% FCS (PAA Laboratories, 
Pasching, Austria), 10-12 M dexamethasone, 10-5 M ascorbic acid (both from Sigma-
Aldrich, St. Louis, Missouri), 1% penicillin/streptomycin, 0.5% gentamycin (both from 
Invitrogen). The isolated primary ASC were grown until they reached 90% confl uence. 
At 90% confl uence, adherent cells were released with 0.05% trypsin/ ethylenediami-
netetraacetic acid (EDTA, Invitrogen) and then stored in liquid nitrogen until further use. 
ASC at second passage were used in this study.
CULTURE OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVEC)
Commercially derived pooled HUVEC (Lonza, Verviers, Belgium) were seeded at a 
density of 1*104 cells/cm2 in culture fl asks and cultured in endothelial growth medium 
consisting of human endothelial-serum free medium (Invitrogen), supplemented with 
5% FCS (PAA Laboratories, Cölbe, Germany), 20ng/ml fi broblast growth factor (FGF2) 
and 100ng/ml epidermal growth factor (EGF) (both from Peprotech EC, London, United 
Kingdom). Cells were released at near confl uence with 0.05% trypsin/EDTA and sub-
cultured. Passage 2 HUVEC were stored in liquid nitrogen until further use. HUVEC at 
passage 5 or less were used in this study.
CO-CULTURE OF ASC AND HUVEC IN FIBRIN
Previous work with ASC/HUVEC spheroid co-cultures showed that an ASC: HUVEC 
ratio of 1:5 was optimal for the formation of prevascular structures in vitro [11]. How-
ever, the fi brin culture environment is different from a spheroid culture environment; 
therefore we tested 3 different ASC: HUVEC ratios (1:1, 1:2 and 1:5) in fi brin. Besides 
that, we also tested a low (1.0 *106 cells/ml) and a high (10*106 cells/ml) cell seeding 
density. Constructs with only ASC were used as control.
Fibrin matrices were prepared with the fi brin in vitro angiogenesis assay® (Millipore 
Corporation, Billerica, Massachusetts) according to manufacturer’s instructions with 
some slight modifi cations. In short, ASC and different mixtures of ASC with HUVEC 
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(1:1, 1:2 and 1:5) were each suspended in 30 μl of fi brinogen solution at two different 
densities (1.0*106 cells/ml and 10*106 cells/ml) leading to a total of 5*104 cells or 5*105 
cells per fi brinogen solution. After addition of 20μl of thrombin solution, the cultures 
were immediately placed in individual wells of a 96-wells plate.
After gel formation, the plates were incubated at 37ºC in 5% CO2 in a humidifi ed 
environment for 15 minutes to ensure polymerization of the gels. Following polymeriza-
tion, 200μl of endothelial growth medium was added to each well. After overnight 
equilibration, the culture medium was replaced by 200μl of a 1:1 mixture of endo-
thelial growth medium and adipogenic medium (consisting of Dulbecco’s modifi ed 
Eagle Medium 4.5g/l glucose (Invitrogen), 10% FCS, 1μM dexamethasone, 0.01 mg/
ml insulin (Eli Lilly, Houten, The Netherlands) 0.2 mM indomethacin (Sigma-Aldrich), 
0.5mM 3-isobutyl-I-methyl-xanthine (Sigma-Aldrich), 1% penicillin/streptomycin and 
0.5% gentamycin) from now on referred to as endothelial/adipogenic mix medium. 
Endothelial/adipogenic mix medium was changed every 2 days.
IN VIVO IMPLANTATION
Nine ASC fi brin-based constructs and 9 ASC/ HUVEC (ratio 1:5) fi brin-based con-
structs each seeded with a total of 5*105 cells were obtained by generating 3 ASC 
fi brin-based constructs and 3 ASC/HUVEC fi brin-based constructs with cells of each 
of the 3 donors. Since in previous experiments, cell-free fi brin-based constructs could 
not be identifi ed and retrieved after 7 days of subcutaneous implantation in nude mice 
(data not shown), cell-free fi brin-based constructs were not included as a control group 
in this study. The mice were placed under general anesthesia with 2.5% isofl urane after 
which two separate 0.5 cm incisions were made through the dorsal skin. Next, two 
separate subcutaneous pockets were prepared by blunt dissection of the subcutane-
ous tissue. One pocket was fi lled with an ASC fi brin-based construct and the other 
pocket was fi lled with an ASC/HUVEC fi brin-based construct. Pockets were closed 
with discontinuous sutures using Mersilk 5-0 (Ethicon, Somerville, New Jersey). Seven 
days after implantation, the mice were sacrifi ced and the constructs retrieved. Six 
ASC fi brin-based constructs and 6 ASC/ HUVEC fi brin-based constructs (consisting of 
2 ASC fi brin-based constructs and 2 ASC/HUVEC fi brin-based constructs generated 
with cells from each of the 3 donors) were embedded in paraffi n and used for histomor-
phometry, whereas the remaining 3 ASC fi brin-based constructs and 3 ASC/ HUVEC 
fi brin-based constructs (and thus containing 1 ASC fi brin-based construct and 1 ASC/
HUVEC fi brin-based construct generated with cells of each of the 3 donors) were 
embedded in Tissue-Tek (Sakura, Finetek Europe, Zoeterwoude, The Netherlands) 
and snap frozen for Oil Red O and vimentin (immuno)staining. All animal procedures 
were approved by the institutional Animal Experiments Committee of the ErasmusMC 
(EUR. 1292). (i.e. adherence to the rules prescribed in the national Animals Act, which 
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implements the ‘Guidelines on the protection of experimental animals’ by the Council 
of Europe, 1986: Directive 86/609/EC).
HISTOLOGY
Fibrin-based constructs harvested 7 days after culture or 7 days after implantation 
were embedded in Tissue-Tek (Sakura, Finetek Europe, Zoeterwoude, The Netherlands) 
and snap frozen or fi xed in 10% formalin in PBS followed by embedding in paraffi n. 
Paraffi n-embedded sections (5 μm) were deparaffi nized and rehydrated. Cryo-sections 
(5 μm) were fi xed with 3.7% formalin in deionised water for 1 hour.
CD31 STAINING OF IN-VITRO CULTURED FIBRIN-BASED CONSTRUCTS
To determine HUVEC organization in the fi brin-based ASC/HUVEC constructs, a 
monoclonal mouse anti-human CD31 antibody (Clone JC70A, Dako (cat no. M0823), 
Glostrup, Denmark) was used. All sections were treated with 3% hydrogen peroxide 
in PBS to block endogenous peroxidase activity. Antigen retrieval was achieved by 
boiling at 95˚C for 15 minutes in Dako Cytomation Target Retrieval Solution high pH 
(Dako, Glostrup, Denmark). Non-specifi c binding of the monoclonal mouse anti-human 
CD31-antibody was reduced by blocking with 1%BSA/10% goat serum in PBS for 
30 minutes. This was followed by an overnight incubation with CD31 (1:40 dilution in 
PBS/ 1%BSA) at 4˚C. Sections were incubated with goat anti-mouse secondary anti-
body (1:200 dilution in PBS/1% BSA, Dako, cat no. E0433) for 30 minutes followed by 
incubation with streptavidin-horseradish peroxidase (1:300 dilution in PBS/1% BSA, 
Dako, cat no. P0397) for 30 minutes. Diaminobenzidine (Sigma-Aldrich) was used to 
visualize CD31 expression. The slides were weakly counterstained with hematoxylin, 
dehydrated through graded alcohols and mounted with Permount (VWR International, 
Amsterdam, The Netherlands).
CD31 STAINING AND VIMENTIN STAINING IN FIBRIN-BASED 
CONSTRUCTS POST- TRANSPLANTATION
To distinguish seeded human cells from mouse tissue and to determine the number 
and relative area occupied by human vascular structures in construct sections post-
transplantation, monoclonal mouse anti-human vimentin antibody (Clone V9, 1:40 
dilution in PBS/ 1% BSA, Sigma-Aldrich, cat no. V6630) and monoclonal mouse anti-
human CD31 antibody (Dako) were used, respectively. To reduce unspecifi c binding 
of the secondary goat anti-mouse antibody (Dako) to mouse IgGs, the mouse-on 
mouse HRP-Polymer Kit (Biocare Medical, Concord, California) was used, accord-
ing to manufacturer’s instructions with some slight modifi cations. In short, antigen 
retrieval was performed through incubation in Rodent Decloaker® (Biocare Medical) 
for 60 minutes at 95˚C. Non-specifi c binding sites were blocked with Rodent Block M® 
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(Biocare Medical) and sections were stained overnight with CD31 or vimentin at 4˚C. 
The MM-polymer-HRP® secondary antibody (Biocare Medical) was used, followed by 
incubation in diaminobenzidine (Sigma-Aldrich) to visualize vimentin or CD31 expres-
sion, respectively. The slides were weakly counterstained with hematoxylin, dehydrated 
through graded alcohols and mounted with Permount (VWR International).
OIL RED O STAINING
Accumulated lipid in ASC in fi brin-based constructs was detected after 7 days of in 
vitro culture and after 7 days of implantation using Oil Red O staining as previously 
described [11,19]. In short, cryo-sections were fi xed, rinsed and immersed in Oil Red O 
working solution for 30 minutes. Hereafter, sections were washed with deionised water 
and counterstained with hematoxylin for 1 minute. Finally, sections were rinsed with 
running tap water for 10 minutes, and covered with Imsolmount (Klinipath, Zevenaar, 
The Netherlands).
HISTOMORPHOMETRY
High resolution (0.23 μm/pixel), low magnifi cation (40×) digital micrographs covering 
2-to-3 complete vimentin or CD31 immunostained cross-sections taken from middle 
sections of each retrieved construct were made with a Nanozoomer HT (Hamamatsu 
Photonics, Hamamatsu City, Japan) for analysis. Subsequently, the total number of 
vessel lumens (mouse- and human-derived), the number of human CD31-positive 
vascular structures, the area occupied by these structures and the complete area 
of human tissue in the constructs was quantifi ed in each entire cross-section using 
NIH ImageJ software (http://rsb.info.nih.gov/ij/). From these data we calculated four 
parameters: (1) the total number and (2) density of all lumens and (3) the number and 
(4) density of all human CD31-positive lumens per cross section area.
STATISTICAL ANALYSIS
Differences in the number and density of (mouse- and human-derived) vascular lumens 
per cross-sectional area between ASC/HUVEC and ASC-only fi brin-based constructs 
were analyzed with the unpaired t-test with Welch correction and are expressed as 
mean± standard deviation. Statistical signifi cance was defi ned as P<0.05. Statistical 
analysis was performed using Graphpad Prism 5.01 software (Graphpad Software, San 
Diego, California).
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RESULTS
HUVEC ORGANIZATION IN ASC/HUVEC FIBRIN-BASED CONSTRUCTS IN 
VITRO
Cross sections of fi brin-based constructs seeded with a low cell density and cultured 
for 7 days showed that CD31-positive endothelial cells were highly dispersed through-
out the fi brin matrix at all ASC: HUVEC ratios, showing no formation of organized 
structures (Fig.1A-C). In cross-sections of fi brin-based constructs seeded with a high 
cell density more CD31-positive endothelial cells were present in cell clumps. Only in 
1:5 fi brin-based constructs the formation of lumen-consisting prevascular structures 
was seen (Fig.1D). No CD31-positive endothelial cells were present in the fi brin-based 
ASC-only constructs (Fig.1E).
ASSESSMENT OF SURVIVAL AND IN VIVO ADIPOGENESIS
High cell density (10*106 cells/ml) ASC-only fi brin-based constructs were implanted 
subcutaneously in nude mice. In addition, we implanted the fi brin-based constructs 
that were seeded with a high cell density (10*106cells/ml) and a 1:5 ratio of ASC and 
HUVEC, since these constructs had already formed prevascular structures in vitro.
Seven days following implantation, we could readily identify all implanted fi brin-
based constructs both by visual inspection and by microscopic examination. Remain-
ing traces of the biodegradable fi brin could be found within some implanted tissue-
constructs (H&E staining Fig.2A).
Oil Red O staining of both ASC (/HUVEC) construct cross-sections revealed the 
presence of red-stained lipid containing cells within the implanted constructs (Fig.2B). 
Similarly, anti-human vimentin staining showed that numerous human vimentin-positive 
cells were still present within the implanted constructs, suggesting that lipid containing 
cells might be from human origin (Figure 2C-D).
HISTOLOGICAL ASSESSMENT OF CONSTRUCT VASCULARIZATION
To assess construct vascularization upon implantation, cross-sections of the retrieved 
constructs were stained with H&E to determine the total vascularization (both mouse- 
and human-derived lumens) (Fig.3A), or stained with anti-human specifi c CD31 
antibody to determine human-specifi c vascularization (Fig.3B-D). Four quantitative 
parameters of construct vascularization were measured in stained cross-sections: (1) 
the total number and (2) density of all lumens and (3) the number and (4) density of 
all human CD31-positive lumens per cross section area. Total graft vascularization 
(mouse- and human-derived lumens) was not signifi cantly different between ASC/HU-
VEC and ASC-only fi brin-based constructs. In ASC/HUVEC fi brin-based constructs, 
both the number of lumens per cross-section area (19±32 lumens/mm2) and the lu-
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Figure 1. HUVEC form prevascular structures 
in ASC: HUVEC fi brin-based constructs seeded 
with a high cell density. Fibrin-based constructs 
seeded with two different cell densities (1*106 
cells/ml and 10*106 cells/ml) and three different 
ratios (1:1, 1:2 and 1:5) of ASC: HUVEC were 
cultured for 7 days in vitro, and immunostained 
with anti-human CD31 (brown), showing orga-
nization of HUVEC. Cross-sections were coun-
terstained with hematoxylin (blue). (A-C) Fibrin-
based constructs seeded with 1*106cells/ml; (A) 
1:1 ASC: HUVEC seeded, (B) 1:2 ASC: HUVEC 
seeded and [C] 1:5 ASC: HUVEC seeded. (D) 
Fibrin-based construct seeded with 10*106 
cells/ml and a 1:5 ASC: HUVEC ratio (white ar-
rows point at prevascular structures). (E) Fibrin-
based construct seeded with 10*106cells/ml 
and ASC-only. Note the absence of anti-human 
CD31 staining (brown). Scale bars= 100 μm.
A
C
E
D
B
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Figure 2. Histological analysis of the fi brin-based constructs 7 days postimplantation. Fibrin-based 
constructs were cultured for 7 days in vitro, and then implanted subcutaneously in the right and left 
scapular region of nude mice for 7 days. (A) H&E-stained cross-section of an ASC: HUVEC fi brin-
based construct containing some fi brin remnants (indicated by #). (B) High magnifi cation image of a 
cross-section of an ASC/HUVEC fi brin-based construct stained with Oil Red O (red). (C) Low mag-
nifi cation image of a cross-section of another ASC/HUVEC fi brin-based construct stained with Oil 
Red O (red). (D) Consecutive cross-section of ASC/HUVEC construct shown in [C] immunostained 
with vimentin (brown) and counterstained with hematoxylin (blue). Oil Red O-positive, lipid-containing 
cells are present in the constructs. Note that Oil Red O-positive cells and vimentin-positive cells are 
located within the same area. Scale bars= 100 μm. (see color section for a full-color version)
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Figure 3. Vascularization of fi brin-based constructs 7 days postimplantation. Fibrin-based con-
structs seeded with ASC or a 1:5 mixture of ASC: HUVEC were cultured for 7 days in vitro, and 
then implanted subcutaneously in the right and left scapular region of nude mice for 7 days. Cross-
sections were stained with H&E to determine the total amount of (mouse-and human-derived) vas-
cular lumens or immunostained with human specifi c CD31 antibody (brown) and counterstained 
with hematoxylin (blue) to determine human-derived vascular lumens. (A) Vascular lumens could 
easily be identifi ed within H&E stained cross-sections of fi brin-based constructs (white arrows point 
at some vascular lumens). Inset shows general overview of H&E stained cross-section. Inset scale 
bar= 100μm. (B-C) Images of human CD31-positive lumina (see black arrows) in an ASC-only (white 
arrow points at unstained mouse vessel) (B) and (C) an ASC: HUVEC fi brin-based construct. (D) 
High magnifi cation image of human CD31-positive lumen containing erythrocytes (see black arrow) 
in an ASC-only fi brin-based construct. Scale bar = 100μm. (see color section for a full-color version)
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men density (1.4%±1.5%) were not signifi cantly different from ASC-only fi brin-based 
constructs (54±67 lumens/mm2 and 3.5%±1.8% respectively). We next assessed the 
relative contribution of human-specifi c vascularization. Surprisingly, only 1 out of the 
6 ASC/HUVEC fi brin-based constructs contained human CD31-positive lumens (6 
lumens/mm2 and a lumen density of 0.3%), whereas 2 out of 6 ASC-only fi brin-based 
constructs contained human CD31-positive lumens (20±35 lumens/mm2 and a lumen 
density of 0.6%±0.1%). In both ASC/HUVEC and ASC-only constructs a subset of the 
human vascular lumens (1.2 and 11.5±0.5 lumens/mm2 respectively; lumen density 
0.3% and 1.3%±1.3% respectively) was fi lled with erythrocytes, indicating that these 
lumens were perfused (Fig.3D).
DISCUSSION
The results of our study show that, in contrast to ASC constructs without HUVEC, 
lumen-consisting prevascular structures are formed in adipose ASC/HUVEC fi brin-
based constructs in vitro. The presence of these human prevascular structures within 
the adipose fi brin-based constructs however, does not promote vascularization of the 
constructs after implantation. Moreover, our study shows that neither the addition of 
HUVEC, nor the presence of human prevascular structures in vitro is necessary for 
the generation of human CD31 positive-vascular structures in adipose fi brin-based 
ASC-constructs in vivo.
Fibrin-embedded combinations of tissue-derived stromal cells and HUVEC for 
the purpose of prevascularization have been used before [21,22]. To our knowledge 
however, this is the fi rst study in which ASC are suspended with endothelial cells (EC) 
in fi brin gels without the use of a secondary carrier material. Such carrier materials 
are often not-clinically applicable (e.g. microcarrier beads). We found that prevascular 
structures were formed in ASC/ HUVEC co-cultures with a 1:5 ratio of ASC to HUVEC. 
This is in line with the fi ndings of Chen et al [23], who used a similar ratio (1:5) of 
HUVEC/human lung fi broblasts. Upon implantation, the prevascular structures in the 
ASC/HUVEC constructs however, did not contribute to a higher number or density 
of vascular lumens when compared to the ASC-only constructs. This is in contrast 
to our previous results. In previous experiments, using similar cells and the same 
culture medium but using spheroid-based constructs, we showed that co-culture of 
ASC/HUVEC actually can improve the amount and density of vascular lumens after 
implantation [11].
Clearly, the specifi c fi brin environment is of infl uence on the different outcome of 
our current experiments. Fibrin may change the paracrine signaling and/or interaction 
between the ASC and HUVEC in this experimental setup, hereby causing the different 
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results compared to our former experiments with spheroids. Although the difference 
between the outcome of our current fi brin-based experiments and our former spheroid 
experiments is as yet not fully explainable, a difference in ASC function when comparing 
different ASC formulations or delivery methods is not entirely new. For instance, Amos 
et al. (Amos et al., 2010) recently reported that ASC spheroids had an increased in vivo 
therapeutic capacity and an increased secretion of trophic factors when compared 
to ASC suspensions. Alternatively, fi brin itself may induce vessel ingrowth, thereby 
masking any pro-angiogenic effects induced by the ASC/HUVEC co-culture.
After 7 days of implantation, we found that human-derived CD31-positive lumens 
were not only present in ASC/HUVEC fi brin-based constructs, but also in ASC-only 
fi brin-based constructs, demonstrating that prevascularization, or even the addition of 
HUVEC to ASC in fi brin-based constructs is not necessary for the formation of human 
vascular structures in vivo. Moreover, we found that a subset of the human-derived 
lumens contained erythrocytes, indicating that these human-derived lumens were con-
nected to the host vasculature and contributed to construct perfusion. Since we found 
no CD31-positive cells in the ASC-only fi brin-based constructs prior to implantation, 
the ASC themselves may have differentiated to CD31 expressing cells and may have 
contributed to vessel formation. Previously, Scherberich et al. [24] also showed that 
human CD31-positive vessels can be generated within ASC-only constructs after 
implantation, albeit these researchers used osteogenic constructs. The number of 
constructs that contained human-derived CD31-positive lumens however was low, 
implying that most detected lumens were host(mouse)-derived. Upon further inves-
tigation, it appeared that all our ASC/HUVEC and ASC-only fi brin-based constructs 
that generated human-derived vessels in vivo were derived from the same ASC donor. 
This indicates a substantial variation amongst the ASC donors used. Heterogeneity in 
ASC plasticity between multiple donors has been reported before [25], and may refl ect 
differences in the composition of the adipose tissue between the donors.
The results of our study show that in vitro formed prevascular structures did not 
contribute signifi cantly to vascularization upon implantation. In the current study 
however, we still used relatively small (1.3 ± 0.5 mm in diameter) ASC/HUVEC and 
ASC-only fi brin-based tissue constructs. It may be that this construct size is too small 
to reveal any differences in the vascularization potential between prevascularized ASC/
HUVEC and nonprevascularized ASC-only fi brin-based constructs upon implantation. 
Further in vivo studies, using bigger, more critically sized fi brin-based tissue constructs 
(e.g. cm3 scale), should reveal whether any positive effects of prevascularization can 
be observed.
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CONCLUSION
In summary, our study indicates a similar rate of vascularization of small-sized (≤1.8mm 
in diameter) ASC/HUVEC as of ASC-only fi brin-based constructs, suggesting that pre-
vascularization of these fi brin-based ASC constructs with HUVEC prior to implantation 
does not promote the vascularization. This may be because of the pro-angiogenic 
infl uence of fi brin [26], either directly on the host vasculature, or indirectly through 
affecting the paracrine signaling and/or interaction between the ASC and HUVEC. Our 
results further indicate that not only endothelial cells, but also ASC may contribute to 
the formation of vascular lumens upon implantation of adipose fi brin-based ASC con-
structs. This fi nding is interesting since it demonstrates the possibility of vascularized 
adipose tissue engineering from a single cell source. In addition, our results illustrate 
variation amongst ASC donors with regard to their ability to support vascularization. 
This fi nding merits further investigation; a better understanding of which (subpopula-
tion) of ASC can support vascularization is important for improving vascularization of 
engineered adipose tissue after implantation. Altogether it is clear that the success of 
prevascularization depends on multiple factors. These factors amongst others include 
the adipose tissue engineering environment (e.g. biomaterial) and the cells (e.g. ASC 
donor) used. Both these factors can infl uence the interaction between ASC and en-
dothelial cells and the interaction between the implanted constructs and host tissue
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ADIPOSE TISSUE ENGINEERING AND VASCULARIZATION
Reconstruction of soft tissue defects represents critical challenges for contemporary 
plastic surgery practice. Currently, autologous microvascular soft tissue transplants 
or synthetic materials are used for reconstruction of soft tissue defects. Because of 
optimal tissue characteristics and low risk of immunologic rejection, microvascular 
autologous adipose tissue transplants are common practice. Despite advances in the 
transplantation of adipose tissue, donor site morbidity continues to be an intrinsic 
drawback of this procedure. Therefore, scientists have been encouraged to engineer 
adipose tissue equivalents. In the fi eld of adipose tissue engineering, biomaterials are 
generally combined with adipose progenitor cells. Human mesenchymal stem cells 
derived from adipose tissue also referred to as adipose-derived stromal cells (ASC), 
are commonly used for this purpose as they can be readily obtained, expanded and 
differentiated to adipocytes [1,2] (CHAPTER 1). Indeed, various studies including our 
own have shown that in vivo implantation of ASC can lead to the formation of new adi-
pose tissue [3,4,5]. However, a critical obstacle in the engineering of tissue equivalents 
is the ability to maintain larger masses of living cells in vivo. To date, the size of most 
engineered tissues is limited owing to the diffi culty of providing an adequate blood 
supply upon implantation. Several strategies to enhance vascularization in adipose 
tissue engineering are currently being explored such as the delivery of angiogenic 
factors [6,7,8], improving scaffold design [8,9,10,11] and in vivo prevascularization 
[12,13,14,15]. In this thesis, we investigated the angiogenic potential of adipose tissue-
derived stromal cells (ASC) in relevant (adipose) tissue engineering settings (CHAPTER 
2 AND 3). Besides that, we investigated the potential benefi cial effects of in vitro 
prevascularization on in vivo vascularization of ASC-based adipose tissue constructs 
(CHAPTER 4, 5 AND 6).
ANGIOGENIC POTENTIAL ASC
ASC have been reported to promote ischemic tissue revascularization [16,17,18,19]. 
Two mechanisms on how these cells promote vascularization have been put forward: 
(1) via endothelial trans-differentiation and incorporation of ASC in ingrowing vessels 
and (2) via secretion of diffusible molecules (e.g. angiogenic factors) that stimulate 
vascularization [19,20,21,22]. In particular the latter mechanism has been shown to 
play a key role in the benefi cial effects of ASC in ischemic tissue revascularization 
[19,20]. Since ischemic tissue revascularization and vascularization of engineered 
tissue constructs share many similarities, we hypothesized that the ability of ASC to 
secrete angiogenic factors could also be benefi cial for promoting vascularization in 
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ASC-based adipose tissue constructs. However, little is known on the secretion of 
angiogenic factors by ASC in an adipose tissue engineering setting. This led us to in-
vestigate the angiogenic potential of ASC in adipose tissue engineering settings. First, 
we investigated whether adipogenic differentiation infl uenced the gene expression and 
protein secretion of angiogenic factors by ASC (CHAPTER 2). We examined changes 
in expression and secretion of important angiogenic factors during adipogenic dif-
ferentiation of ASC and evaluated whether differences between undifferentiated and 
differentiated cells affect endothelial cell numbers in vitro. We showed that expression 
and secretion of the angiogenic factor VEGF was increased in short-term (7-14 days) 
adipogenic differentiated ASC when compared to undifferentiated ASC. Moreover, 
conditioned medium from differentiated ASC strongly enhanced endothelial cell num-
bers in vitro compared to conditioned medium from undifferentiated ASC. From these 
in vitro experiments, it can be concluded that in vitro adipogenic differentiation of ASC 
for a period of 7-14 days improves their in vitro angiogenic potential, (as compared to 
undifferentiated ASC) and may be benefi cial with respect to vascularization of ASC-
based constructs. In addition to this, Weiser et al.[23] showed that short-term in vitro 
differentiation of ASC is also suffi cient for in vivo formation of adipose tissue and even 
improves engineered adipose tissue survival. Taken together, these fi ndings indicate 
that short in vitro adipogenic-precultivation of ASC is potentially the better choice for 
adipose tissue engineering applications.
Next we investigated the angiogenic potential of ASC constructs in vivo. A con-
struct for in vivo implantation can be generated with and without a scaffold material. 
We were interested in the effect of the scaffold environment on ASC-based construct 
vascularization and angiogenic factor secretion (CHAPTER 3). Numerous studies have 
used a scaffold/extracellular matrix-based tissue engineering approach for the genera-
tion of adipose tissue. Although the effect of the extracellular environment on stem 
cell differentiation has recently gained interest [24,25,26] there remains much to be 
learned on the role of the extracellular environment on stem cell behavior. To date, 
little is known about the infl uence of the extracellular environment on ASC angiogenic 
potential. In CHAPTER 3 we compared ASC-based constructs with and without the 
addition of the extracellular matrix fi brin. We showed that a fi brin environment clearly 
improved vessel ingrowth in vivo and also enhanced ASC adipogenic differentiation 
and secretion of angiogenic factors (i.e.VEGF and HGF) in vitro. Our results indicate 
that the fi brin environment impacts ASC angiogenic potential. Besides that, our study 
indicates that fi brin is a very promising material for adipose tissue engineering. This 
is not only because it improves ASC angiogenic potential but also because it sup-
ports ASC adipogenic differentiation. The positive effect of the fi brin environment on 
ASC-based construct vascularization may be partly explained by the improved ASC 
angiogenic potential. However, being a naturally occurring scaffold in wound healing 
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and tissue repair fi brin itself may have also contributed to increased vessel ingrowth 
through its angiogenic properties (such as binding of growth factors, facilitating cell 
migration, interacting with endothelial cells through VE-cadherins) [27,28]. In spite of 
its positive effect on adipogenesis and vascularization fi brin has limited structural sta-
bility, which can complicate the formation of volume-stable adipose tissue. A method 
to compensate for the poor mechanical properties of fi brin could be the combined use 
of more rigid supportive structures with fi brin as demonstrated by Cho et al [29,30].
IN VITRO PREVASCULARIZATION
Although the rate of blood vessel ingrowth in implanted ASC-based adipose tissue 
constructs may be increased by short in vitro adipogenic precultivation of ASC or the 
use of fi brin as a scaffold, vessel ingrowth will probably not be enough to supply thick 
implants with a suitable blood supply in a timely manner. For this reason, a tissue 
engineering approach that includes a vascular network within the tissue construct is 
likely to be necessary for thick implants.
CHAPTER 4, 5 AND 6 are mainly directed towards our second aim, which is to 
investigate the potential positive effect of in vitro prevascularization on the in vivo 
vascularization of ASC-based adipose constructs.
Recently, Rouwkema et al.[31] demonstrated that bone marrow-derived stromal 
cells (BMSC) can support the organization of endothelial cells into a three-dimensional 
prevascular network in vitro. BMSC and ASC share many similarities. We therefore 
speculated that ASC, similar to BMSC, could support the organization of endothelial 
cells into prevascular structures in vitro. Although indirect and direct co-cultures of 
ASC and endothelial cells have been described before, these studies mainly focused 
on the interactions between ASC and endothelial cells [32,33,34]. In CHAPTER 4 we 
specifi cally focused on the ability of ASC to support the de novo formation of vascular 
structures from endothelial cells in vitro. We compared angiogenic factor secretion and 
endothelial organization between BMSC/endothelial cell and ASC/endothelial cell co-
cultures. Our experiments showed that both ASC conditioned medium as well as direct 
co-culture of ASC with human umbilical vein endothelial cells (HUVEC) supported the 
organization of HUVEC into vascular-like structures in vitro. In contrast, only the direct 
co-culture of BMSC with HUVEC was suffi cient to support the formation of prevascular 
structures. Furthermore, we found no signifi cant differences in the secretion of the 
measured angiogenic factors between BMSC and ASC. Although the exact mecha-
nism by which BMSC and ASC support endothelial organization remains unknown, our 
conditioned medium and direct co-culture experiments suggest that apart from the 
secretion of angiogenic factors also direct cell interactions (through cell-cell contacts 
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and/or reciprocal signaling) play an important role. In order to optimize the formation of 
vascular-like structures in BMSC/endothelial cell and ASC/endothelial cell co-cultures 
more research is necessary to better understand these direct cell interactions.
The results described in CHAPTER 4 illustrate that ASC can promote the orga-
nization of endothelial cells into vascular-like structures in vitro. The ability to form 
vascular-like structures in ASC-based constructs in an adipose tissue engineering 
setting was further examined in CHAPTER 5 AND 6.
In CHAPTER 5 we investigated if it was possible to induce the formation of vas-
cular-like structures in three-dimensional spheroid ASC/HUVEC co-cultures while si-
multaneously enabling adipogenic differentiation of the ASC. In addition, we examined 
whether these in vitro generated prevascular structures could integrate with the host 
vasculature in vivo. For this, we fi rst determined what co-culture medium is suitable for 
both HUVEC and ASC, and what ratio of HUVEC/ASC is optimal for the formation of 
vascular-like structures. Several media (adipogenic medium, endothelial cell medium, 
1:1 mix of adipogenic and endothelial medium) and several combinations of ASC 
and HUVEC (95% ASC/5%HUVEC, 80% ASC/20% HUVEC, 60% ASC/40% HUVEC 
and 20% ASC/80% HUVEC) were tested. We showed that a 20% ASC/80% HUVEC 
co-culture in 1:1 endothelial cell/adipogenic mix medium leads to the formation of 
vascular-like structures while simultaneously enabling ASC adipogenic differentiation 
in vitro. Next, we implanted these 20% ASC/80% HUVEC co-cultures subcutaneously 
in athymic mice and determined if in vitro-formed vascular-like structures could inte-
grate with the host’s vascular system. In spite of limited organization of vascular-like 
structures in vitro, we did fi nd human-derived lumen-containing vascular structures in 
vivo. Moreover, a subset of these human-derived lumens (3.6±4.2 lumens/mm2 of the 
total amount of 23 ±15 lumens/mm2) contained red blood cells, indicating that these 
lumens were able to anastomose to the host vasculature and contribute to construct 
vascularization. Apart from this increase in vascularization through human-derived 
lumens, we also showed an increase in vascularization through enhanced host ves-
sel ingrowth in the in vitro prevascularized ASC/HUVEC constructs when compared 
to non-prevascularized ASC-only constructs. Collectively, these results demonstrate 
that the formation of vascular structures in vitro is a promising strategy to promote 
the in vivo vascularization of adipose ASC-based constructs. However, these results 
also raise new questions for future investigation. For example, it is unclear why only 
a limited number of the human-derived lumens were perfused upon implantation in 
vivo. Although Rouwkema et al [31] reported similar results for in vitro prevascularized 
(BMSC/HUVEC) bone tissue constructs, Levenberg et al.[35] described a high percent-
age (~41%) of perfused human-derived lumens within in vitro prevascularized skeletal 
muscle tissue constructs. It is uncertain what caused these differences, however 
several reasons can be proposed:
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(1) Difference in endothelial organization in vitro. In our study and the study of Rou-
wkema et al.[31] the endothelial cells mainly formed interconnected strands within 
the constructs, whereas in the study of Levenberg et al.[35] lumen formation was 
commonly seen in vitro. This could indicate that the vascular structures formed in 
the study of Levenberg et al. were more mature, increasing their ability to anasto-
mose with host vessels. This difference in endothelial organization could be caused 
by the use of different cells and/or the use of different culture media.
(2) Difference in extracellular environment. In the skeletal muscle tissue constructs, 
myoblasts were suspended in Matrigel and then seeded on poly-l-lactic-acid 
(PLLA)/poly lactic glycolic acid (PLGA) scaffolds, whereas in the adipose tissue and 
bone tissue constructs no scaffolds or matrices were used. As mentioned earlier 
(CHAPTER 3) the extracellular environment can affect cell behavior and cell interac-
tions. Besides that, Matrigel is known to stimulate angiogenesis [36]. This may also 
have caused differences in endothelial organization and vessel ingrowth between 
the different tissue constructs.
Even though cellular spheroids as used in CHAPTER 5 have been shown to be able 
to form bigger macrotissue patches of mm3 scale [37], the use of a biomaterial is 
likely needed to produce in vitro prevascularized adipose tissue constructs with more 
clinically relevant dimensions (cm3 scale). As shown in CHAPTER 3 fi brin has a posi-
tive effect on adipogenic differentiation and vascularization of ASC-based constructs. 
Besides that, fi brin can easily be scaled-up and used in a clinical setting [38,39]. There-
fore, fi brin was chosen as a biomaterial in subsequent prevascularization experiments 
described in CHAPTER 6.
In CHAPTER 6 we determined the optimal co-culture conditions (i.e. cell seeding 
density and ASC/HUVEC ratio) for in vitro prevascularization of fi brin-based ASC con-
structs and compared the ability of in vitro prevascularized- and non-prevascularized 
fi brin-based adipose tissue constructs to promote vascularization. Different mixtures 
(1:1, 1:2 and 1:5) of ASC with HUVEC were cultured in fi brin at two different densities 
(1.0*106 and 10*106 cells/ml) for 7 days. We found that prevascular structures solely 
formed in 1:5 ASC/HUVEC fi brin-based constructs seeded with a total of 10*106 cells/
ml. After implantation of these constructs and ASC-only fi brin-based constructs, we 
found that there was no difference in the rate of vascularization of ASC/HUVEC and 
ASC-only fi brin-based constructs in vivo. This outcome is in contrast to the results 
obtained in the spheroid experiments (CHAPTER 5), where we showed that in vitro-
prevascularization of spheroid constructs increased the amount and density of vascular 
lumens after implantation. Clearly, the specifi c fi brin environment is of infl uence on this 
difference in outcome. Our former experiments of CHAPTER 3 already showed that the 
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fi brin environment can infl uence ASC paracrine signaling and thus also may infl uence 
ASC-HUVEC interactions and vessel ingrowth. 
We further demonstrated that human-derived vasculature formed in both prevas-
cularized and non-prevascularized fi brin-based constructs upon in vivo implantation. 
This exciting fi nding (combined with the absence of endothelial cells in ASC-only con-
structs prior to implantation) supports the notion that ASC not only secrete angiogenic 
factors that stimulate angiogenesis, but also can differentiate towards endothelial cells 
and contribute to the formation of human vascular structures in vivo. This fi nding is 
especially exciting since it demonstrates the possibility of engineering vascularized 
adipose tissue from a single cell source. However, in the current experiments the 
amount of constructs containing human-derived vascular structures was low. Ad-
ditionally, all fi brin-based ASC constructs that generated human-derived vasculature 
in vivo were derived from the same ASC donor. These results illustrate that a better 
understanding of which (subpopulation of) ASC differentiate(s) into endothelial cells 
and what factors are involved in their endothelial differentiation is indispensible for 
optimizing this vasculogenic potential of ASC. Altogether it is clear that the success of 
prevascularization depends on multiple factors. These factors amongst others include 
the adipose tissue engineering environment (e.g. biomaterial, culture media) and the 
cells (e.g. ASC donor) used. Both these factors can infl uence the interaction between 
ASC and endothelial cells and the interaction between the implanted constructs and 
host tissue.
CONCLUSIONS AND FUTURE PERSPECTIVES:
The aim of this thesis was to explore the angiogenic potential of ASC in different adipose 
tissue engineering settings and to investigate the potential positive effect of in vitro-
prevascularization on the vascularization of ASC-based adipose tissue constructs. The 
work presented in this thesis showed that ASC have marked angiogenic potential in 
adipose tissue engineering settings. This angiogenic potential not only involves the se-
cretion of angiogenic factors (CHAPTER 2, 3 AND 4) but also involves the ability to in-
corporate into new vessels (CHAPTER 6). Strategies that can promote ASC angiogenic 
potential are short (7-14 days) in vitro adipogenic cultivation (CHAPTER 2) and the use 
of fi brin as extracellular matrix (CHAPTER 3). Although these strategies can improve 
the natural vascularization response, vascular ingrowth will probably not be suffi cient 
to supply thick adipose tissue constructs with the appropriate number of new blood 
vessels in a short period of time. Our studies showed that in vitro-prevascularization 
of engineered ASC-based adipose constructs is a promising strategy to overcome this 
problem (CHAPTER 5). However, our results also pointed out that the contribution of 
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prevascular structures to vascularization of adipose tissue constructs is as yet limited 
and needs to be improved. Besides that, it was also shown that different adipose 
tissue engineering environments yield different results regarding the success of in vitro 
prevascularization (CHAPTER 6). Hence, further research is required to improve the 
contribution of in vitro-formed prevascular structures to the vascularization in vivo 
and to determine the right adipose tissue engineering environment for both in vitro-
prevascularization and clinical translation. Future directions of research may include:
OPTIMIZE PROTOCOLS FOR IN VITRO PREVASCULARIZATION
In this thesis ASC and HUVEC were co-cultured and seeded together to form prevas-
cularized adipose tissue constructs. Although this approach was effective to some 
extent, alternative seeding and culturing protocols should be tested to optimize the 
formation and organization of prevascular structures in vitro. Preliminary work of Kang 
et al. [40] already showed that seeding HUVEC and ASC together delayed HUVEC 
growth. Next to seeding order, spatial cell organization can also greatly effect tissue 
development [41]. In order to fi nd the optimal in vitro prevascularization method, stud-
ies should be conducted in which ASC and HUVEC are seeded in different arrange-
ments and/or at different time points.
FOSTER THE CONNECTION OF ENGINEERED PREVASCULAR 
STRUCTURES WITH HOST VESSELS
Anastomosis of the engineered vessels and those of the host is critical for the in vivo-
success of in vitro-prevascularization. In order to be able to foster their connection, 
a comprehensive understanding of the cross talk between host tissue and implanted 
cells is needed. Besides that, it seems more likely for mature prevascular structures 
to anastomose to host vessels than for immature prevascular structures. In vascular 
and skeletal muscle tissue engineering settings, mural-precursor cells (e.g. embryonic 
fi broblasts) have been shown to enhance the maturation and stability of prevascular 
structures in vitro, resulting in a high functionality of these structures in vivo [35,42]. 
Future studies should therefore test whether the addition of mural cells/ mural-
precursor cells is also benefi cial for the in vitro-maturation and in vivo-anastomosis 
of prevascular structures in our adipose tissue engineering setting. Interestingly, we 
found in ASC/HUVEC co-cultures (described in CHAPTER 4) that ASC expressed the 
smooth muscle marker alpha-smooth muscle actin, suggesting an affi liation of ASC 
to the smooth muscle lineage. In line with this, other studies showed that ASC could 
differentiate towards smooth muscle cells in vitro [43,44]. It may be worthwhile to 
examine the use of ASC-derived smooth muscle cells for improving the maturation of 
prevascular structures in our adipose ASC/HUVEC co-cultures.
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STUDY THE LONG-TERM FATE AND FUNCTION OF PREVASCULAR 
STRUCTURES IN ASC-BASED ADIPOSE TISSUE CONSTRUCTS IN VIVO
This thesis (CHAPTER 5 and 6) shows that a subset of human-derived lumens in 
ASC-based adipose tissue constructs is perfused upon 7 days of implantation. In 
future studies it would be interesting to examine what happens to the perfused and 
non-perfused human-derived lumens in the long-term. Besides that, more research 
is crucial to assess human-derived blood vessel maturation and function in vivo. Im-
portant parameters of vascular function are: vascular perfusion, vascular permeability 
and tissue oxygenation/survival. In order to determine the vascular function of human-
derived vasculature these parameters should be examined both in the short and the 
long-term. Levenberg et al. [35] already demonstrated techniques to qualify vascular 
perfusion (intravenous injection with fl uorescently labeled lectin visualized by Xenogen 
IVIS device) and tissue survival (viral transfection of implanted cells with luciferase 
combined with injection of luciferin for determining cell survival and TUNEL staining 
for determining apoptotic cells). Additionally, oxygen microelectrodes or porphyrin-
based oxygen sensitive dyes could be used to give an indication of tissue oxygenation 
[45,46,47,48].
STUDY SUITABLE ENDOTHELIAL CELL SOURCES FOR 
PREVASCULARIZED ADIPOSE TISSUE ENGINEERING
As mentioned earlier HUVEC are not suitable for clinical use due to their incompatibility 
with the recipient’s immune system. Apart from being compatible with the recipient’s 
immune system, the ideal endothelial cell source for in vitro prevascularization must be 
available in suffi cient quantities, be able to form prevascular structures in engineered 
tissue and be capable of being harvested with minimal donor site morbidity. At present, 
it is unclear which source of mature endothelial cells or stem/ progenitor cells is most 
suitable for clinical application. As shown in CHAPTER 6 of this thesis ASC themselves 
can contribute to vessel formation in vivo. However, the number of constructs in which 
ASC contributed to vessel formation in vivo was low. Future research should attempt to 
identify which (subpopulation of) ASC contribute to vessel formation and what factors 
play a role in this vasculogenic potential of ASC, since a better understanding may pro-
vide clues on how to stimulate this potential. In addition, it may be also worthwhile to 
differentiate a selection of ASC towards endothelial cells in vitro (as has been previously 
shown [22,49,50]) and then use them for prevascularized adipose tissue engineering. 
Next to this, other potential alternatives for HUVEC should be investigated. These may 
include mature microvascular endothelial cells derived from adipose tissue or vascular 
progenitors derived from the blood or bone marrow.
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STUDY ASC DONOR VARIATION
Our results in CHAPTER 6 of this thesis pointed out that there was marked hetero-
geneity in the ability of ASC populations to form vascular structures in vivo. Similarly, 
differences in adipogenic potential amongst ASC populations have been reported 
[51]. Multiple factors could potentially infl uence variations among ASC donors. Among 
these are age, gender, health status and genetic background of the donor. In addition, 
variations could also be due to differences in harvesting and culturing protocols or due 
to variations in the composition of ASC populations at the time of harvest. To date, 
there are no specifi c parameters that allow quick and reliable selection of ASC with 
clinical potential (e.g. successful formation of adipose tissue/vascular structures in 
vivo). ASC consist of a heterogeneous population of cells, and culture of ASC without 
selection for well-defi ned subpopulations may reinforce already existing variations 
in the composition of ASC derived from different donors. Future experiments using 
selected subpopulations of ASC with different phenotypes will need to be conducted 
to determine their potential for clinical application. These experiments could lead to 
optimized protocols for isolating and culturing ASC, resulting in better defi ned/charac-
terized cell populations and less variability. Such a better defi nition/characterization of 
cells and cell-based products will also be needed to get EMEA approval for future clini-
cal application of engineered ASC-based products. In the new European Medicines 
Evaluation Agency (EMEA) regulations (in effect from September 2008, www.emea.
europa.eu/pdfs/human/cpwp/41086906enfi n.pdf) it is stated that tissue engineered 
products intended for future clinical application require an extensive characterization 
of cells and used scaffold/matrices. Thus, to be able to meet the new EMEA regula-
tions and to be able to qualify ASC populations for future clinical application, further 
research is needed to establish adequate characterization and to develop relevant 
effi cacy essays.
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VET WEEFSELKWEEK EN BLOEDVOORZIENING
Herstel van defecten in zachte weefsels zoals spier, bind- of vetweefsel na bijvoorbeeld 
trauma of tumorverwijdering vormt een reconstructieve uitdaging in de plastische chi-
rurgie. Naast synthetische implantaten zoals siliconen wordt lichaamseigen vetweefsel 
vaak gebruikt voor het herstel van weke delen weefseldefecten. Het voordeel van het 
gebruik van lichaamseigen vetweefsel is dat het een natuurlijk zacht weefsel is, en 
daardoor optimale eigenschappen heeft voor opvulling van zachte weefsel defecten. 
Bovendien is het risico op afstoting van dit lichaamseigen weefsel nihil. Echter, het 
oogsten van grote hoeveelheden vetweefsel van de donorlocatie (ook wel donor site 
morbidity genoemd) is één van de belangrijkste nadelen van het gebruik van lichaams-
eigen vetweefsel voor het herstel van zachte weefsel defecten, ondanks verbetering 
van de huidige transplantatie technieken. Om deze reden zoeken wetenschappers een 
manier om levensvatbaar vetweefsel buiten het lichaam te ontwikkelen door middel 
van weefselkweek (ook wel vet tissue engineering genoemd). Voor het kweken van 
vetweefsel worden in het algemeen vet voorloper cellen gecombineerd met implantaat 
materialen. Humane mesenchymale stamcellen geïsoleerd uit vetweefsel, ook wel 
adipose-derived stem cells (ASC) genoemd, worden vaak gebruikt als vet voorloper 
cellen. Deze cellen zijn eenvoudig te isoleren uit vetweefsel en kunnen gemakkelijk in 
kweek vermeerderd worden. Bovendien kunnen zij gestimuleerd worden om zich te 
ontwikkelen tot vetcellen (vet differentiatie) (HOOFDSTUK 1). Verschillende studies, in-
clusief onze eigen studies (HOOFDSTUK 5 en 6) hebben aangetoond dat onderhuidse 
implantatie van deze gekweekte ASC inderdaad kan leiden tot de vorming van nieuw 
vetweefsel. Echter het volume/omvang van het gevormde vetweefsel na implantatie 
is tot op heden beperkt. Het ontbreken van een volwaardige bloedvoorziening na 
implantatie wordt gezien als de belangrijkste oorzaak hiervoor. Immers, onvoldoende 
doorbloeding van ASC in geïmplanteerde vetweefselconstructen resulteert in een te-
kort aan voedingsstoffen, wat er uiteindelijk voor zorgt dat de cellen in de constructen 
afsterven.
Verschillende methoden om de bloedvoorziening van gekweekte vetweefsel 
constructen te verbeteren worden momenteel onderzocht, zoals de lokale toediening 
van middelen die de ingroei van bloedvaten stimuleren, aanpassing van het construct 
ontwerp om de ingroei van bloedvaten te vergemakkelijken en het chirurgisch om-
leggen van bestaande bloedvaten door het vetweefselconstruct. In dit proefschrift 
onderzochten we de mogelijkheid van ASC (de vet voorloper cellen) om de ingroei 
van bloedvaten in vetweefselkweken te stimuleren (HOOFDSTUK 2 en 3). Daarnaast 
hebben we de mogelijk positieve effecten van het in kweek realiseren van primitieve 
bloedvaten in vetweefsel constructen op de doorbloeding van deze constructen na 
implantatie onderzocht (HOOFDSTUK 4, 5 en 6).
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DE MOGELIJKHEID VAN ASC OM BLOEDVATINGROEI TE 
STIMULEREN (ASC ANGIOGEEN POTENTIEEL)
Onderzoek heeft uitgewezen dat ASC in staat zijn de doorbloeding van slecht of matig 
doorbloed weefsel (bijvoorbeeld na een infarct) te bevorderen. Men denkt dat ASC dit 
doen via twee mechanismen: (1) via inbouw van ASC in ingroeiende bloedvaten en (2) 
via de uitscheiding van eiwitten die de ingroei van bloedvaten stimuleren (angiogene 
factoren). Vooral het laatst genoemde mechanisme speelt een belangrijke rol in de 
gunstige effecten van ASC op de doorbloeding van slecht of matig doorbloed weefsel. 
Aangezien het stimuleren van de bloedvoorziening in slecht of matig doorbloed weefsel 
en het stimuleren van de bloedvoorziening in gekweekte weefsels veel overeenkom-
sten vertoont, veronderstelden we dat het vermogen van ASC om angiogene factoren 
uit te scheiden ook gunstig zou zijn voor het bevorderen van de doorbloeding van 
gekweekte vetweefsel constructen. Er is echter weinig bekend over de uitscheiding 
van angiogene factoren door ASC in vetweefselkweken. Dit deed ons besluiten hier 
onderzoek naar te doen.
In HOOFDSTUK 2 hebben we eerst in kweek onderzocht of vet differentiatie van 
ASC de uitscheiding van angiogene factoren beïnvloed. Hoofdstuk 2 laat zien dat een 
korte (7-14 dagen) vet differentiatie van ASC, zorgt voor een hogere uitscheiding van 
de angiogene factor vascular endothelial growth factor (VEGF) in vergelijking met ASC 
zonder vet differentiatie. Verder laat hoofdstuk 2 zien dat kweekvloeistof afkomstig van 
ASC met een korte (7-14 dagen) vet differentiatie bevorderend is voor de kweek van 
bloedvatcellen. Aan de hand van deze resultaten stellen wij dat korte (7-14 dagen) vet 
differentiatie van ASC in kweek gunstig is voor hun angiogeen potentieel.
In HOOFDSTUK 3 onderzochten we het effect van het implantaat materiaal fi brine 
op de vet differentiatie en het angiogeen potentieel van ASC in kweek. Ook hebben we 
het effect van fi brine op de doorbloeding van ASC-vetweefselconstructen onderzocht. 
Dit hoofdstuk laat zien dat de doorbloeding van ASC-vetweefselconstructen verbeterd 
door toevoeging van het implantaat materiaal fi brine. Verder laat dit hoofdstuk zien 
dat fi brine de uitscheiding van angiogene factoren en de differentiatie van ASC naar 
vetcellen in kweek bevorderd. Hieruit stellen wij dat fi brine het angiogeen potentieel 
van ASC positief beïnvloed en bovendien een geschikt implantaat materiaal is voor 
vetweefselkweken.
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DE VORMING VAN BLOEDVAT STRUCTUREN IN ASC-
VETWEEFSEL CONSTRUCTEN
Hoewel de natuurlijke ingroei van bloedvaten in ASC-vetweefselconstructen na im-
plantatie zal kunnen worden bevorderd door stimulatie van het angiogeen potentieel 
van ASC, zal deze respons waarschijnlijk niet voldoende zijn om in korte tijd grote 
vetweefselconstructen van voldoende bloed te voorzien. Een relatief nieuwe methode 
om de doorbloeding van weefselconstructen te bevorderen is het (in kweek) ontwik-
kelen van primitieve bloedvaten in de weefselconstructen. Het idee achter deze nieuwe 
methode is dat cellen van de bloedvatwand een netwerk van primitieve bloedvaten 
kunnen vormen in weefselconstructen tijdens kweek. Als dit netwerk van primitieve 
bloedvaten na implantatie snel kan aansluiten op ingroeiende bloedvaten van de pati-
ent, wordt doorbloeding van het weefselconstruct sneller tot stand gebracht en wordt 
weefselverlies door cel sterfte voorkomen.
HOOFDSTUK 4, 5 EN 6 zijn voornamelijk gericht op het tweede doel van dit proef-
schrift; namelijk het onderzoeken van het mogelijke positieve effect van in kweek gere-
aliseerde primitieve bloedvaten op de doorbloeding van ASC-vetweefsel constructen.
Humane mesenchymale stamcellen uit beenmerg (BMSC) zijn tijdens kweek in staat 
de vorming van primitieve bloedvaten uit cellen van de bloedvat wand te ondersteunen. 
BMSC en ASC hebben veel gemeenschappelijke eigenschappen. We veronderstelden 
daarom dat ASC, net als BMSC, de vorming van primitieve bloedvaten uit cellen van de 
bloedvat wand zouden kunnen ondersteunen tijdens kweek. In HOOFDSTUK 4 verge-
leken we de capaciteit van ASC en BMSC om de vorming van primitieve bloedvaten uit 
cellen van de bloedvat wand te ondersteunen gebruikmakende van ASC-bloedvatwand 
cel en BMSC-bloedvatwand cel co-kweken. In Hoofdstuk 4 hebben we laten zien dat 
ASC, net als BMSC, in staat zijn de vorming van bloedvat structuren uit cellen van de 
bloedvatwand te ondersteunen. Verder laat hoofdstuk 4 zien dat zowel de uitscheiding 
van angiogene factoren (in vooral ASC-bloedvatwand cel kweken) als direct cel-cel 
contact (in vooral BMSC-bloedvatwand cel kweken) een belangrijke rol spelen bij de 
vorming van deze bloedvat structuren tijdens kweek.
Of cellen van de bloedvatwand ook in staat zijn bloedvat structuren te vormen in 
ASC-vetweefsel constructen is onderzocht in HOOFDSTUK 5 en HOOFDSTUK 6.
HOOFDSTUK 5 beschrijft een bolvormig kweeksysteem van ASC en cellen uit de 
bloedvatwand voor de kweek van bloedvatrijk vetweefsel. In dit systeem onderzochten 
we of gelijktijdige vorming van bloedvat structuren door cellen uit de bloedvatwand en 
differentiatie van ASC richting vetcellen mogelijk was. Daarnaast onderzochten we of in 
kweek gevormde bloedvat structuren in staat zijn aan te sluiten op ingroeiende bloed-
vaten van de gastheer na implantatie. Hoofdstuk 5 laat zien dat cellen van de bloedvat 
wand zich tijdens kweek konden organiseren in bloedvat structuren, terwijl ASC dif-
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ferentieerden richting vetcellen. De vorming van bloedvat structuren werd echter alleen 
waargenomen in kweken samengesteld uit 20% ASC en 80% bloedvat wand cellen. 
Daarnaast was de mate van organisatie van de in kweek gevormde bloedvat structuren 
beperkt. Na onderhuidse implantatie van de constructen in immuungecomprimeerde 
muizen echter, ontwikkelden de bloedvat structuren zich verder, wat resulteerde in 
aansluiting van een deel van de bloedvat structuren op ingroeiende bloedvaten. De 
conclusie was derhalve dat in kweek gevormde bloedvat structuren in staat zijn na 
implantatie bij te dragen aan de doorbloeding van een vetweefsel construct.
Hoewel de kleine bolvormige weefsel constructen, zoals beschreven in hoofdstuk 
5, kunnen worden opgeschaald naar grotere weefselconstructen met een volume van 
mm3, is het gebruik van een implantaat materiaal waarschijnlijk nodig om bloedvatrijk 
vetweefsel te maken met meer klinisch relevante afmetingen (cm3 schaal). Hoofdstuk 3 
heeft laten zien dat fi brine een geschikt implantaat materiaal is voor vetweefselkweken 
en bovendien een positief effect heeft op het angiogeen potentieel van ASC en de 
doorbloeding van ASC-vetweefsel constructen. Daarnaast kan de vorm en grootte van 
een fi brine construct eenvoudig worden aangepast.
In HOOFDSTUK 6 hebben we daartoe ASC en cellen uit de bloedvatwand ge-
combineerd in fi brine voor de kweek van bloedvatrijk vetweefsel. In dit hoofdstuk 
vergeleken we de doorbloeding van ASC/bloedvatwand cel-fi brine constructen met 
de doorbloeding van ASC -fi brine constructen na onderhuidse implantatie in im-
muungecomprimeerde muizen. Zeven dagen na implantatie ontdekten we dat er geen 
signifi cant verschil was in de doorbloeding van ASC/bloedvatwand cel en ASC -fi brine 
constructen Verder vonden we na implantatie bloedvat structuren van humane oor-
sprong in zowel ASC/bloedvatwand cel fi brine-vetweefselconstructen als ASC -fi brine 
constructen. Dit doet vermoeden dat een deel van de ASC in de ASC/bloedvatwand 
cel-fi brine constructen gedifferentieerd zijn richting bloedvatwand cellen en bloedvat-
structuren hebben gevormd.
Concluderend laat dit proefschrift zien dat ASC in vetweefselkweken een duidelijk 
angiogeen potentieel hebben. Dit angiogeen potentieel van ASC uit zich met name 
door de secretie van angiogene factoren. Mogelijke strategieën om het angiogeen 
potentieel van ASC te verhogen in een vetweefselkweek setting zijn korte (7-14 dagen) 
differentiatie van ASC richting vet en het zaaien van ASC in een fi brine mal. Hoewel de 
natuurlijke ingroei van bloedvaten in vetweefselconstructen zou kunnen worden bevor-
derd door toepassing van deze strategieën, zal deze respons hoogstwaarschijnlijk niet 
voldoende zijn om in korte tijd grote vetweefselconstructen van voldoende bloed te 
voorzien. Dit proefschrift laat zien dat het realiseren van primitieve bloedvatstructuren 
in vetweefselkweken voor implantatie een veelbelovende strategie is voor verbetering 
van de doorbloeding na implantatie. Echter in het bestudeerde vetweefselkweeksys-
teem is de bijdrage van de in kweek gevormde bloedvat structuren aan de doorbloeding 
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na implantatie nog beperkt. Bovendien lijkt het succes van deze strategie afhankelijk 
te zijn van het kweeksysteem dat daarvoor gebruikt wordt. Toekomstig onderzoek 
is nodig om de factoren te identifi ceren die nodig zijn voor een hogere bijdrage van 
bloedvat structuren aan de doorbloeding na implantatie. Daarnaast is meer onderzoek 
nodig om de optimale (kweek)omstandigheden te vinden voor zowel de vorming van 
bloedvat structuren in kweek als uiteindelijke toepassing van het gerealiseerde vet-
weefselconstruct in de kliniek.
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